var title_f26_57_27536="Prenatal ultrasound of normal fetal kidneys transverse";
var content_f26_57_27536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound, transverse view, bilateral normal kidneys in the second trimester",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 299px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAErAakDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD508mSB3iPLA5xUqRNsLOvykcV79qXww0e9/0qwu1SRuQCeD7VwviDwNcabuDEFSeCKAPPrUxJaksvQ+lVZdTTcQchR2FdzF4dNxaiJIx5h6YrEuPCU0M226iZM9CR1oAzYNWgEGVYhh2PepIryG4GX288E1YPhtGnVMBWx3GKrpoEsd40SjIbpigCvuRZnET8jpTh5jyK20fUVYbSjE+x0KyCnCN40bCncp6mgBQSz4IIA61eG6TYw3bBx1rOVZJvmBO4elKLlopArttU0AdE5iEAwwZhzya5u5vVe6AAwvenyvG2Tubp1zWROQJ8gnZQBYfAdnDcZpruvDZy1PWMMOMhe5qorDzWUD5R3oAtpOZHABG0dsU6dtmQh5PpVBpd0m2Nce9Kk+xskZxQBpwgImQ2TjvSSXDmIArnngiqb3iOmNu3FNjlYwnax69KALTTvGu5XyT1GKdFcMqHzgctVOFA7kyE02VyHAZjtFAFtblQW2nP1qWPe1uTu5NZqJuywBPtTnlkSQKc49qALEdw9tIf42PrTp9QuSPm6dsU2C1kmRyQcdQakjiAGyXKjHegCNNQvYV3RyuAfSrNtqU6gsWG4+vWpNOhhffvx5a+tSXdpAQrIR5h4AHagB+pa1K9pDHnbg8sKiOsyhSBOWIGBmqz2i7WWRskc4NINLdl3nKrigCxb64BaskhyWPpUVxcpLF8h6dqWGxjfhR90+nWrEluqSKPLx65FAGTEqyHAXJz1q/DFvKhcjsRV67tYRbKYwN+e1TabGWUkjbjnpQBn/Z/I3bkznvmmCMAszOxB96vX8hLBAN1UN5WFicDd60ANuni2L5Iw+OBUdvMTiOTp3PpSwxNICRHhlGc0tvDJHK5mAAI6UALMimX91l1A61FbrKN/wApAFOScwbliK8+tJHcMwYKRuPWgDNllBmkJO0jsaqu3BwR1zU97Fly2fm74pkUKtt3HigBUlYREZBJ96mhZwmXzSNbooJBzSm4VY9mMH1oAbcrui+X7xqk+9GAfnHY1M0+MgfnUDEu2CaAOm8P6tDZQZYDzK6K31n7TBj+JvXsK84RSG4PIq3JfyLt8okEUAei3V/EYVjJyO+KzleFt54Ud6xtIke4UNM1aDSQrIwGGoAglcFXIUlB1OKwdTmhkJSMZIPXFbl1eu0TQxIFB4JrIMcUanHzMTyaAMposJk9ewqKtK4s5QDIvTtVJ4WRNzUAQ0UUUAevXWqa1o48i786PB+XOeK39H8UT6rEttfKZf8Aarvdam0HX7Zo5kTno4NcDc6EdFume3mVoX+6M80ASI0lvegxRlR7V19tf22oWcUN1bI0inG4isXR7Wa4Je4T5QPpUUsokdo4W2bW6+lAB4s0azknje2kRJFIyvc0/TtGs4kSWQZl+lZWp6hA0g8z/XLxvqe1uncbWlJQjk0AUNc0iP8AtITQy70PUelVLPSUuJXVhhG7kV0llocl9fbbVjOpGevSuhvPDzQxQ+am0rQBwJ8PWlmjm4XbxwRXnfie38qYyRybo84AHavX/iPqVhFoSx2oUTDhiOa8S1C8Lwt5b5z1zQBBFOxiXJ46U9WXfknKjk5qjZtlsNwvvUgniVmBGfpQBfub1RGI1xsI6iqe/Mg4wKpyENJxwtPEoA29qAJlkIYhU49akUAgljiq+5QNykipY/nU89aAJXWIrwetNQiEE5zTWRowMjIquSwViRx2oAnWdmYsBwaRpPMIJ4xxinRKjwrjhvSr6ac21XfbtoAghPyHBwKjF6gIj25I71oJp6yoVDlT2FSx6OqKWlADUAQW+qiBSuAVqSXVoZtx8sZxTf7G81jtI25q4NHEABJU4FAGcgkCFl4B7VZiiVrbe8wV+3tWoLUSxqpXAHf1q7D4aN0q5CqoG7nvQByrfLL/AKwuT3Falpqhk2xyIAo4rct9Ps7ScJ5BkHQ4GaZLpkDM0kMRjXPANAFYXMcbKixLk9DitEpHKUkmRc47VU/smV/nXhQM5pROIRHHOcYOdxoAuR2kCN++hwW6Vlyx/wCktHG2Aew7CtHVdViu4o4YFPmjjcBxVGFHhkbzoyWI4PtQBFHbqH3v8yg4+tPk0cXas6RlVHOPStmwaM2u0IMrz71djuLoWoFvaEo/BcCgDC03SZIISzYbPQGql3aM8h3Rn34rZvBdQIxAYEDkVl/20fIaN1Ac8EmgDFvLKPeAnWsiSN4ZQijGT1ravIsESxucHkjNUWuI96nZkA85oAp3MDoQo+YtyfaqczbGC+nWte/nDhSg249KyptpYsenegCvuO7ljilkJx/epHG8/KuAKQOFHY0AKqFuAATS/Zn3Y6UiEs3ynFSSSYIBfIoAbJERJtjOeOTUBBHJ65q0JAoygFRoQZCzgYoAltbidFIQnAq/ZzuweRm/A1SjmRCePl7UzzGZyIhigC/PdNgY6n0pYv3uBwB3rMLbT8+cVespVCnJ+WgCW4vfLHl9QO9ZUzl2JJ4q7NGJWbb8q9qigt/3h3AECgCiQAeKSrk8Kl8xjjvVfyn/ALtAHpNtfSNOqicoM9AcV1ejTO0io7eYG6FjmuOhhEgR1I39sVu2b3VrCGWLkc0AdndajJaoyBD8o6qK5yOd5pHnQsvPzcU258Q+dAQ1syt3fHFRJegw/wChEByPmBHWgCZ47O8iZ3k+cHGMd629M09mtFjkXKsODiuCgup479c7eG+b3r3vwAtjrPkwyyIrMoHPY0AcjoU8+gahkLtjPVzW94g+Ils2kvDJBGWIwWHWu08a+Bt2nyJbSxuQM7lbkV82+Irf7G8kc6sZFJBoAz/Et1a3yyPbylc5yhNec3JAkODkdMVe1Kcx3UgTO01lEkkk0AGaAcHNJUkaBgcnBFAADmpEAJpqr3A6datCASEFeBQAyRMjHpToA68AZokhaFt2cirFrMnlkbaAAz54x+lMncsu3GPrV23kiTaxUHHb1qa5uLadfuBT64oAyVOxAB+dW7e5nJ2sflHapIxDH6H61JuiLg7Rx6UAXLJ5JJF3AKB0rRlfd99s1Wt2idFZTg+lVrqQbyokAPvQBfSQY2q+F9BVmMhnES/NnrmueSbyZCSQV9ami1uCFW3nLdsdaAO+trUEQRQxgyMQMe9bl74e1GJI3ZCD6D0rx/8A4Su7hlR7ZyCpyMnpWufij4gZVV5FYKMUAeiaVag3Kq8Dbt3zE1tah4UnvZFmtVURd1zivHB8R9X3ZyoPtUM/xF8QSKVW7ZFP90mgD2MeELkxSkyJHGOgLCi1+H9veQxm5uEOMk4avCJvFutzDD38xHpmmJ4o1lE2JfzBfQGgD0/X7DT9JvZLWBoz5R5OeazJNctRZyLKFyvANeaTajeTOzy3Dsx6knrVVnZvvMT9TQB1y+I1t7wtE2Y+hBrubD4r2Vn4d+yfYla4U8NXi9JQB2Wq+N7q+uWk27FPYViS3wun3MdpFZNKjbTmgDaM/mRIgYkmmG2dmznC1mec4xg4xTzeSlcbqANOdgke1Blqota3BXzCpwTRDfFAAyhvetC51pZbcRJHtwOtAGXcgoApGKrcGnyyM7ZY5pqrn6UAPZiF4pvXtSHPXBxSh+eRxQBJHEWOFP60jIYyQ3WlQnOVBFD5c5NADQ4HuaejlfamhFxnPIpp/WgCdXBXDdfWogSCNpqZIt0eSQDTcInfcaAGuzYHzEVPBcbSqEDB6k1Vdi8mOlTFUj27uWoA2IrZJ1AQ4HtR/Z8frUKXQjt/3Qycc1Q+2zetAHcQWssMi4Y4znrXf6FG13a7YijvjGDXFgSz/ISN3bBp1nPqGj3CujleaAOlvvMtlkt5rdBJn72K5+YOScPtI67TU+o69LfRmSc/vOnFZVrITMWckhqALdlESzZwxFdHourXmnMJLfchXqV4rBsT5Ep5OGNWb+9NmD5R+91oA6W6+Kd7CZImmfLDG49c1wWseJzcqxkIdmOSTyaxtcmSZWcH95mubklJyehFAD9Vla4mLhMD1rPPFWXumKbcCqx5JNACU9OFbIz2pY495OSBUiQhjgtQAkR2qasQS8gdqhEanO1sY9ajc46daANlZIGQgruPvUJhDozqcYPSsxJGzn0q9bMxBJOM0AABUZyR7etSRqXUkxnNSwBHJaQggVbt3wCBgKT1NADLOzwS0owCOM09IUjZmOMdqiv72QHbjK9OKpTXsjRgfdx0zQAS3jxSkIec9qrXVy0uCeD3IqCaQu2ajJJoAd5jf3mx9aaeTSU5VLHCgk0AJRg1sado8kxBlXAPQYrqNO8MQyK3m7UUDqaAOAVSxwoJPtVhLG4dcrESK7ptIsbU5iUsQetTrGiKpjUD1oA4yHQrp4TIyEenFOGg3R/gYV2Et/IXWJSoXvxUM+qNBIY8DHqaAMODwjcyWxlyR7Yqe38MY2+e3TtWjBrmzKNNgHnFRPrLgl9p8v1xQBFL4YidC0RGfaqMnhtinycN69a3I7kPEWgfbkc1Wt9T8iR1k5OetAHMXmjXVsQGXPpWdJG8bFXUgivS7G7trtlacgnPArM1a1tTO4EY+YdRQBwtJXQy6NGVd1YBR2rNfTZgCygFKAKFFKylSQeDSUAOQFmCgZJPStg6ZItuHZQtZ+nSJHdIz9BXSXUhnjXDnHpQBg3UeyLHFU1PY9K0Z7Vizbi3tVB4nD7T+FAFgoPKGSAtVnKg4TmpsYKiTJHpVyG1gZs0AZ6xFk3HpSOFX7vNbr2qmE44FZ726ZIoArxoCvLGmTR7EznipJvLjwI85qF5C2A1ADYgd3FSlSXG4/WlijY88AVFIfnwGJA7mgB78cKTikzTNwJ606gD0seZFGskTAkd6sS3n2hE+0qGX1WiW1k+ybEQhvX1rOtWmUFJ48beMUAR3hiSQrGCFPIpY3QrhG+b3qvdEs5wOnemGNolV1P3utAGvAI/KYNPh+vXpTHYuh+YMR61ktE6ncH3A+lWoGLIQp5xQBk6rhcl0APtXP3ZBPygitTWZH8wqXrKUhpDuPFAFcjoaTB9c1JKBkimockACgCxDEhXLHDe1OmhEcQcNxSkHCnAIqSdA8ZweKAKsQ3Nz0qSaLaAVGRUCqcnB9quW+5owrnA96AKvlMPmx1p0KEygE4q3KrIAAQahnfYwKgA0ALOTGcIcYqEXL/3uKjllLsCe1RGgC+98CuCuSKqTSmRskYqKnKpbpzQAlKoJIA71etrIllaRSw9BWxFplvO6BV246igDPstJabaSM963bKwt7eQByqt61p21qsEG5eWxiqs9ss25xJt9jQBbXULa1/dRupalt9WiZ2SaTOe1cddWV0brMKs4z1FdD4e8HalqkqFEkVWOC2OBQB2ematp723kSxKR61DcaGl5GfsQLTOcKqmn6z4GutI0vzVcsRyareE/EY0u6WOZcsDxntQBT1Pwb4jtkxDYO/GcgZrm73wb4reRftGnXQ38j5SBX2J8NvG2l3kEkOoiLdgYLAGus8Q6zo82nLJGIjJnC5A4oA+BT4W1S2f/SbV1Oe4q/f6Wy2IMkgVlH3a90+IN1JKkgtI4+D94LXkt3ptxfk+aT7gCgDl7SQQNl8bBVhru2m4QA5PYVaOkQjcjuwPvU1lplvG+A2FzycUAU4raQSh1XavatTyI2GZG5FWdbktbazCwvuIH3q5WGad5NyFm9s9aANKXTLuRzLEGMA6DHWmIiruEgPT7vpXa+FRNd2hSRkU44B7VzurQtHfOpC5z2FAHNXOnJOWZVYYrEubV4GOQSvrXpGmWsEzBHIye1XdR0WyMflhRubvQB5LGQG+bpWhZXZEypnIzxW1rPhtLY7kJ57ZrDjsZYpydjFV9qAOjvLeNrYMrgPisSGIgtK43DPFWJkuZkVQCoPrRDbMjhZnwB2oArXEakBhjntVWTIYeWTgda1L23Y429PWq0ccaErjJ96AFFwwgCspA9aq5Mkn3ht71dlUbNpGAelMWziY434NAFSSOMPkAnFQttzkrtHar91bpCBtfrWfcPnCgdPagBjyluFHFR45605MAHPWg4I60ANHDdM0/cPSpYIc/e4p/wBnj9aAPQ4725jk2eZj0HrUTXEou98g3Z7Z61cnskkQOM7xWTP+4mPJ+hoA1Fto5WklbABHC+lZtwIkO0twDxip4J3lXaBg037L83zBTQBizMY5D8xCVXXUDExCFi3TmunWy+0fIkIbPesnWtGe3OShUjpxQBg3k/mq25fmNZjYwT39KuySbMrJ1FUGf5sjFACkdCRinjaCMGm+exXBApHk3gDAzQBYckKNpyPQVHuZcgtwahViO9PUg0AKuRzzV0XIWEDb19qqxlscfdFSswK/TpQASy42uSfpUE8gkOehqOVy7fSmUAJRS0+OJ5DhFJoAailztUZNbVlYCIo8n3qn0u0SGDdIvznmr8Lb3KyJ24oAWXPl5CgD2pkNysY4HJ70/ZIoIEZIpkiZhZmGMUAXINUMciKWBQHmuks4rPU5UAi2L/E2K89hmDzbAp+uK7fwxBNJjyizY9KAPZPCng/RzAkjxoq45YjOa72OPTNHsAYYIwq9SUABryfRtburdDC5KlRjFReINY1G7tTGZcRelAF34heJU1VGtLWONQowWTGK8hu9Kkht3uGcbgex60mr6pc2Uz7AX965e71q9lPJOzuKAOjttWu9NVZIZyOeQproNN8ZXkq7Vldj23GvLUvJGmBLHbnkV1fhuEXUyvGevYnrQB69o+y+07zb+63O3AU1JfaJ/Z+nGeNchhnNVNG0l1s0uJdqRA9zWxqbXmo2n2aGRfLC4GMYoA8vvIRHMz3C4VjwQKzrwgBUtVMrN7V1E/hvVL4yQ7lAj5PNZ8WkT2bPlR5i/rQBz4tpnBhkiO4jv2q/pujlI2YqCw61au5JRIryDa3Q1UubuSIho3IU8GgDc8P/AGaB2a7k8oZ9apazBbTzu9rL8g53E5JrFuLtlBLDchFZKXhE2DIQhPSgDUIWOZfLcgj+KrC3UoidndmYnirVlawXaRlW359O1TXUEVshVhgAUAVIoyzJJcHcvoeaXV7q0W2xBF8/pioYb3c7Kir5YH3j2rKvnbefKQl+WI68f/q/z1oAbLFOYhMWGOwqlGdxdpmyR3FbfhOw1bxPqUek6TYzXd3L/DEudo9Seij3PFekjw/4L+Gv7zxI6eJfEY6aVbSZtrdv+mz/AMRH90fQgjmgDkfBHw71nxVbPfs8Wl6DDzNql8dkKAHnGfvH2HfqRVb4hW/hC1lsrDwg99eSW6sLrUbj5VuWOMFI8fKo5688+2SeO/HmueLrmMarcKtnDxb2VuvlwwjphUHtxk5PvXLxJPjKRjae5oApvb75lDMdlWvs+4BYkwPU1btLRpGaQkcdqtWzGSVtwAC9KAMVdIkmclicL61Dc2UduAzuCw7VvzSNNIyRHag6kVlX8SeX8hyx60Ac/dENICikA0kcRI3dcVfkt9/vUaLsUgUAVyzFcAHJqPH/AE0P5VK7HkVFmT0b86APSUvo5lIGcmqN8/I3oRjviqjzyR3ICAcVtW+pQS22y5jGenFAGUJsKNh59qkikljxJyV7io38kTPsYKO1XYZYxbkSBSfWgCd9a8lYzbpg96r6lq0k9tmZQayrq3+0kmF9hHpWTN9ogcxu+9aAKeojzJWZfyqhVmfO45aqx69c0AJSg4NJRQAuM1NFHkEn0qML74qWFih45zQAqSBVI70x5CwwKnZUZST8pqsVPJHIoAZSqcHpmlAGOTTolO8EDigCzbRjdhwAM8Zrct7RY0WRMEGoYbTzrXdIBjHFMiuJIv3YbKr05oAtwSedKUwRipTFOk4IUlfaq+ny5nJKrn616t4J07RLiJH1i6WLB9RQB55BfSGXyxC/pnbV46Pf3+xbW3kbfxwpr658NaN8On0+GSNdOlfby0rAHPepdU1rwPpELw2Islmxw0f3VP1oA+XrD4YXlrbNNeFo8889q6Lw9DBp1s0XAIPU1ueNPHMNzLJbxTIcHO5BxXATar9vJ8vgDqR3oA6s3djb3JkuZAGI454rI1bW7eTMNswct2Fc1qI/dBy5cjsTVS0niicTeWBtPc0AT6p4fv7+3MyRSCPqTisC08OXMpkXY+BxyDXqnhbxZbyt5E5VgRwOmK6lNXsVjaOOGIsRnAXmgDwO58MyCAr5bKR3xVaC3u9LiMkcmAvQZr2TUNKuddmf7I4jX+7iuo8F/ByLUoVk1BmlyeQBwPrQB4F/wnt+tr9nkkcoB93tVWLxpqaoywSuB9cV7z8QvgrpOnq0sX7rAyMdDXgPiDRotKmkWPkcigDT0vxhemcGW6dT3wetdXHqAvpBJFKWbGW3d68m09HLfKvI712Hh23vZC0kWCBwc0Abt9cxztsLBTnkmob+O0jtB+8BIHaql3BdLdrviVs9KVrBi7PIMjH3RQBQjW3mbb5jc1btNChlBkkA2DkD1p502NEEkTkP6elWrSKSOMuZWIxxzQBdtmtrEhLVSGPaknuobiYxPGc+pFZyStGHlDZftTk3mPzQ2ZW7UAPj0gXlxFb2ySzSzNsjihUlnYnAAA619T/B74TWPhbSWutctYbnWruIxyhwHSCNhgxjtkg4Y9+nTr8/eD/Gr+CC9zaaba3OsMCkdxcMWWFD12oMfN7knjjHXLNe+I3i3X5GGp6/Otux/wBTA3kpj0KrjI+uaAOi+OOt3/gO/m8JeELW00LQ5I1keXT2/f3WRyJZPvDnI29cdyCBXhEM0qsSTuJOTk5rtL5Df2qwxpu2DG41zM1r9nlKFenU0AEJWcHYmW9TT3eSGNlZgAB0qgLoRTYQnjtUF1c+czFsluwFAFy3u5SGVD9aeJsP8zc+gqLT7WeWPdgKKa0Eol3EcA8UAa1tHKIiRwD1qB4lR8bPm75qVJGeEKGwfpTYYCrEzOSPc0AU3CDf0B9BVW2tXcsSvHvWwY7UyYDD86J7q2ihdVIz7UAcvewk3BWMZx6Un2eX/Jq5gybvKHU8mo/skn/PQ0AdHqNlcI4lUZBPNVCHHMi4IrYub5xmNgNnWq800U0ePLBPqDQBkXLgoCUwR3pYpsxBg2TTr6BhHkEFPTvWcqFGzk49KALal95ZWxmlMSsrFmBNVnuPl2oCM96o3EroPlYmgBl5GzPlVGKijt9w+Y8+lAnkwQaaSx53EUARyJtYihOKk28c0sUak4IoAbHgN8w4qUHJ3KBgdqUw85HK1MhihUgqcmgB0BDcuOKZcSxruEY9qB8xJGMVVuDl+BQBFk5xV6yhfh1OR6VTWNiw4NbtnA7RYhUE4oAfJK4AjU4z2rT03So7lSznGBWM8E275zhvQVMk15anakmAaANKXSGJY25OVrOuG1CIEbH2jvV2yutQAIAGCeprTgnlCbJ0Vgx5JoA523fWJhtjuZEX2JFXbeDUA+JLiWT6tV/U3itwohxk9hUMU4WFWRiG780ATixmciSQsF7g1oPbyrAptsDI5rOTVpAQrKNvcmrLa2DFsQDdjtQBj373qSYD9+RVKSa4HM4IFTXmoys+FXLGs+eeabiUAD2oAvaZLcGQyRHbjpivcvhfZ2bRfbb+QyMRyjdjXg9i0sGArYU+tdbo3iO60y0Kefwx+6KAPpbQ5LS2nknW0R4yeMity5+IlhpdlJb2ghjkA555B9a+bIPHeptaCL96kPcjqRWTcavJO7tFvBPUv3oA9D8ffEC4v0/cyiU5+teJ6/cS3U7TTtwe1a8chkkO8AvVPXIYfI4T953oAwrLaH+Xjmu18Pm4RuEIi7nFcfaWLeYsg5wc4rp7jxHJbWoiiiG/GOBQB6TYNpP2QtKVEvfNcpqd7aQ3DMhDA8Bc1w6nXtXuVjtIJSW6ACta48AeM4oRcy2cu36UAbGkhL/UUS5YJE3RRWzrVnDbbYYSBGTya5K18J+JgRcSRMgj5OR0q5pV/Ml8o1Jt6qehoA0jbW0TBYEaXPWob6MsyGIiM55Wum1Ka1urISWu2LjnHFce8MiM8wlBUfnQBYg0pbi8VvNHqQafeaFIJTL5gCj0NZJnnjfem761ImqXJjaNgxzQBLqF8NJiXyiHJ681zGoagZ3Zxhc9atXsLzOFdskngDmnw6Sm4ed+VAHLSTKXZs456UfaEAzg7qteIdMNlP5iD5G6YrJBB6mgDp9IvT5WJDzRdXYZyC/HtWIlxtUYU/Wrlk8e7LAlqANCO5YAbAKkyr8zO2ewplpJFJcAdK1Lm0iSNXCjB/WgDNuLfbCDF8znvSW2jOcPcuMf3RWxDBKsO4RYX1qrcbiP3YYt3JoAq3AgtkMaDJqn56elaMNjLOCSmB/eNTf2Mv8Af/SgCvFOZBicfN0zVR5WhlPGR7VFi4Zi2cLRIT1zzQBFLeFpOD17Go2kb+JflqYKjrk4DfSpkt0kXryKAM7coJ4601rcSDIYAGpbuPyydqk1RZpAcZoAnmtMINrA++aqlDu2gZp4aYHjOKdbktJ8xGaAIACpwetWfKbZucYB9KkvFUMDt5+lONyNoDJ0oArIxRtpztHrSyzKT0ptzOr9FNQrGz/dzQBKsg5IP4VE7bpOtSfZsIWLc96gUFm4GaAN7Q4InY+eV/OtQSxW1wRFgisvTLbzYflU7x71agtJHk2uNuKANELFK2Tjd7GrENrCX3SnGB3rPCrAw3E/Wpmui0Z8vB+poA0nCmI7cBBWRczgMFVWC/3qfFPLwW5WrMyrMAUwBjpQBnvD5zKV+bPrVi20eeR8KM/jVNjLDIxBwO2aa+o3aAhJSPcUAdBb+F5XDMZlB7gmsHW9HuNPmO2ZD9DWbda3qI+XzWwD1xVN9QuLhv37kmgB0yzW7hiQc0wGctuGD6VftF81CWVmx6ipVV0yDEcfTpQAlhdqjqLiMH1r03wb4f0XXLyJp5VjA7Z5rzL7KrtvB59BXR+Ho5oZUdmKDrwaAPfdW0fwno1gDw5x9a8W8U6lYyXBTTowqg9hS6/czzw4+0tgDpXKlSrZ3ZIoAtw3BEq5QD1NTardpOAsQG49TWXeaxFFhCvPc4qGK6t7t0WMEMe9AF+KOeXCRp9SK6/w14QgvHV5513dweawLFJIWCodwbvXR6Y8lvIPLPzdeDQB63p50Twtp6OPLEmMbvenXvj5ru08q3lSVPavNNQkkuYgs6szYwFBzWbFaSWThmOyM84zQB2ms6zfSWMn7xBGwwVXrXleoYe45IXmuxiuFmkSK3YHPXJqtquiid2lfaFA7UAc3DNI8YiEgWMdT61pQW0EhVcu57ntWZdWyQOmwsR9K3LK9SNQFhJOMZAoAsJZG4YBSghTjnikutIQsSEwccYq3azqrrKy9P4D3q1/akvmESwjnoMdKAOZjsVsZRJKpL9efSprm6spV+ZPmHStLVW+0HLKEJHGa4pleDURufcufWgC3qenrdrwpwR3rhtZtYrSfYhyw7V6n5ySWrKxC5XAIrznxRbRpcFojuJPJzQBn2rwpBmQnNXrW4g2EIB9TWOImK5H5VdjtNsIdmH0FAG1ZwRu2YiMk9a3rW2QsGnk3begzXKWLuG4U56AV0NmGVN8rEk+tAGv9vhXKNkKKp3M6ysDFERH3Y96iMaSAzSEsfTHFXbeUyQhUjzjj6UAQySl2RVyqKOan8yL1X86uafo5uW33LYT06Vof2LY/wB79aAOCl3RxkHBA9azXPz5Dce1aN5E77thBHcGsacNC33eDQBafYe2D7UsUzQg5XPvVVZSVHrVtN3l/vFyKAJkeG4Qs45qtPbo7bkAOKh80JuEa8UyCZ95Gw4PWgCC6jaLJU5FUBIytlSQa1LlCysEDD61mOmDg9RQBoW1ysmBNgkdKkuGjK/KOvtWVCcSDvVqactwVxQA1ojncBxVi1QFt2CKrLO33cjFXbVd7bVNADLxiVHlqffFTaTaCSUGVRt7050eBiNykH9Kv2BCZY4INAHRwafb/Zd1vwwHaoEljSNlmT5h3PWq9tO4iZo3YAds1Ru78Sg7uCO9ADp76MqyHFZltM0tzsHAPcVSch5HJOfSt3wfouq6zqYg0rT769f0tYGkx9cA4HuaAL62TxnbK/GOKRoQpwrgeteq2vwZ8QR29zqviWSz0TSoI97yXc29lHqFTPPsSCa84lNol5MlrI8sSsRG8ibSw7EjJx9MmgDNSNGkw53D6Vv6Vp1hcPhwq+zVnlircqAfYVDJNPG2YzyaAPQ7TwvobWx84xnd19q1bPwV4SbbucM+fUV5mmo3q24UyADHJzUUOrtHMCZGHqQetAHZeKNL0LSN4jXAxxXntzcQSK2xgQKr+Kdba9YKrM6jqTXP2kxafCnA60AakKXLzZgiyme9dAtxNDAu8Kh96yLa+ltwCo3AVs2moW7IHuos55oAo3V/M4PKkYrDubiRmbkCt3U5LacM0IIX0Armr0Mx2oDz14oAoXblpOTmruiPtmXjv1qsLZTwSd1XtPtZt4Ece4/WgDuLCMtBvVhxXRaLZl7Zpmf5h0ya53R0MUW2YFR35rbgaKGRPszOyHGRQB1+h6SbmBmjZHmOTz2rivFMeoRTvE0ZVVOCw9K7AazBa2ojs0ZZyOSBXPa0b+4Qnqre3WgDlLe+NmSTnf611fhy4OsRGF+oPU1y91bMCRKnPcYq5bebZWTSwKUGMZBoA7S4sNIsFAvHEjgdOuKw729tQCLSH8RXINcajfsVtonlb1rf0XR9VMebgYH93FABDfXEZykZLdiaa39p3cvm71HoBXW6H4Q1DXLtYoVCoDycV6Npvgaz8OXCS65JGycEKDQB49aeFtUvj513Iyp/dPFZsmgPDqP7zDqDwBXrvjnXtN83y9IeONOmM5riHcqQxbLk9qAMrW7EDT8RxFWC9q8y1K3SJnMx3PXrusXYMG0ntXl/iC0DSNKnQnkmgDld7ZxjAzV/TwZ5CM4A96zpQVcjnjvVzS5nRmC9aANJpltHyxzU0OqPcSKiAkDrWRekZJY5arOhX1vayFpQMe9AHZWyT3EQAjCR9ya1LW6tLOL96QzjoBXKzeKGuR5FspAPHAp0EUuQ8pOTQB0F1fXdyCYB5a9gKrZv/wC8an0aKWV8ygrEPfrXQ5s/agDzJpcMWRsg9qqFhIxGeSehqNVzyG49KtfZC6hk470AQi0JBK55q1ZxO4MRfmrthAdvUZ9DTjDslJA+YelAFT+zmDMM7iKVIGY7QuCvHSte1IJD4IYdjUdxMHuB8uMccCgDm9RMkTMFGayNxkbJxzXUazaK67kYiuWmUI2BnPrQBbjtHyDgZqSVB5WJBhh0qBbyZUAzzjjFTwMbk4c4oAoFdpzUkJdXyrEVZlsmDnBqa3tBJkFsUAPsreSd8sQV9TWrDZLESobP0qlbwvGCBJkVoWPmsSoIH1oAW9lS3tii8MaxhvZGYgbR1JrZktp7yZLaJHmuHYIscSFmYnsAOSfpXoFj8ONL8JWMepfFTUmsI5F8yHQ7Mh724Hbd2jU+p+mVNAHnfg/wjrfjHVBZeHdPlupuruBhIh/edjwo+tfZHwd8RaN4c8MHwrqPibTdQ1HQrUzXU1spEMcQY/KH6SFOASMHlRjNfNXif4l3Ws6YNA8MWcfhzwypx9hsiQZR6yycM5Pfse+etYVrawWCBo8neOec0AemfGD4kXfji9+zWwkt9AhfMMJ4Mp/vv7+g7fWvMmt8DcmQR61MMbgVl3Z7EUy4Z1QkZwe2KAKpupYyEk796nBUYy4JNVJHWYAEkEe1QyM0bAA8CgC7dW8zx7lBKCsMOskpjkygHeuitLl3hKygbPXNTR2WnXEy+ZKise2KAOYMUDsY1yx7GmxaPJu3xr+VdnPpemxScSqDjtWNJOltO3lvlM0AQWlhPwAPwNbVnpDMuZ7d9nqBWdJrCr88bfMPSqt94vvPJMcZPpwKALmrzabZxsqcPiuKvrrzZSYyQKjvbmW6kLykk571WzQBdscsCTnNbNgJ0YNGxGKytLJLYPIrprdo4kBHUdqALdj5xOZd2T6V0+iJNFMD5ZAPciuUi1cRurBB8vrXRaf4rknkSMrGiqPxoA7STS3miBSRc9cAVSNw8cn2e5VQF9Ryak0fXZZ5SLeNcf3jU16baWcPI4klPXaOlAESLpk5Iuiq844qhqGm2ZIjhc+RnPLVLe2XzBo14PQEU57aJQPO3bsfdFAE+gXdjpF2kUFusm7gsDXaw2qXr9UiVh2IryXVpGjm22CurA9a1fD8mss/zTSbz0zQB3Wqaq/h6Hbpkp871JrjtZ8Qanrj/wCn3bKq9ADitJNMubiQi9n3seeBniquqadBEPJjG6VuA1AHGkwLcl2cuwPc5res9ThWFQU4HTIrq/DPw4tL/bNcyhehOTXU3Gi+GNFQpKsc0i9D6UAeUXkouYmcwts65x2rmtUhSa2KpEdgHpXoHiTxDpySPBZIhXpgCuI1VpvLMhG2M9hQB53q6KjlUQiqtlIIWJIzmtPVJBK7k8e9Y9srPOAuTQBPPEZyXT8qriFjIFxgmtsW8/lAKoUetQ3ECW8fmF8yUAa+h2ccUYbABHUmtmDyPMDSOoUds1wq6nPjamQD2BrQ0m5BuP35yf8AaPAoA7ia9aRAsZCQgdqo+dH/AM9v1qe0SG5jy8gVAOg71L9isf76/pQByKQq3+qABq3ayNCdsig4qqu5dxA+arVohuCATg96AL8UQldWQbanv7B1USIwPrVu0s5YUDAbkq9aQvchkCc+h70AYVrGwUkYY09YS8m3b87dOK0LnTHjkJUNGw7dq2vDyRPOom2uQcEYoA5fUdMlt7ctOnB6GuF1CMJK2RkdiK9j8SPDJJ5Y4j/unoK4DxBp8aEvCqlfQUAcgE4yGA9qcrvHyhxVh7QuxK5T61VmieFtrGgCcXbPxIcVPGxUZRs/WqUbgjaV59atwL5a5PINAGhZylDmTnPStaNRwyEAmsuzWOTuR7VoRxFWBJO2gD0m68f6R4Lsha/DnTHi1CWMC41zUFWS5yR8yxLyqDtnv6d68o1K5udTuZr2/uJLi6kbfJLM5d3PuTyanu3Pmncvy+9UmjMxIQc0AWNOLzShQoUV3umGzistsiAynHDVxmkW7o/uK25PNZSXAGPegDaDWjqUmiUP221SkhDq6HGO26smG4k83C5zVuaacgb/ANKAKj2pV2G3I9fSqXktuYrnArYt5snY6tzwTVXUI4kb5HIJ7UAZEz3LkKrcVKiSQqHZST60iK/nB2Xcg9DWlDMAMCPPsaAMS51BlbLAn2rNmvJZS2xD19a276A3M2GQIKQWUVqu51zQBkW0M/3nBx6VeRkUfNEB9av2l1CrEnaQOxqpqV1DKhwQp+lAGXdqsu7ZtFZjRkN1FXjbmQEg8E9RVaWJozjgge9AFnTiI2AJGT6VuwqAuVO41zVurF8itqzEkRLFdy0ANu4neTcFqvGzrIN+VANX5HZiAy4H0qxHbR7N5yT7igDqfC1zbSIEM7KcYPNd7o1pZI4aGUOW9TzXjum+WLoLg9ei8V63olpaRaaJTcKjAZ+9zQBuaukq2Za2td20dRXGteSmY+dERIelWdR8TX4c21q4aIcZA5NYzahJJIfNjbfnrQBrxqHwxQBhWnpk5TJZPkH4VlaaZfLLbGwefm5q/ZWdzqJbzsrADzt4oAn1PX2O2K2MaMeBt5NQQXawv5t6gkYComjt9LlJiiVnzwWGTVK9IuJA5OZH4C0AWNR8TXkhItEaOI8AL1p9rb6nqsRMpKIerGux8FeDbe88ttRkWMtjvXrll4F8PoFMtyroOirIFH40AfMFz4We1naQ7pHJyPSuc8UXM1rbmGROvFfUPxTsNOs9O36ZbxAInLKfSvlXxXdfbblgxHB6UAcLfszZwDU2ixkyj5CSDzS3G4uRkYzW34ZtZA+8oCPU0AX7kLHagujAgVxuq3PnTkKflB6V23id2+zMC6quOFHWvPGOWJoAmgYAgAVp2cSSnEaln9e1ZEKhm61vaVcxWYyep6UAa1rp19KqpCDirf8AYGqepqfTdXmlOyMKme/pWr591/z9GgDimlJbPp1xUqS7WDI+DWfDKig5amySMnzJgigDs9J8QPAAk0YdOlddpk1tfMGiKxua8iivpAmSK3dD1EkgoxjYUAeqS2CFCswaTI61hrEmnzkxow571p+H9ZaeJI5HRnHH1q3fX0RV0ltsOOA4FAHIatCZ5Q8ZwD2qlLphaFi4IIGfY11EbRz5jK4PZqrahYTlcCZAuKAPJtRVlumVRxmsq5Dq+WOc12WsWZtbhsAPnvXPahAZCGCce1AGXDIEb51ytWYpUZ8AkA1C9v8A3T+dRIjt9xTx6UAa0ayRsCOVJrVjvQu0NWJbzSIoDgj61YZmbBH50AaN9cq4APSqULb32o21qrzFyoBOKWBmiYEgfWgDVge4hlBLg1df7ZMNyn5frVc2sssaSouB6itvSgsi+VIwye1AFC2lCLhgfMFT+czH5zn6VevdM+zPvBwD61lXdvu+ZXJx2FAGnaZJB3jaD0IqK9ZLiTYFAI7461RtlcZwxx71ZAckFcD3oAWK2VGIzz6AVGyPHL86AD61q2FxbI/+lL83rVu8trO8bfDyAO1AHPSIzSDaVqG8triVdjkAe1bJsYFHyBlI9TWfejycbHyw9TQBinTJI1IB+Y1k3lrcRkqy7vpXTRmWcl5B+VUb9pIULDBx680AYSW93tyFIpxtHcZlkwe9LLqs4O0DAqlNcvIckkfjQBoIIbVMkhz9as2967EbQCtYAYlhuJNaCDaAU7UAdHA6zD5sDFLO/GyM7vpWfBK+wDFbFqWSMMYzj1oAp25Ns+58g+4rv/B1hJ4idYo5CkY+8wrzzV7kOVWMfMTjmvTPhHNFpsnmTzjn+E0Ad23hOPR7ZXKh/ViK5O/jT7SzxxjAOelejeKfEENxppW2hMr44AFeTXlxqFxOV8pohnpigDThv5JVYGLAXpWHPqutCZorZ9kZNb9jaxR2m67mO484Aqg9/b29yRBAzsOhI60AVdO0+/1G6AuZirDnmtq20NpLnPn/ADKe3NUrGe4lu/MEbKx449K0W+0wszAke2aANJrHV4FEq3m1QeMmpbXU72OVWuLuR0zzg1nC81G9hMYiYRr/ABHvTre0eaLy5ZFjJ7ZoA6PxJ46tho/2WOHzmwQSRntXgWvpNczSXDRlAxyBjFe5x2Gl6LZ+deGOZ8Z55ryXxtr8GoXxFpbhI1OAF4oA4cwOAQUO4+grQ0qSaORVZiq56dKtW5R+oAND7BIW7CgB+uEtCfLBY46muUi0u5uZDhQK683KvFsCY9zTBENv7nOT3oA5z7DHZH94d8noKqSn94CRjmupTSfMJaRhVWfR8hyrDFAEGnSyquQ2Kvfa5PVqy4FaCYIHBrT3H0oA5wIH6nFTKqhcFulZ+XB7ipFc52sefWgCSWTDbU6VqadceWQCKyWCg8jmrVu4boRkUAdjp+orFKGGRj3rrLfVZLlVUKSD615nY3KB9sgz9K6zRdTgRghbHbk0AdpApSPei4Y+1QQRtLMReqQoOQelSWN9BgCGUFz/AA9c1swaJfauu6Bwq+hFAHBaukEs7oyDaDx71x+p2hjcmMkD0NevX3hA28xWcs59QOK5fxN4deGEyISR9KAPMlRZSQ+FHrQqtbcxYIPWpryIRllJ+YVQaaUIVwR70APuZXfkISKri4dWHBwKsW0+/CvVsR27OA4696AIhmVRkCrLWx8jcp5HtViG1hAzGwrThgi+zMN/zY6UAUtKvXb90+SB61qacsZucltrGsGOJoZy2/GT6Vs23y7XkZWz+dAG9LMv3JGDj3NVHgDEiPAT2qG4QsoMShs+9VRLJG2HJX6UAWZ7ZwAAmVqKVHSMAqQvtU9veGPBbc/tinf2glxLtZdooAzowhf5nK49avWt0tu+EfI+tJcxh2zGqlfWs65GG+VcAd6ANXUtRdx8oBGO1Yj32TtkT8aVgXHDmk8uM/6wHPtQBFNcsYzs+7WfcTuy4K+3JrVezH8DHb6VR1C3IUY6UAY9xGWGSQD6VRYYNXrlSijOetUW60AIOtaVnKiqGYg+1ZlKDQB11rfQY4iGfWrH2mR/uAhawdNjSQD5zn610sVuBACGoAoi1kklLqm7nvW5pk8tsVKZDelMsLxLZTmNScdzUv8AaD3BIihRc9TQB6F4V8SxWZ/4mJVjxhQK73RlstRY3flxKvUAjrXh+maU1zIv70lyeg7V3Fis2mWhUzO5x0B6UAX9duLdryRMoqrntWJZQvcXReKDeg4yBWRfajvuyojZsmun8PeLksYBB9jPT722gDOm8yxu9zxsMHgetWvtxlO5omx/u1X1fXo729DzDagPTFbWn3cEsStbxFz2OKAKiS3UybVjaOM9zxUtnYxxM08xDBeQM1aMF/dKzCDYnqx6Vkz3TWjMj5kPfHSgDl/GOs3FxO8EG5YgcYxXFXFpIOQ+Gauu129RGZxEoc9jWFaxSXL+ZIBk9hQBHp2mhIvMlYlzUcscUZZmBI9K2XiMcW0NgVi3U6K7IwzQBkXupLETsH0zSWmskptOBjsKo6lb7pGKgknp6VSijZGyxAFAHULqAdcbto96gkuGkyN5Vf51z73BBwuSaliuJnIVFJY/pQBt29ojvleB61d+yp/fNZ1q0yRjd1qx57/3WoArf2YZFwozVG80yW3IPb0JrrbKN9oYL3q1IIrjCzx/pQB55IzDggGq5LK3GRXcap4ZjljaS3OO+MVx15Zy28hDKcDvQBatGZtuOvvXR6ZCXZcqSfauStZnhYE9BXa+Gb5HkQy57c0Adfo9odwMQIkXnDCu70PVL+2Ow4B7DHFYdkssvlTWrx/IORUureIpEAiEQjccE4oA9U0J4tXKw30aDJwX6VS+IfhK1hhEWk3kTMwyQRXmFt4zuVXy3GwdNwo/4TK6ifKyl19HOaAON8Q+EriK4fdAfMz2FcpfaHfRDc8ZC+hFexP4yt7kqb2H5sdVFUtZv7W+twsKKDQB4pc6dJEN5BFQq5UgE5Nel6haQGH54wTiuO1KxiDny0INAGWty0bZzV+3uw7qAeayLhGQlTkGrFgjZGOSKAN6ViiBmiBB74qOGSOR8kHPpmmBpnQByoAoijwc9aANuO4WNARgccCoJLoyvkqNw6cVnl33fdzirCXUW3a2FYUAWhJLIhUgIKqSxOp3RsMinyStOvytj6UtsqofmPzUAS2EzsCrHGOtMu5H+YIARUxjQtvL4NOjC5yw3LQBnwuTxjn6U2aOZB5jOMegrQmEagsvArLnumJwQdtAGdeam2doyD61XaeR0OWaprhI5AWbAqIxx+XxJigDPleQsdzHFV3OTVm7Cgj5s1VNACUUUtAFnT5RFcBnOBXQf2nGY8K2Sawra3jkTJbk+9aVnZLkYGeepoAkt3llmH7t2BPavQPDfhy8vosw2r/Wsvw5AlrIHlePb6EV6GvxDs9KtPLiKAgY4FAD7bw5LpkQdm+cjle9Xra4tYU23MZ3dPrXE3nxFe9uCSePaqupeIZ7uFdnA65xQB6TDodpc/v38tF7AHk1Nb+HLRSXX5z6Zryu08RuoC3Uz7R2ycV1Fl49hsoMIC+OBnvQB2I0mxhy08MS+gNEN5aWrE+UuwDgDiuEbxJquv3iw2VnId3dQSa9H8L/AAv8QaxapNen7JE3eQ8kfTrQBVvfElqLYrGVViORmuF8Rau0iMIGVU9R1rqfHngaLwzIyPcmebHQdOa8r1izuVjwuQT/AA0AY0xe9uyZHYgGtK2ikXCw5qtY6TM8yqX574r1HRPDgi0syyqMheCaAPPLq2kCbnY8CuYvZo0kYM3IrpPFc8sE0ih+QeFXpXBTw3VzO27oTQAtxqGchOaoMzOeT+VblroLMm6SiTSRASQAT25oAoW1ozIHVcj3q1FMLcY2jPrSyRzopyQo9BWZI77z1/GgDobS4aRsLHu9zVvM39wVj6RcMhwBkmtnzn/umgDt9Pt7dk67RjrVtLKASA7kZfrWLFciJQV5UjkVo6dMsr5CZHXFAGstlazKw8vap4yDWdqHgxLiNjAVYehGTWu1rG8O6Pej9wDViOWWK2JjD7h3oA8rv/C4tpWVufcDpWZJFJYttA4HfFei6m4lJZiQx6gisi905bqDIPPtQBl6PrU9rgpMdo6rmtC9143DBwD+NcpqdnJayH5sD61WF6yJszQB0txqzdQuT7Uj6iskI3YU1zX2wKhLDiqS3rvcY3fKfWgDqEuJAdyuSPQVJLfyFNysQRWQl0kag559qkku4mhOD83pQBqWuqSE/OwK98jNWb3yLiINH8r9zXMxTYzyKnjvgCUYmgCK+gbnBB5qkJTG2MAH1rTaZV5yCKrTRxTKSMBjQA0TF+A2TV6CObBwuc+hrOhsGzw1ado80OFYH60AOKTop3KPrVPEhkzKygfStxwzw53DOOlZN2rhvmSgC3bqsi/upF3U5omJOTlvUVm2yMku8E49K1EbeMDIHrQBF91sv29asrcl1xGg4qGW2MgJ3k47UllE0TcnPPegBl3cyIh3JkVUe4eRAvlFR9K09RnATBVRj0qlEVYkswxQBV+yK0RJOCaoXEPlrhZFxV+6KOSFfj61jXaKp4bNAEbw7sneDVdhtOM0/IprY7UAMpaSpIdu75xxQBas5I1GHx+NaqXwjUbAuT2xWRmDkbRmkaN2kXy80Aayy3V2+F3Ae1aEehvMg8wuTVvw7azJGrMqnPqa6NJHjPIU0AZej+D7+cq0UOY8+ma6O/8ADckFr1CMByOldDoHje20y0WFrZWf1xWd4l8Wi+UkqiJ9KAOSt9KBuAZXXb35rZh/se3kUTw79vWudmvGkYsj8UQSeY2FjaRvXFAHqfhn4laRoF3G1lYgSKRzivcNE+Ja63Yl7W3SOQjhmPA/Cvl/TNOtmAe5h69q9L8OahbWVmsccYQdsUAbHjWUySyzXMoklPJYnivH9WIkmZweBXYeK9aW4ZoEXJJ65rlVsS8371SxPbtQBH4eyJmdLdp3J4J7Vu6vc6lb2UpnbZGRwqnpTbQvaqsdpGFY96zPERvAjJLPuz2FAHner3ry3TE7jz3qGzJc7nUe2RWw2nGSTc4/StGDTERQzIDjtQBFa2peLdMwRPQVmatDGJAUfI9K2ZtMubtgkXAPGBV+28EX7qHaJmU9TQBwFydwwkZJ+lZk8DqjMwAOK9iXwVKib5IwAO1cLrunpFdFN3APQUAcrp1yqyAPwR1rc+3Rf3mrG1KMQSF06VQ+0PQB39nIxXHNaekXTQXYBHymuUiv3jkGCQuetbEF+hZWJoA9f02USRjcqkMPStKXSZGi8yIgDuprzvRNdEZVWlBX0Nek6PqkE1uN2ShoA5jW9It3h3O5R+nArkb2A2/+pkGB717DPHp17GRHjceMN0rl9W8FRS7pFLR55yvSgDyDVYRMCS241zcsBDnaOhr0fWvCU1m+RcZXPHNcxqekmLlCD6mgDk7ssgwfyqlGN78nFb1xaA5DjIqhcWagZQ4NADSdo+9T4pB96q7RttwMGiGOQN049KALibXJzuz7U3eY2I6/WmSyeVjHBNRTT71AHWgBzs+47SMH3pqynoWINMjX1alWDfJyeKAL0FzJGQR8wrcsblpiNsbbvcViW2IZVVV3Dvmut0tMKJFA47UAXbdlVAJITvqK8gieF2kjNLdXMhI2R4YdxTZLieSPa6/pQBzu8pKwjHA9atJeSp96M49qnlszktzn2FSQWbzjapIYeooAW3u9yHyoWLEUBpCxZkx7VOtjcxL1APtVdoiXIaXmgCpeDzk5BU/Ss6Kxkkc7ScVqvZsAR5+R3BFOgjNuC+7d7YoAx7vTHHJJ/OqElhxnpitS+vJXkO1SBmsi4klyeTQBFJBFtxu5FVHUDpTyrM2T60hjJPJoAjxzTgtGznGau26LgZGT60ANtoAxyVrXtFRXUEDNVhENvykj6U5RJEwKtn60AddaQSGIFGAGKJrl7chcAmueW/ulXAk46cCnxmWU7t5JoA02nAk8zHNV7u8Nyu1RzVNonLEM7fhWlpUUEBzJ19SaAG2VpdMvyx8e9benRTWzc7QM8k05tVgC+XCaqves7Yx8v1oA7K2mWWEKoByOSKqX+oTW52QZwO+ayLeZ3UKgYA+laKW7bASGY9yTQAaeJpX8yQEk9Sa3tPk82bawKqO/WsJrlIlIDsGA6DvT9L1aeKU4jBU+tAHSaleW1qmy2+eTHOa5a7nmmcs+OauSq1zIZJWOD2HFVbgpEpKr09aAI7We2QbZiBitvw1ZLrN95ccDmPpnpXCvNuuw0hVQTgCvZvhbFNvSSaRVjHI7CgDs/DHgCxtttxdwsVGDgDOK2tbu9Is18m2hAZRgg96l1zxxbafpwi8+GNQu07eM143rviuGaWWSOYc9MUAaHivWAyOm5I19AMYFeK+JLq2MzeUcnuat61qc95M5adtpNcrfygkqvHvQBlakTLnGFUevU1mbD6H8q1pICTwSc0fZD/eoAaZSXGAau2d0yMAelZ29lPH5mpo3IGQMUAdEtzFgNnafaus8PeKWtFWNiGToMivN4ZQzYJNX7b1RjQB7lp17FeqJY32N3wa0Gvboo0UMhPYZ5rynQtWeAqhYhSa9BFw0Nos0UyneOc0AZGuzXcDZukEoP92uVvLxJtwWEp9a7szxXEeZgJF9u1ZN9pFpJloScnnFAHDtbJICNoJNVm02Ek7lIrS1Cxa1kZkZsg+tVIpULf6RuzQBiXukEMWh6ZrLkR4XIccD0rtJtuwiJcisS/gyCzD8KAOdkXzG44+tQFWViAKvXFuWH7sEEVWCSR9RzQBGh2uC4qYSL/CcGlTlvnQZqQwjGdtAFiFHG1kcZrd0m8mXh48muaUSqw2q231zWlZvdA5BwKAOsDzkBliUge9XIbrcNssGKyILi48oDIJAqN7y5hkBaI49qANxnii5aIkGsm71Z4JT5Ufyn1FaFpqyOAJYMHFMvYorlSyhQOtAFSHUPNXMqkZpksa53q+M+tIIVBwh5qG4WVmAHzD2oATzJF6MCKrTy5++3NXJ7KVIt+MA1UXTxKu6R8Y96AKc0xKFVHArHuVfd97rWzcQxIhCPlh71jySopwwLUANRdo+Y5oJjwc0gnTn5SfQVBL879CM0AO3Rl8Dg+varkCrt5YZqCK3G0E5GKc21T3NAGjABn7659K0ooYgmZiAK5xGRXDbjWhCVcDLEjPegDoY1sDHjAJqK4iiRf3XH0qpEFC8KM1YilWH5pKACCwMo3lmFPezXI+c9emasx6msq7UUKPenxR+ZKMvge1ADoLeIIMLhvXFP8qCHlmOevSti2soli3SPgVRnjheQ7Mtj0oAu6VeWuQCx49ql1TWI4V2xVkqju3lxIEJ71ow+FA0fm3EhYnsTQBQtLrz24GCfWultox5ICr85HWq2naZDayZ2hgK0pfNkT9wioo9TigCtJGkCF5WLHsKy7u68yJjt47AU3Uo5492+UH/AHay4p5GUqTn8KAKexGuvNYHIPHNdEnie+t7YR27sqj0PSsyDTnuHBKsB+VT3tjDbQZckn0FAGfqOpXV22+aZ3c/7XFUReNGDvOT9abPIOQg2j1NZ9xKqrydzUAF3dyyZ2E1ntFIzEyH9akM/lZL9e1VJrkyZJJxQBIc5KocGm7ZP7xqGC4jUEsOaf8AaR/cagBg/wBs4o87ZyDTHJqNx0oAvRzhhyBV23OCCDxWPGcLV22Y460AdBY3DxuMDOK6K11WeRViYnb0Arj7V2ByCc10GnkswJ5NAHX6JG6Tr56loW9DXb22k2TxFoZDg9iOlcHYSOIeGIx0r0DwcfNZBJ83PegDgPFWnPDORGrNGe+K5O4t1wdw56V7/wCOraGPTmZI1DbeuK8QukUvJketAHPO3lEojZH1p2EZOck0SxqJG4pE4JA6YoAqybUztQZqkAsjHzOMVdl6ms9ydxoAja2RnwjmnyRywr/eFNPByODQ0jbRzQA6K6UffUVeW/hMYAwGrM+91xVKQkEkGgDp4LtQM5FXYb1ZvlODXFpNJ03HFXbORw3DGgDrP3YILEfTNMM8QbGePasdHZl5JNOhJ5PegDSn6bo22Cq0EzpJncSRUbyOY8lqp+Y4bINAGtfX0jxYLYFY2JpGIWUhc1KzFj8xzSooG3A60AQvYkDJck/WoGtFHb860pmKx5BxVNXZjyc0AU2jEbcAZpjsVOSoJqa761WHNAEnmAj5zj2pMZbMfzD1prqPSnRcLxxQApVmxnaKkhZo/Q1HH8zfNzTiACKANbTXkc5dMitKZQyABBWVaMVUgEirQlfA+Y0ATx2sa8sSDV+1mjTO3JqKzUOBu5qxMqpjaMUAWBIZ+ZXKoOeKrvqEELbYzxVe5dhFjJxWRMoEme9AHSW+qD/lhGA396r9tqEzNuuJi3oo4xXJW7spOCRWhpbs7nexPNAHUnVHB2qpPvmnm5BjGA7SemahiRdgOOasgkJxQBUmaRvvjAPY1CJ4YcKijee+K0MBlywBNZFx8lwduBzQBfhmIwELPIe1R6hazzJukY4x0AqTT5G87r+laiu0kD7znigDz+8hZCeAFFZroiuS3Ird1cDziuOM1QmRRGcAUAc7qDhidowM1UtraW7k2RqSKsTjdcENyM11Xh+KMRghBmgCbw/4OWVA0wzkV0H/AAh1p/zwf866Dw4AUOew4rU3GgD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral normal kidneys (arrows) in the second trimester on transverse view. Note that the echogenicity is similar to other abdominal tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27536=[""].join("\n");
var outline_f26_57_27536=null;
var title_f26_57_27537="Osteitis fibrosa cystica findings on skull x-ray";
var content_f26_57_27537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Osteitis fibrosa cystica: Findings on skull x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skull radiograph shows the typical \"salt and pepper\" appearance caused by osteitis fibrosa cystica (A). Skull radiograph of same patient&nbsp;six months after removal of the patient's parathyroid adenoma (B). The bones have returned to normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology, The Essentials, 3rd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27537=[""].join("\n");
var outline_f26_57_27537=null;
var title_f26_57_27538="Patient information: Chickenpox (The Basics)";
var content_f26_57_27538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15375\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/48/34575\">",
"         Chickenpox rash",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/0/14338\">",
"         Patient information: Shingles (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/40/2691\">",
"         Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/12/13507\">",
"         Patient information: Shingles (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chickenpox (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chickenpox-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H394844288\">",
"      <span class=\"h1\">",
"       What is chickenpox?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chickenpox is an infection that causes itchy, red bumps to form on your skin (",
"      <a class=\"graphic graphic_picture graphicRef66287 \" href=\"UTD.htm?33/48/34575\">",
"       picture 1",
"      </a>",
"      ). It is caused by a virus called varicella-zoster virus. This virus can linger in your body for years and later cause a painful rash called &ldquo;shingles.&rdquo;",
"     </p>",
"     <p>",
"      Chickenpox used to be much more common than it is now. Today there is a vaccine (a shot) that helps keep people from getting infected. The vaccine is called the",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844295\">",
"      <span class=\"h1\">",
"       Who should get the varicella vaccine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Almost all children should get a shot of the",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      when they are 12 to 18 months old. Then they should get a second shot when they are 4 to 6 years old. Everyone needs two separate shots for the vaccine to work best. People who have not gotten the second shot can still get sick with chickenpox.",
"     </p>",
"     <p>",
"      Adults who have never had chickenpox and have not had the vaccine should get the vaccine if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Work in healthcare or with small children",
"       </li>",
"       <li>",
"        Are in close contact with people who have trouble fighting infections, such as people with cancer or HIV",
"       </li>",
"       <li>",
"        Live or work in a college, prison, or other place where a lot of people live close together",
"       </li>",
"       <li>",
"        Travel outside the US and Canada",
"       </li>",
"       <li>",
"        Are women younger than 45",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844302\">",
"      <span class=\"h1\">",
"       Who should not get the varicella vaccine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do NOT recommend the",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      for:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Children who have trouble fighting infections",
"       </li>",
"       <li>",
"        Women who are pregnant or plan to become pregnant soon",
"       </li>",
"       <li>",
"        Children and adults who have had chickenpox",
"       </li>",
"       <li>",
"        People who were born before 1980 (most people born before 1980 have had chickenpox even if they don&rsquo;t remember it)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844309\">",
"      <span class=\"h1\">",
"       What are the most common side effects of the varicella vaccine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common side effect is pain where the shot was given.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844316\">",
"      <span class=\"h1\">",
"       What are the symptoms of chickenpox?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you first get chickenpox, you usually:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get a fever",
"       </li>",
"       <li>",
"        Feel sick",
"       </li>",
"       <li>",
"        Get a sore throat",
"       </li>",
"       <li>",
"        Do not feel like eating",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      About a day after these symptoms start, the chickenpox rash shows up. It starts out as groups of small, usually itchy, red bumps. These bumps usually swell with fluid and then pop. After that, the rash dries up and forms a scab. The rash lasts about a week.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844323\">",
"      <span class=\"h1\">",
"       How does chickenpox spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not had chickenpox or the",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      , you can catch chickenpox just by being around someone who is infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844330\">",
"      <span class=\"h1\">",
"       Should I go to the doctor or nurse if I think my child or I have chickenpox?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Do not go to the doctor or nurse without calling first. Your doctor or nurse may be able to tell you what to do over the phone. That way you will not risk infecting other people at the doctor&rsquo;s office.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844337\">",
"      <span class=\"h1\">",
"       Will my child or I need treatment for chickenpox?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You may need treatment, but your child may not. Most young children get over chickenpox on their own without any problems. On the other hand, older children and adults with chickenpox can sometimes have problems. For them, doctors and nurses recommend a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?26/16/26881?source=see_link\">",
"       acyclovir",
"      </a>",
"      (brand name: Zovirax&reg;). It helps people feel better faster.",
"     </p>",
"     <p>",
"      There are also non-prescription medicines you or your child can take to help with symptoms, such as fever and itching. But you should NEVER give",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      to a child who is younger than 18 years old. In children, aspirin can cause a dangerous condition called Reye syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844344\">",
"      <span class=\"h1\">",
"       What should I do if I was near someone with chickenpox?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not had the",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      , call your doctor right away. It might still be possible to avoid getting sick! The varicella vaccine can work even if someone has already been near the virus. People who cannot have the vaccine can get a medicine that can help keep them from getting sick, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844351\">",
"      <span class=\"h1\">",
"       What if I am pregnant and think I may be getting chickenpox?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse right away! Call also if you were near someone with chickenpox or shingles, a painful rash related to the chickenpox virus.",
"     </p>",
"     <p>",
"      Getting chickenpox while you are pregnant can cause problems for you and your baby. But there is a medicine that can help &mdash; if you get it soon enough.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394844428\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/0/14338?source=see_link\">",
"       Patient information: Shingles (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=see_link\">",
"       Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"       Patient information: Shingles (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/57/27538?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15375 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-00EEC62513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27538=[""].join("\n");
var outline_f26_57_27538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844288\">",
"      What is chickenpox?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844295\">",
"      Who should get the varicella vaccine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844302\">",
"      Who should not get the varicella vaccine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844309\">",
"      What are the most common side effects of the varicella vaccine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844316\">",
"      What are the symptoms of chickenpox?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844323\">",
"      How does chickenpox spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844330\">",
"      Should I go to the doctor or nurse if I think my child or I have chickenpox?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844337\">",
"      Will my child or I need treatment for chickenpox?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844344\">",
"      What should I do if I was near someone with chickenpox?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844351\">",
"      What if I am pregnant and think I may be getting chickenpox?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394844428\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/48/34575\">",
"      Chickenpox rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=related_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=related_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/0/14338?source=related_link\">",
"      Patient information: Shingles (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_57_27539="Patient information: High blood pressure emergencies (The Basics)";
var content_f26_57_27539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17188\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/46/5859\">",
"         Patient information: Acute kidney failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/8/9347\">",
"         Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: High blood pressure emergencies (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/high-blood-pressure-emergencies-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28990095\">",
"      <span class=\"h1\">",
"       What is a high blood pressure emergency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A high blood pressure emergency is a serious &ndash; and even life-threatening &ndash; condition that can happen when a person&rsquo;s blood pressure gets much higher than normal. When a person&rsquo;s blood pressure gets very high, it can lead to problems in 1 or more of the following organs:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eyes &ndash; Problems can include bleeding in the back of the eye, or swelling of the nerve that runs from the eye to the brain.",
"       </li>",
"       <li>",
"        Brain &ndash; Problems can include swelling or bleeding in the brain, or a stroke. A stroke is when part of the brain is injured because it goes without blood for too long.",
"       </li>",
"       <li>",
"        Kidneys &ndash; Very high blood pressure can lead to kidney failure, which is when the kidneys stop working.",
"       </li>",
"       <li>",
"        Heart &ndash; Heart problems can include a heart attack, heart failure, or damage to a major blood vessel.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When your doctor or nurse tells you your blood pressure, he or she says 2 numbers. For example, he or she might say that your blood pressure is &ldquo;140 over 90.&rdquo; When people have a high blood pressure emergency, their blood pressure is usually &ldquo;180 over 120&rdquo; or higher.",
"     </p>",
"     <p>",
"      Other terms doctors might use for a high blood pressure emergency are &ldquo;hypertensive emergency&rdquo; or &ldquo;malignant hypertension.&rdquo;",
"     </p>",
"     <p>",
"      Sometimes, a person&rsquo;s blood pressure is much higher than normal, but it hasn&rsquo;t damaged any organs. Doctors call this &ldquo;hypertensive urgency.&rdquo; Hypertensive urgency is not usually treated the same as a high blood pressure emergency.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28990110\">",
"      <span class=\"h1\">",
"       What are the symptoms of a high blood pressure emergency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the organ or organs affected. They can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blurry vision or other vision changes",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Passing out or seizures &ndash; Seizures are waves of abnormal electrical activity in the brain that can make people move or behave strangely.",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Urine that is brown or bloody",
"       </li>",
"       <li>",
"        Pain when urinating",
"       </li>",
"       <li>",
"        Pain in the lower back or on the side of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28990125\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Call your doctor or nurse right away if you have any of the symptoms listed above, especially if you know that you have high blood pressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28990140\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms, do an exam, and check your blood pressure. He or she might use a special light to look in the back of your eyes.",
"     </p>",
"     <p>",
"      Your doctor will also do tests to check how serious your condition is. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        A CT scan or other imaging test of your brain &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        An ECG (also called an &ldquo;electrocardiogram&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in your heart (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28990155\">",
"      <span class=\"h1\">",
"       How is a high blood pressure emergency treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A high blood pressure emergency is treated in the hospital. Your doctor will give you medicines to lower your blood pressure quickly. These medicines usually go into your vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      Your doctor will also treat any problems caused by your very high blood pressure, if they can be treated.",
"     </p>",
"     <p>",
"      People who have a high blood pressure emergency usually need long-term treatment to keep their blood pressure under control. This usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taking medicines",
"       </li>",
"       <li>",
"        Following a low-salt diet that includes a lot of fruits and vegetables",
"       </li>",
"       <li>",
"        Losing weight (if you are overweight)",
"       </li>",
"       <li>",
"        Getting regular exercise",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28990170\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       Patient information: Acute kidney failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"       Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/57/27539?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17188 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27539=[""].join("\n");
var outline_f26_57_27539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28990095\">",
"      What is a high blood pressure emergency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28990110\">",
"      What are the symptoms of a high blood pressure emergency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28990125\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28990140\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28990155\">",
"      How is a high blood pressure emergency treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28990170\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_57_27540="Active trachoma follicles";
var content_f26_57_27540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Active trachoma: follicles and their sequelae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) WHO grade TF (trachomatous inflammation, follicular). To make a diagnosis of WHO grade TF, five or more white or yellow follicles &gt;0.5 mm must be visualized on the upper tarsal conjunctiva. B) Herbert's pits. Herbert's pits are shallow pits in the cornea that form as a result of follicle rupture. They are pathognomonic for trachoma but are not assessed in the current grading scheme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27540=[""].join("\n");
var outline_f26_57_27540=null;
var title_f26_57_27541="Uric acid renal diseases";
var content_f26_57_27541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uric acid renal diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27541/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27541/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27541/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27541/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27541/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27541/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27541/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/57/27541/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three different types of renal disease induced by uric acid or urate crystal deposition: acute uric acid nephropathy, chronic urate nephropathy, and uric acid nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/1\">",
"     1",
"    </a>",
"    ]. The first two disorders will be reviewed here, while uric acid nephrolithiasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE URIC ACID NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute uric acid nephropathy (UAN) is characterized by acute oliguric or anuric renal failure due to uric acid precipitation within the tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This is most often due to overproduction and overexcretion of uric acid in patients with lymphoma, leukemia, or a myeloproliferative disease (such as polycythemia vera), particularly after chemotherapy or radiation has induced rapid cell lysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less frequent causes of UAN include tissue catabolism due to seizures or treatment of solid tumors, primary overproduction of uric acid due to the rare syndrome of severe hypoxanthine-guanine phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome), or hyperuricosuria due to decreased uric acid reabsorption in the proximal tubule, as can occur with a Fanconi-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/1-4\">",
"     1-4",
"    </a>",
"    ] or with exercise in patients with familial renal hypouricemia due to an inherited deficiency in the activity of the urate-anion transporter URAT1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H25#H25\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Lesch-Nyhan syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7177?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypouricemia: Causes and clinical significance\", section on 'Familial renal hypouricemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7177?source=see_link&amp;anchor=H17#H17\">",
"     \"Hypouricemia: Causes and clinical significance\", section on 'Acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;UAN is typically associated with no symptoms referable to the urinary tract, although flank pain can occur if there is renal pelvic or ureteral obstruction. The diagnosis should be suspected when acute kidney injury develops in any of the above settings in association with marked hyperuricemia (plasma uric acid concentration generally above 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 893",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    This is in contrast to most other forms of acute kidney injury in which the plasma uric acid concentration usually is less than 12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (714",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    except for prerenal disease in which there is an increase in proximal sodium and urate reabsorption.",
"   </p>",
"   <p>",
"    The urinalysis in UAN may show many uric acid crystals (",
"    <a class=\"graphic graphic_picture graphicRef61827 graphicRef73642 \" href=\"UTD.htm?23/39/24177\">",
"     picture 1A-B",
"    </a>",
"    ), but can be relatively normal due to no output from the obstructed nephrons. Overexcretion of uric acid can be documented in many patients by a uric acid-to-creatinine ratio",
"    <span class=\"nowrap\">",
"     (mg/mg)",
"    </span>",
"    above 1.0 on a random urine specimen; in comparison, the value is below 0.60 to 0.75 in most other forms of acute kidney injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Release of other intracellular constituents also occurs when there is marked tissue breakdown (as in the tumor lysis syndrome), possibly leading to hyperkalemia, hyperphosphatemia, and hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Hyperphosphatemia may result in acute kidney injury, independent of uric acid precipitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is the best therapy for UAN, which usually occurs as part of the tumor lysis syndrome. Prevention in patients at high risk (eg, high-grade lymphoma and some leukemias) consists of aggressive intravenous hydration and recombinant urate oxidase (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    , which converts uric acid to the much more water soluble end product allantoin) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    (which reduces uric acid formation by blocking xanthine oxidase activity), with rasburicase being preferred. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If prevention is not possible, therapy after the onset of acute kidney injury consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    and an attempt to &ldquo;wash out&rdquo; the obstructing uric acid crystals by increasing the urine output with intravenous fluids and a loop diuretic.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given at this time, particularly if the patient does not have a metabolic acidosis, since it has not been proven effective and may increase the risk of calcium phosphate precipitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/8\">",
"     8",
"    </a>",
"    ]. Hemodialysis can remove the excess circulating uric acid in patients with persistent oliguria or anuria, and is useful in managing the volume status and other complications of acute kidney injury. The prognosis for complete recovery is excellent if treatment is initiated rapidly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC URATE NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic urate nephropathy is a form of chronic kidney disease induced by the deposition of sodium urate crystals in the medullary interstitium. This results in a chronic inflammatory response, similar to that seen with microtophus formation elsewhere in the body, potentially leading to interstitial fibrosis and chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/9\">",
"     9",
"    </a>",
"    ]. Although urate crystals in the renal medulla are demonstrable on biopsy, the clinical features of chronic urate nephropathy are nonspecific: renal functional impairment, bland urinary sediment, mild proteinuria, and serum urate concentrations often higher than expected for the degree of impaired renal function. Thus, it is difficult to separate this disorder from the multiple other causes of renal impairment that can occur in patients with hyperuricemia, such as hypertension and diabetes mellitus.",
"   </p>",
"   <p>",
"    In the 1980s, many patients thought to have chronic urate nephropathy had lead nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, the applicability of this association to current practice in developed countries is uncertain in view of the reductions in population lead exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link\">",
"     \"Lead nephropathy and lead-related nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic urate nephropathy was primarily seen in the past in patients with tophaceous gout [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/12\">",
"     12",
"    </a>",
"    ]. However, it is currently thought to be uncommon and some feel that the diagnosis cannot be made on clinical grounds in the absence of renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/13\">",
"     13",
"    </a>",
"    ]. Others feel that chronic urate nephropathy can be considered in patients who have chronic kidney disease, the above nonspecific clinical features, and hyperuricemia out of proportion to the degree of renal insufficiency, which has been defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater than 9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (535",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the serum creatinine concentration is &le;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (132",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Greater than 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (595",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the serum creatinine concentration is between 1.5 and 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (132 to 176",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Greater than 12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (714",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      with more advanced renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are at least two potential problems with these definitions of hyperuricemia out of proportion to the degree of renal insufficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum creatinine concentration may not be an accurate estimate of glomerular filtration rate (GFR) since it is also determined by muscle mass. As an example, elderly or chronically ill patients may have a marked impairment in GFR with serum creatinine concentrations that are only modestly elevated. Estimation equations have been devised to account for this, but these equations have not been used to define serum urate concentrations higher than expected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"       \"Assessment of kidney function\", section on 'Estimation equations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease often have hypertension treated at least in part with diuretic therapy. The ensuing volume depletion can raise the serum uric acid concentration. Treatment of hypertension with angiotensin inhibition, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      , may lower both the blood pressure and serum uric acid concentration. These issues are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"       \"Diuretic-induced hyperuricemia and gout\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively modest hyperuricemia in chronic kidney disease",
"    <strong>",
"     not",
"    </strong>",
"    due to urate nephropathy may reflect mechanisms that partially compensate for the reduced efficiency of renal excretion: enhanced intestinal uric acid excretion; and decreased production resulting from reduced xanthine oxidase activity. The first mechanism has been demonstrated in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and the second only in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27541/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential role of modest hyperuricemia in the progression of chronic kidney disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H16#H16\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Hyperuricemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial juvenile hyperuricemic nephropathy (FJHN, also called medullary cystic kidney disease type 2) is an autosomal dominant disorder characterized by hyperuricemia and gout early in the course of the disease and by progressive renal impairment. The available evidence suggests that urate crystal deposition in the kidney is not a primary pathogenetic mechanism for the chronic kidney disease in this disorder. Issues related to this disease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link&amp;anchor=H2#H2\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\", section on 'Uromodulin-associated kidney disease (UAKD)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28934988\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute uric acid nephropathy and chronic urate nephropathy are uncommon renal diseases related to the deposition, respectively, of crystals of undissociated uric acid in renal tubules and crystals of monosodium urate in the renal interstitium. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute uric acid nephropathy is characterized by acute oliguric or anuric renal failure due to uric acid precipitation within the tubules. This disorder is usually due to overproduction and overexcretion of uric acid in patients with lymphoma, leukemia, or a myeloproliferative disease, particularly after chemotherapy or radiation has induced rapid cell lysis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute uric acid nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute uric acid nephropathy should be suspected when acute kidney injury develops in an appropriate clinical setting and in association with marked hyperuricemia (plasma uric acid concentration generally above 15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 893",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      The urinalysis in acute uric acid nephropathy may show many uric acid crystals (",
"      <a class=\"graphic graphic_picture graphicRef61827 graphicRef73642 \" href=\"UTD.htm?23/39/24177\">",
"       picture 1A-B",
"      </a>",
"      ), but can be relatively normal. Many patients have a uric acid-to-creatinine ratio",
"      <span class=\"nowrap\">",
"       (mg/mg)",
"      </span>",
"      above 1.0 on a random urine specimen; in comparison, the value is below 0.60 to 0.75 in most other forms of acute kidney injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of acute uric acid nephropathy consists of intravenous hydration, and the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      . Prevention of acute uric acid nephropathy in high risk clinical scenarios is discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevention and treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If prevention is not possible, therapy of acute uric acid nephropathy consists of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      , an attempt to &ldquo;wash out&rdquo; the obstructing uric acid crystals by increasing the urine output with intravenous fluids and a loop diuretic, and, if required, hemodialysis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be given at this time, particularly if the patient does not have metabolic acidosis, since it has not been proven effective and may increase the risk of calcium phosphate precipitation. These issues are discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevention and treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712100#H21712100\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Treatment of established TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic urate nephropathy is a form of chronic kidney disease induced by the deposition of sodium urate crystals in the medullary interstitium. The clinical features of this disorder are nonspecific: renal functional impairment, bland urinary sediment, mild proteinuria, and serum urate concentrations often higher than expected for the degree of impaired renal function. Thus, chronic urate nephropathy is difficult to separate from the multiple other causes of renal impairment in patients with gout, such as hypertension and diabetes mellitus. It is thought to be uncommon and some feel that the diagnosis cannot be made on clinical grounds in the absence of renal biopsy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic urate nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial juvenile hyperuricemic nephropathy (also called medullary cystic disease type 2) is an autosomal dominant disorder characterized by hyperuricemia and gout early in the course of the disease and by progressive renal impairment. The available evidence suggests that urate crystal deposition in the kidney is not a primary pathogenetic mechanism for the chronic kidney disease in this disorder. Issues related to this disease are discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Familial juvenile hyperuricemic nephropathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link&amp;anchor=H2#H2\">",
"       \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\", section on 'Uromodulin-associated kidney disease (UAKD)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987, pp. 418-425.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/2\">",
"      Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/3\">",
"      Crittenden DR, Ackerman GL. Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med 1977; 137:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/4\">",
"      Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/5\">",
"      Kelton J, Kelley WN, Holmes EW. A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med 1978; 138:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/6\">",
"      Monballyu J, Zachee P, Verberckmoes R, Boogaerts MA. Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 1984; 22:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/7\">",
"      Razis E, Arlin ZA, Ahmed T, et al. Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol 1994; 91:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/8\">",
"      Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/9\">",
"      Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/10\">",
"      Batuman V, Maesaka JK, Haddad B, et al. The role of lead in gout nephropathy. N Engl J Med 1981; 304:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/11\">",
"      Craswell PW, Price J, Boyle PD, et al. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int 1984; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/12\">",
"      TALBOTT JH, TERPLAN KL. The kidney in gout. Medicine (Baltimore) 1960; 39:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/13\">",
"      Beck LH. Requiem for gouty nephropathy. Kidney Int 1986; 30:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/14\">",
"      Murray T, Goldberg M. Chronic interstitial nephritis: etiologic factors. Ann Intern Med 1975; 82:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/15\">",
"      Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 1965; 8:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/16\">",
"      Sorensen LF. Gout secondary to chronic renal disease: studies on urate metabolism. Ann Rheum Dis 1980; 39:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27541/abstract/17\">",
"      So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120:1791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7379 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27541=[""].join("\n");
var outline_f26_57_27541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28934988\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE URIC ACID NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC URATE NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28934988\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7379|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/50/11040\" title=\"picture 1A\">",
"      Uric acid crystals in the urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/51/21309\" title=\"picture 1B\">",
"      Uric acid crystals under polarized light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7177?source=related_link\">",
"      Hypouricemia: Causes and clinical significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=related_link\">",
"      Lead nephropathy and lead-related nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_57_27542="Adenomyosis 6a";
var content_f26_57_27542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53441%7EOBGYN%2F66196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53441%7EOBGYN%2F66196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    35-year-old woman with menorrhagia and dysmenorrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal fast spin-echo T2-weighted MR image obtained before embolization shows global uterine enlargement and diffuse adenomyosis. Junctional zone thickness (arrow) is 14 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal spin-echo T2-weighted MR image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 365px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFtAWUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDK+ET+ZpCA9hXdySFWxXnvwgONJUj0ruZHDs3PNdkj5abfO/Upa2oms5R1ODXy/wCLbc2+tXCn++etfUs8e6Fj1FeB/FHSWj1Rp0U7W9PWsKkdbo7cDV5Z2bPPKcqls47DNIVIbGOasQRtyWBAx3rI9tuxWNFKepxSCgZp2kYe2JPvWc/DED1rQs2JtmUfSqEisrkMKbMqd+Z3GU+I4cURxs5wB+NPVWikUsMc4pGjY65jx83r1qvVy4dfLIyM8cVSoFC9tRaVSQQQeabRQUSmVz1Y1p2krYDo2D2rIqzZyFX29jQjOpG8dDv/AA/4jktAoeQ49zXrnhHUpneK5iYsh5POa+eEBZeK9g+EOptsFrOOM8ZreB4+JhZXR9D6fcC4tRLGDuxyK0bTU9kbCY4x61kadA9jEk2MxNzUniBA8CSxcBupFW0eXd3NZL+C53LGw3ViahI+mRTT3txmEDOCayNV1jTdC0/7Q06+YBkjNeC/Ev4nXWtxPZ2UpSI8Eis5TS0R0UaEqj8i/wCNfiNJb6tI+ky4Kt/CeK6n4ZfG+W4vYtP15QEkOBITXzkjMzZdtzHvTnJjcOhIIPBHasmr69T1Pq8bcp99XMYZE1DSpAdw3EBshhVqGW01e12TBd44I6EGvkDwh8WNY0S1W3nkaeIDAyegrqdM+JM9/dGeCVonHJXPWrjUl21PPnhZwb7Hu+pQalpNyJLRy9t/dHYVcttSsvEFq9nOAJcYIPWvNdE+Kc1062l5CCD8u7Ga7GC2tQUvrUlZH54NaJ312OeScdGea+LrG88J6uwcs9hK3X0rkvGvhVdVslvLEAsRnivoPxFpUHiPRWguQPMK/KTXlEdleaBO9ldRs9vnCk+lapdS6dVrrqfPBsrnTNS3bWR0PcVc1K/lvL2FnB+XAxXvd54TsNWjMqIvmnnpWJZ/DDzrnzJYjtU1HsU9Ynb9dvrNanQfCy3SKWCc9SBXvFheq0J5GRXj+i2B0ZCGGAvSup0bU3eKWRm/dqKXLZ2OGcnJ8yNbxR4wj0TS7medgrqCEGa+UzqN1rfiO51Sd2Jlc7QT712fjvVJfEfiD7BHIfJQ/NiuN1pBpOsWcMQxHuGaJLQ6KN0rdT3z4daM8+hnzlwGHevH/jR4MWwu2uoVHXJ4r6P8A3UMnh63CABtozisX4paBHfaPNKVyQKum1JWZzxqzp1Oa58VSKVBHGfSvdf2UtUddVubRnO3qBmvHtbsmtr+VHUqoYjkV2vwC1FdO8exRqwAlGMVx11ynszl7Si7H2heBmj+U4IqSMnyhk84pHbNvu9s0lsSYRmutW0Z4mtz5o+PlpJL4phdV6of6UV6D8VtIW81a2cJn5W6fhRXRZF06rjFK55l8IXH9iL9K7MA72NcN8HHH9jY9q76HmRh2NYyCorTfqOhOYyrVx3jLRY76N9yg/hXZSRlDzxVe4gE3GMipaFFtao+ZrrR3g1ZoSpznANNvtNkt87lOPWvZPEegKNRSRUAJPXFUtf8OLLp+UTLEdqjkVjvWMbaueFTxeW3FRAEkAVv65pUtpIUkXnsaraVpUtzcIoUnJrHlbdj1I148nM2bnhfSPtUBLDIq1rfhRgiNbDJPau08N6SLKzww5xk0+5kCxyORkLXQ0lozyHiJ87lFnm134en0yx86ZevWubum3SYHQV6x4kvY7zw052jcPavJZQd78d6wnvoehg5yqXctyM0UlFQdwUUUUAFPjJEi49aZSr1FAG7avt2/rXsnw+0397BLF3wTivGY0xCH7V798JD5ukpKfvAV0UzxMYrLQ9iivP9Fjt3PAUZrkPGvjeGxs5LKPG7HX0qtrOsHT4pZZH5wcZrw/xFq73k1xPITkk45pSZx0aN3dmF4l1+81C9lD3DmItwueK5+brkcmlmyzlvWkC5GazPYhFRSsOtEMkiqRyas6jCYW2kcYpLL924l2k7a7S00+11/S2MZCXCjvVxS2M6lTllfoefirNpLJbyB0JBHvU95plxbXDRlGbB6gcVLb26yuqfdPcYpctipVItaHUeHPFsVrMgmiBYHrXsekeL47+0jRCAR2FfOFxayQSkhTgd66jwZrotrtRLwuaNU9TkrUYtcyPqPStaivLRY1YCZK2Z7G01WzxOgMi98V5hps9tthvo5sA4yAa9K0a4WOOOY58qQDmtE7bHmzjZlI+FERDJYttcdqm013hzb3cW1hxkjrWvqLvp+25tvmQ9R1qeVYtT08TRY34zxVXuTqcx4m0hr+z8uyH70+lc5eWNxougSLcNscr3r0rTAsEBeU/MODXm3xyu3k0b/RGxjriqVmVG7djy2xthFdSXSHc7Hk03XfD0mobLzbnYc1F4FnF2vkTSAyZr0rVIEs/DcgIGdpxUxaZ0SvBo2fhhqCf2WInIBQVY8UeKLeaZtP3DmsT4WaTJe2TSbiFJrN+KegjRZEv7Zi0g6jNKEeqMnZzszyD4uJDBfRrAACeSa47wXfNpvi7TbnOP3gB57VreM7yXUZklkUgrxXJRMY9TtnyQA68/jWOIu73PawkV7JxP0T0qcXWj28v96MH9Kt2h3RfSue8DTi48H2TKcnygP0re08EQ4brmrpO8Is8WStNowvE9os88LMoJANFbN/CsjJuHTNFdNznktT5c+Do/4k3HWvQLT/XEn1rzr4MEjTyD0NekqoEhxUS6eh1VfjfqW7hRKBimxW/7xRUkaEKCashdpRhUmdzF8T2eGiwvJp62MRsQJAM4rV8SqGW3cCsi9n2mNc4GKVxrWx5v4s8OwXN0Syjg0aB4ZSIh44uB3rf19S0uV5rQ0m4VLEgfeApxdkauUrWOZ8RXC6ZbNnAOK82vNfYxyp/ePFdB8SL2STKjOM84rzG6lPy9jmsJSZ34agpK51k1xv0bYX+9XOSWmV5XI9ac0reSi7jj0rrvDVrHeWqiVQc+oppczNHJ0FdHBSWUgJ2jIqu8bofmUivc4PB0UkG7yxjr0rJ1jwfBInlxR/vPYVTpLoOGYr7SPIOtBUjqMfhXqX/Cu5Y7fzCQpPqKmHgm3NrtlIMnrS9izT+0KfRHkwqW3TfKorsdQ8FXccn7mMunqOKt6T4NnbBkjwfpzQqMrlyxtPlumWvDfg+51WzDhSE68V7V4M01NF0jYQRtHOa0fh7oy2mh4dPmAwOKseJDHZ6NMx+U4NbOyVkeHOrKrKx5F8UNf/eeXC3Hsa8zubxrlVXPPtW7exHXdSmSJuQTgmoLfRY7R3a6kXcnQVi1fU76XLCNupRfSZI7H7RKQoI4HrWfZRo8rCRgqjuTVvVdQluf3Zb90pwAKw4pHeYgHgVDZ1U4SlFtmvaXkcVyY8BkPBzV2W5m0ubzbNyqOM8VjLGBl+N1a+mxHUIHhY5KcimtSJpLXoa+jeJIEydRTdu6tjNWtR0+3nUXunn73PHauL1G3kRGQKQVro/h3qsX72wu2+8CUzTUnF2ZE6S5PaQJ7iynmsWO4FqyLdBbRSl1xIOlbNw91bX0wGDDnI+lRzokltJI+FOKpmcZWOo+H+qSajttJWKoh7mvpTQzDf8Ah4WtqQzxqOR2NfGnhvUpLLUkijODK4X8+K+x/AujT6T4eikVvMmmUMfxohucmLhyu5lWeuy2N42m6twCcKTXUaRDNZXOUO+1l6e1cB8WoCtor/cueoYcHNWfhP4tfUrIWN42Z4+ATVS91+Rz8t43R3t8rrcsq/ccZrznxzaNNDLC+TnoDXpV1OIpI/OGAeAaxPE+kecBdJygGTVxZnF2dz5gt9L1DRdcF1EjeTuyevSvUV1SLxBp62iyBXxgit/UdPguIGURrk8dK8h1i3vPC/ieKYK/2aQjpnAqZRt70TqUvaaPc+g/AVuNN04WsXL96yvib5AjCTyBpD/DmrHw/vw1o94/IK8Vi3Og6j4l8QS3MquLfdhcjinDuYNWlqeSavokN35gCADHFeRapbtb6iY2GAjda+y7jwDDa27yyuM4r5j+J+lpZ65MIBlTn86KseaFzvwNe0+U+pfgRdNc+B7XzG3EKOpr0aFQC2K8Q/Zov3l8L+VK2NnFex6fdrNNIinJU1hh37hy11aq0XZV3EUU8jNFdBm0fI/wfk22Fem237yXNeXfB/5tPIFen2hCuQeKb6ehpV+OXqabkKqikuJSixkdKaWyoPWq91IfLH1qTKxpay4ksoH7Vg6zGHt0aPggVs3BaXSUOOlZ9/Cf7OD9qVhxORucFSGbLVBDMYonAoug3nnnjNPtUErlMdaZqcXryRzxzGavKNTUCc7fu5r2Dxhp728MzDODnFeUXcH70Buuc1jNHo4KSWpBP9yLH96vQvBimO3jZx8tcXcW4RIT3Iziuz8NmR4oogMDFVTW4YqXNBHpNpcSXSLHCcKBzVqS7s9KXzLkhmHrUVjGtlpnmdGxXnPjnVGmjZQxqpNo8+nDndjc8V+NUkKi1xt6cVhxeInZ0ZmGzvXCku8ZJzgVLCxZQgzkGoTd9Tt9hFI+h/BT2mrQrvQHjriu0k8PWa2++CNSx9BXkHw41QWkCQ4Yue9e2aSl2IIndSyPitk2eZVXK9zofD2kJFYruHXtXmnxRzGtzbn5Rg4r2i1Cx26AkDivGvi/Z3LaiZkUmAjk9ql6ip6SufMyX0thdTmHhiSM1kX19KzlmZmZueTW9rti8upyC3jJBPasa90xoGzKME1jJM92jKno2Z0lwzJgcZ61HA22VSO/FTzw/KSMkj86jtV/egvwBUWOxOPLoaIyI81oeGrj7Pqce7lWO003Fu+nt5Z/ejqDW38LrWwuPEKrqZAQcrn1zV6XOGb9yTNLxlZJaWq3IjG2QYNeepMLW+WWM4PX6V7Z8atHLaVDLpZEkCddnPavFI9PeUBjuLDqKqavsLCSj7NuTNyTVXCrI4yCO9WiZNXtA1sAAOoNYLblURuDxU8VzLaqFtnIDdcUttwcFbTcbdRSWdwr9HQggjsRX1j8EPiRb69oUdnfOEurdQp3Hrivlm6D3ECyS/e/nUehanc6NqST2kjIQRuweoqJJp8yInBVYWe6PpT4v6o91cllP7pOhrzHw1rU+jarHexsRFuG7Feg3Qj8QeB/tKEPOU5x64rzKG083S5bXOJlJrd+9E4KdleLPq/T5ovEfh2C5jPLLkEetYv/AAkQtXbTbsZPQE1y/wACNfkOnnSLzIkj+6TXW+JfDourgzQj96OaIe8rPdGE0oysZ1xpl3KwMCfITnNZPibQxqNssFxDmVehxXf6LHMmnKk67WUY5q9bpBKGDopb1Iq07EXZw/g/SXsLIRTkKgOMV6LaRRpAojUAY4wK8m8Sa/Nb+KFsEysRPFep6PKJbCI5ydozUp2lYtK+rMbxaZPs7ANhcV8xePtPS41aQN8x5r6e8ZzxQ2LeawBxxXznr80Euu4yGJNW2kiqV1K6NT4G6n/Zc01lJ8uTwK+gdBtNsj3G7O/mvk+0vG07xdCqHaHavrLwnI0mkQO3dRXPH3ZOJpVjdqRs4opcUVuVDY+Qfgvk2DH3r1CDDOfWvNfguB/Zb7cV6Paf6xqb6ehnW/iS9S7uOzFQMMghjxVnYXXIHSoXXcCO4qDO5qQkNpDL3qqV83TjEw5NLZTBrZoz1FS20RYN7UxbHD6zYtE2V4qpYb4JlJUnNd1qunCZM46VjLYlDtVcn6UItSujJ8S2C3mm5A+YivGdX0RotTRT91jX0VHYSSoEdevtXL+KvCEz3aPDGS3XpScbmlOtydTxLX7aSO8hiVTgAAe9egeEtHk8iKQrzgVsHwXPPexm5iII6ZFdbZ6G9hHtGPxNNLl1LqV+dKKMDWGaOz8v+HHNcRqOlx3sDhRlq9juLHTTYE3sqK31rkdUvvDujWkjtKrN9alyj1IpuX2UeYweHpTA6FD1q0PDZWFWVPmzyKXV/HdsVdNPiJPY1i2vizUpM5Qlc/3elSprodfs6trs+hfhr4Ws7nTFY7TcDtXpluJdNshHdKojTofavlLQ/iXqvh+RJI4mPtWxrXxl17xOsdpa2fk7sDjkmm6jeiOV4WbvJ7H1FZXdpqcBEEymReMA8iuV8XzxDTbiDUJY94yFJPNfPRHi7QpE1FJpvm5ZM8VlazqviXxTdhZWlVT1HSi0l0FGgm78xpX9pHbzzTRupQsea5DxDNGSrDDsfSuph8J6rJarE02R3Oa1bDwbZWhia/UORgnNVyt7m8akYa7nkrRSkb/KYKenFQz2zyKdsbDPTivpa10rw/dLDC0caouM5rq5vCvhL7IjQm3yoGcYqeSHcv684v4T5MsNE1GeMeTBK4+hxWpa+ENceNnit3UgcEHBr6mXT/D32dYrJYtw7jFb2h6LbMmFhRl9cVSjDYylj532PkWPVPEuk2hsr1ZGh6ESKTx9auWTafLZmaRkSbqQa+vNS8E6RqEJSa2XnvivHfH3wNDLLcaI20jnaelV7NfZYliVN++rHj0MWn3aSeaVyOhrl5CI7tkjIIBwCKva1omo6LdyQXcUilTjIziqmn2c95MTCpJTk1k1K9md0Ekm07o0v7NnMAkkOFI4FQWelSXEzpyrY4z3q/Bc37kIYHdI+vFX5NQgadWKmB0GOnenYz5mnZHpXwCaRrfUrHUM+UgO0N9K4bxVdtp3im7+z5Eav0NdL8Brl7vxbcxOx8th379a0vif4OP/AAkjSxofKY5YgdacFeLSOWUlGq+bqX/hjq1u97bTqQkrHB7Zr6DlYRxJPjcMAmvmDwloM11qkaaaWBiOT6V9GeFrm4ltPst6nzIoXPrSSaZz1OVvQ1jKlzAfLOKzJZYrXDTOE56mp/LNvfYXiM1ieIdLm1q8EMLGOJeSavV6GPU5D4x6Yba1tdasBuZGG4r3Fdn4L1uGXQYJ3OAUGT+FU7pEutPm0OdfMZFxk15xe6+vhvTrrT2/1gyEGaUldqRpDX3TX+JOuNqczpZOSqDHBrweznnPivbcMcA45r1XRtMuZPD9xqV1nLgkZ9K8qgVpvEzueMEn9actYnRRsrom8QSf8VdYiL+8MV9e+C3Y6Jah+uwV8YyyNP46s0znEiivtXwzGYtItQR/AKxveqViFaETaFFCnNFbBTfuo+Rvgmc6c46D0r0i04uGA6Zrzf4JHOnSn9a9FsG/0h8etU+noY1vjl6m5CwGQRUc0apFI+KFbjJFWSnnwbF6tUmWxg6Z50ssjICVBro9P+eAkfe71qaPpCWti4IGWFZ9om26kRemaehLlctJF5ibcZJ9qj+yJFPt25etiFFt7feRluwqldTxaTYzalqBChRkA1LkoiV3oht/JaaXZ/aL5kUKM815vqXxk0K11LySm/acZAzXlvxC8cap4u1h7ayLraBioC/xVR8N+CFu78G/Ynvis1zzd9jvhh6cI3qvU7DxP8Z4ZrwfYLZsetcTqnxK1m+ZvKcxr2Fba/D+0m1kxqT5eelaM3gG0sb1cKCOtP2b6s0jOhBaI8zm1zW9QJE9xOQT0BNUbizu7hx5vmEd85NewjR7aK5KJEOB1xWBqukyTXLmFdqjjIo9ki44pJ6Kxzfhfwg19N+8Py967y20O3gt2gt4QzqOoFdH4R8LS2ugy3rA7QOtafhC2kCz3MsYKZ6mtFHl0OarXlN3bPMbbQ2nuXGoQERoeMiui8PaKqatCbCzygI5Arv9btbabTQ6oquxxwK0vBUUdjdWyMo+YjkimjKVSTjYt6iu+2hgvrPYuMZIrltZ0u1tFLIoTPIr2rVbGK9jRXQEjkHFeV+LohP4iSxRSqL1pXMos5QX0UFsQHzJ6Vz2r+III4ysxPmdhWh4itF0/V8A5THSsX+wPt161/OuIV6A0rXOiPLuzmL3V7+5l8mwEm5jgYzXpfhjwrqq6GJLqWRpZBwCa6f4e+GdKS3kv7tVAHTNT3fiJ/7WWCxTMSNwMU7JEzqOWiRl6Z4bv9HVZLp3UOeC1d1bXt1oNqk7kyI3akutXi1iSzs549rBhnFbHitreOzgtkTe2OAB0oepg2+pZ0bxXBfbRKhiJ7mt9LmCbhZEYntmvNLe/t4ZhE1swYCnSRX9y5eyZ4x29qFfoO/c3/FHgbTNbV2kiQSOPSvKLn4R3ulG6k0xVwwJHFdnDqGuaTN/pcjyx56ntWinjjy7diybz0NPmfVDTa0iz5thurvwprLw65bM0DNywFet+HvDXhPxlaxzW4iWQgbhxXVapoWl+N9JZmijWUg9uRXh2saBrXgDVxLYvK1oG5C+lLXeBupqorPRnsd/8Oo/D0AvvD2Flj5IUda6zw9NZ65pQj1CJPteNrButZnwn8W23iLSfLeQeeowysec1s6zoot5mvLM7HQbsDvSUubVbmE04u0iLQPCUek3U88KqC5yK1ZdQfT1LPAducEiue8OeNX1HVGsZ4vKZTjcR1rprrU7P7SLSRQ7MPwovfclqxPI63lvFPD3qr4l1A6XpbTRLl+lX7dVihbbxGOcelNMdvqdswcB16YpoW5zOg3lvdSNcZHnsPmr55+IUrXnxbt7NifKMgyoPFexXo/sfxO8ULHyyOma8m8QWEt18SotQRSQh3E0pp8rRvQspXfY9u12xS38IRwRKFQRjOPpXzH4nnXS9Wd4Tlua+k72/kvfD5icEYXFfM/jayYaq3JO5j05ql/DKw/xu5V8EQtqXjC3uH6K4Y5r7e0NhJpkGOyAV8UfD4PD4oiRQcZGa+0vC7h9KhI/uisIL3zXFatI0VD5OD3oqTGCcUVbWpzpaHyB8EpdmmyD/PSvTtJAeVj715L8HJdmnuPWvX9DCgMe5rXs/IvEaVJepqPgAVdgAjUMKrIm5ualZjnaOlSc+5r2l88ytGOwqtYxhbly3XNGhhfNf1qe0Qy6gyDoDzR5kM1YdiwPcXJ2xR88186fFjx7ceJNYbR9KZhaI21iDwfyrtvjn43/ALJ07+xtOf8A0qYbWx2ryjwrpK2kInuBunk5JPWsl+8l5I7KUFTjzy3Zu+HdBt7dIwEXeRy2K2rHy7bVSuQABVC4uxbooiPzVj27XU+rFsnmtb62Qmr6s1bzWI7PUpGRhuBpBrE106yuGOelc3qGmXUmsdypPNes+G9J046TH523zAB2oS0uwm1HYxLOxuLp1eNCS/tXUf8ACGNJpZKr+9bk8VvWbWGn+WflK1vWGr2ssxRcbcU+ZGEpS6GSLEWfhNbNjhiADWTeXVlp+jJZxbRI/XFbPiWfziBCfk71xeq6Y0l5BMX/AHeeancI+ZPfKq2kAJOM5NT310qPZm14K4zVy9S0ZII/MHQZqjrv2e2iUwOGIFO5S1PSdA1aO5iCu37xRzWJqGnQyXt1fvgsoyK4rw/qxtRJMz8noM1leKvG8tjbOqNkv2zU7BGm29Cvrtp59zJcS8IGPX0qa31DTRYiF5kAHXmuD1jxt9r014I2AmIridJN1ezuskze+TSuzpjQuryPY9c8X28VstpprAqvB296hs/EckEaTx2wZ/pXmKuNPZsgu3XrXU+DvEUE04E8YKr2NCYSpWV0fQng6xS50tdWvo9kpXIHpWdJfTJeS30o3QLnANZo8brNo/2e2QJGoxxWHB4na/gkt9o2LVXucqg9zrtImj1i5kuCgVQcDiu00829rYlm2nFeZeErxpZGgjIVT3rR8RahPp8scMb5Vveh3E46nY3VgmsRHLhVPasrUPBsCaZKtud0mKydH1yWMlXbjHFbem6lcrI8875gHY002hWaPOzqMvh5JIpXMTrnAqhpnxI0PVZnsNcKjPyhmFdj468PxeKJYXtPkUn5mFcV4t+DlpHp4nt5Cs4GSRQ431iawlD7Zhaitp4f1g6j4auz5ZO5lVuK9s8AeKo/EelLucNKBhhXzjpPgHWFuZd7uYRkdetbfws1O58MeNDpl0x8qRuMmokmveNZwjJNJ3Z9EXPh22N0tzABG+eSKu/ZbGzAllAaXpmryRpdQI4Y8jPFZGpQF5415Kqaq99Tk9TdjaMW4MhCoR3OKgZEsojJAAUPJri/i9fT2vhmNLKQpMSMEGqnwz1681OxjsL8lpAvWh6WKtdXRX8TRedqhuW4B71nf2baxMtxwzMeprsfEGmhHCP9096yfEGnx2Oi/aByEGarcUZdCDxPcwaf4eGwrvcYArye40T7Q5urhQSeQDVj+3ZfE2vxWURLQwn5jW5r+23YQ8BVX+lCd9DZJxPONAZLLxI7Mo5bAr6w8IEroELt/EuR+VfKfh23bU/GAhiUlQ/OK+t7GH7Lo8EYGNqCsvtsqs9EWkuGYZxRUlvteIHpRTuZxvY+JPhfcskflg9SK930qILbxkHkivAvhFBJPqK/KdgAr6Fs4/mUDtWq+FM1xelWRqW4+XLdKaAfmapok+TBpshCQn1qTlTLOgAm5cnpUer6rFoMF5dynGAcflVnRl3KMD5mrzP4/wB69naQWUbYknIGAaio7KyLpQ552Z5aXn8VeJ7rVbklolc7AeldE0qQ2bSSnG0cCnaJYR2OlRx7cEjJrIv5Tf6pHYw52bsGmlypRR1SfO79EaOnRy6h86AlRW7oenMdQLt0Qc8V0PhrR1soViZRyuax31FbPVLyFOWAPSqvZ2Mb32IHkhl1K4C4ypxVy1MsGnyNuIPbmuT037R9ruJ2Bwzd67KNll0tFA+ajpqDLenpPc2ytM7Y7c10Wi2wijdmkOcVkPA8WlRlWwaonWTaw4d+SMUMm1zs7WSE6dcmVsuOma5uzv1uy8bsNqk1zNz4hMUE2+TAYetcsNc+yxSyLIctz1qblRptnpWp3VtDGxDgso9a4qfxA1wswXPBwDXGzeJWlZg0h596xr7WpYoWSA4LdTUuR0QoPY7b+2JY4QA5Ofeua8T3shmjZmLL6Vl6TfmTKzyc54yata8ym3UgFj60XuaRp8k7Mo2lv5shmzx2ANWNPvLe0vW8wE5OKqaVZ3l8Sluj49q7rw34GaSVZbxSzdeaai2XUnGKtI5m6mRpi+MIfWq9hdR29/hWG1vSvWtR8CJLa4SMg47CvL/EXhG+0m4LqpMYOQc9KHFoinVhNWZ01pqskcTIpwhFO0fUZI7h1Ukqxya5nR/tM4WOQEDoa67TNPSA5JBY0IymlHQ3bbV5LeVRExQ9yKtaj4hW4jG6TfInesK/sJJISYmw3tWClpOVlQEmWqsZpJnpuhass0Id25ziutur1n0MpCeWHWvBvDWqS2d69pfnYSeCTXrGnThtMIWTdxwKSJqQsz1DwLAh0VDKNz55JrP8c3AtFBB/djrVDwRrubV7diAy1y3xG1t/KljzniqRla7JLrxhZJZCO3QLJ0Y1594xSOO/stZtxlkcFselcQ+rzG+eNmIUmumttQivNJe3lO4gcZpX3TOn2fLqj6W8K6gb7w9aXCHqgBrR1MNLDGkAy55z6VyfwinSXwkkRIJTiu9skBhBPWlHscso+80cj450V77SI8ZZ06ioPh7pqwO0jrtlUYxXcMQSyuBj3rlC8tvr0skQ22uOSKp6oE7Evii9gE6wuwD1y3xV1FNM8CSsWALJgVT8Taja6lrsaW8wLowyAa5X47XoudL03T1b5ndVIBoWjHCN2jG+D2hvFYyapOOZDuyfStnxS8csc8o6gHmt2wSPTPCEEEWAdgrgPFupC00ScsfncECiG12at88yx8BrNbzxJczkbsSH+dfTV23l2xwOg6V4T+z3oM9jZG9l6SndXu7N5gClcisqerbZOIa5rFfTXeSEkjHNFXI0CrhVwKKohI+Pvg5brHCZMDrjNe0WJ4yOteX/AArt9mjxtjrzXp2mZrZ9EXWd5yfmbEYLKDUdwwjTB71JGcHmqV1JmRh1xUGKR0Xh3ZjzG6LXgHxg1Aa38SLaCNswwdR+NeyzX/2Dw5czk7cKcflXznGZbzxBNftk7mIz7VnJXml2OjDqylI6TXLgImyLjC4qx4E8PPfXq3ABLA5zWZdp591DEPvORmvU/C4h0CzV2I3Fa1Wl2xSbS5UZuoX0tpqTQD7yrjFefaLdNeeLb+OYHOa6HVdRafxDJN2OeKxdFkhh8TTSkAFzyalbotJJM3rgQW+nTKBiT6VDp16IrNfN9adqzwiTAIO7nFY2p3MYhVUOAPSi4kjsJ9UE1oADhQK898QawBcHDfdqeTUttkSrdsV51rd47XbYJxn1qJM2o0uZl/Wtce4wiMRjrWT9umZSGYkY6VTdjIeAa6Lw74T1DVnXyYm2nvipScjrahSjqc8zMW4BqxHaXNyv7uN2HsK9z8O/B0tEst5GQcZOa69fBlhpli2Y0+UelX7O25hLGx2ij580TwffXWJGGxf1rvh4Zt4dNAugGPfNaWo69YabJJGhUMp6CuP1nxTJfIyW5wKd0tjNynUd2dR4fj06zOxNg5r0rw5PYGWMMFNfL6avc29xuZz9M11GheNJLS4UyscD3o5hVMPJ6n1yv9nNAC2wDFeMfFBrWW7ZI9uz2qrY+PIru04k6D1rzjxz4ge5vlMUnHfmi5jSovm1Ibq/8mfybdBwcA1Zs7m5guUlum/dE9Ko6GFu7tSwBPrS+LZ2inWFSQAB0peZ08t3ynoFndQTBGRgQRyKuXGi+btubYYPcV47ouuzWV2m9iUzivafC+uxTQx5YENjimpGVSm4anG/EHQJY7SPUI12MvJ7Vd8D6tJJaxq7Z45ya9X8W6TFrHhGQ26ZIUngV4Z4dLWFxLFJnKNim+4oz54tdj1TSnaK+3RNw3pVfxBYC4lZpmyGqnp13tRXzyas67ebbMMTzTXczscRrXhq2SNpYhyec1zOgZ/tCW3yT1GK79J/Ns23cgiuN0mNE12UryWbilI6ISdmmfQvwai2aPMhPINei6U5Mb7uxrznwpL/AGB4We6kGHcfKK7Pwy91caQLicBWkyR9KSRxt+9zIi8XazHYWThWzKRwB61laIt3qGiyvIpBfODTtbisrmTbM26RT0FNsPGGm6bH9jvAYdnAJHBqupKVzz3UPCX9i3UuqG6ZnJyVJrynX9bk1rxVAk7YSFuMmvQviF4oin1GVoZwLQ+9fP8Arep+ZrLy2xIy3BFKo0kd2Foym9T3SbWhPFHbJIDgY4NcH8SLr91b24PLHOBUXw8guLicyzsxU9M1euNDm8S+Oo7NATHEQWx9anm9xjUVCp6H0L8I03eE7VQMEIP5V6DbHI2t1Fcx4F00aXZi2XogxXUDajZ9amCsjim7zuWVGBRTUfIorS6OqnblR80fD+DydCi4/hFd5pQBTNc5odqLbRIB04FdBaOY4FwKtvU5pasvSP8AvMCqE5KsxPXNWA+G3NVW6bMigdCaklaFL4hXJt/BbIpwXFeVW6x2OiJK4G5ua9L+J/8AyL0KfSvKfE0/l6Vbpn5RUbNs6KSukjV0cC41K2lPIzXa+KUli+zMpPlkDiuO8CwG68mT+FSDXoviJkuIIIhjjAq5bEP4jzy9lAvwF4JHNZdkVfWnOcYNbGqQKmokjk1zEZaLX26jJpdTRdS9q+oYvvKDcgVhXF6yuyMxJNXfENuyakjoCd3U1UXRJ7i7EvbHSps2ax5VqyHfLJCUIIB6Vy97C6XZVxk5r0JdHuQgCoT74rX8MfDm61fVI5ZkYpkdqfJcqNeMLs5rwH4Mm1i+hLRkrkHGK+rPBvg+00eyj3QoZAB2qbwh4Ts9Bt0CRr5gHXFb2o38Gn2zSzuFVRmrbUVZHFUqOq7vYq6rc29lbu0jKigV8/8AxM+IEcKy21pICxGODSfFf4gSXCTRWsm1ckDBrw91n1GbczFmb1NZN3OjD0F8UitNeTXl20kzsWY5PNdHpuns9hJIBzisrSrIrqKLMhwDzxXplvZK2nrBbrkuMcU4xOitUUXaJ5X9gnebBU9eak1SCOFE2kh+4r1Kx8HS208ZuVP7w96xfHOgWulTIZmAL9AaHGyCNdSkkcBZ3FwilYmPPpU6Qu10gujgMcnca7jwnpVlPEwADP2q3qHgt9RDNGChXkYoUdAdaPNZkWgafCgjeAg8dqq+L9Buri5S5RTsA5roPAOlSWV20N9ny0PU16YbWxvbdoo1UgDk1XQ5pVHGV0fNOqaWywiSAEkfeA7VZ8HazNp98qys2z3PSvVNX0O1gSbYFANeR+JLP7Fd74yME54qXGx0U6ntFys+tfhnexa54emhODlcfpXjfizRTpfiW4TaQHfIrov2ddb+fyJDwwxXa/FPQvPu0vIkycc4qou6OJr2c2jy2xdhOqMflFQ+JL0+UVycdqb5k0N+yyIQO1Zl/Ddajd7EQhBTLSTZKs7Q6Uzk444qj4Asm1HxAGYEjdUHiK6NrDFZfxHA4r1r4NeFf3aXUi8dSahsuUuWLZ6NZ6GNQtbaGUbbePBIHetC+1q0hb+zbN1M6rt2jtUuoa5aaZdw2JH7yTgY7VmweGrew1R9WMpd3O4g9KtaI5CHSvDxt7uXUNRkO0fNgnivLvjTrGiX0XkWcoWdD1U4rovjH8SbfS9FmsrFh9pkG3IPSvk+7vp7q5aWaRmZiTnNEnyLU6cPh3U97odBrl0h05YlkLMfesbQ/D89/dB9rCPPLEVLo9mL2633L7YU5Yk11K6zCJo7LTFyOhIFZfFud3M6S5YHVaTZiwsy0WBsXtXS/Bm2MmrX2pTpnkgE1yWq3/2HSEhB/fy4H517L8L9IW08LK7Lh5BkmnLpE4JtqLbO408ubSSaMcnpWjYh3iUydaq6WQtntHArTi+4uOlUcqJ0AA7UUISRRTO6nblR4jOojt4IlHQdqt26koBUBjLzLnoKvqAmBjtTOWW4pXchqnKCu0Hrmte1QPzioNTiUKu0c0bEpnN/Er5tDgBrxvxYxaziVRkCvZfiAhOgB2/hFeT2zR3aRiUAruwahK7aOmk+VJnR/DwSQ6cskiFUxXSazeKQhQ1vvpdpB4MiktwA2BnFcrfQp/ZqEEb6uTuzKL5tTMtY2n1ItJyKiv8ASEl1FXRec9qvaUCl0A/etOFCLzBH0osVcpXnh7cIn25PvW7pPhcOVxHkmuv0XRJL+BC64WuvtdPs9HgM0rKoUclqNjFzb2MHRPBlrHCrXEYJ64Iro1XT9Ii+XZHiuW1r4gWMRMenuJGHBINcXresz3oErSHk9M0rthyt7noOp+NbW3YxxYZvWvKvHXi2a43hpSEI6A1SvZgqbyTurhtd864mbJJU9KTRtCCvqc1rqSXk2+M7kJ55qzolpuvolC/IOpq3ZafIz4I+UV0FlHDE6hFG4dSKSR0yqWXKjr/DPg+z1NHO0CTbkGtTwB4bkTxW9pdKWhjORmrnhlgscbQN83fFWLrxPFouspN8u8cN71Zxtyeh0/xMsIbTQ/tkKBfJ9BXyl45199euUPO2Pj617R8TfipY6rosmn2bDzGHzV4NCIlgcN8zHpUM68NDl95nXfDsNbyxufmz2r0NNSki1VY2jxG3HSuU+HNsPsvmyIeOlen6dpaXrpPJDgL0JFUtDGrL3mZGoWkzODFHtV+cgV0Gg2MNnZnzCS78mrt9e2wkS38oKAAM02QJGQwORTMb3Rz3ijS1a0ZoQSxrw/xnYyREkqcA19Iahf2UdmfN64rwb4k6kJJmSBQEJ9KT2N8O3zFj4GXkkXiDYWwowf1r6ltymqTqkoDIor5v+DWkxlftcnEmeK9+8KSyLflCCVPektERibOZmeNvCVoXW5iQIB1xXm2s3UFnG62kYZwMZxX0Jq2nLqFv5TttU9a8l+INrpWmQC0sgkt2/UA5IqzOLs9Tx7w7otz4l8RgyoSqsK+ntDsH0DSI0UDCjBrk/hh4deyg+0zQbXbkEiu51C5N1KLSMcE8motdjqz5iRtPsbwpeXEYMmMhj2rk/H3jC20SwdWcDAq14u1yDRbYReZhlGSM18q/E/xZPrWoyIrsYV4wO9UtFzMdCi6srGP4218axqUs+4lcnGa5uOWMjJYfjVGWRnYk/hUf41zym27n0NPDqEVE0BeOXCREhe9dd4MQR3RnnA2KOprkbCNVcPJ0/pW59ukmC29qpAb5eOpoj5mOIX2Yna2MMniXxNbrbgtDEwzjpX1VoVkLLQYoumFHFeRfBrw8tjZxzTx/vWweRXtUzbLZVz+FaR1fMeLXl9lDLIMLZlHetGyLiMBuar26Awjb1q7bH5MHqKowRaj+7RTUPWig7ab91Hjf/LUVdX7uTVM/60mr3JtqrocstyxYsWBxTNRB+Qd80un7gKlu8PKvqDR2J6nLfEAsNAdSONprwtLswWbYOCGr6F+INqZNBbAzlTXz69hi3nDnGCazu1I66LThqeraBrD33haK3BLcVX1ON444kzWH8Ob+IQGA4O3itrWrkPccdB2rV9zPls2iOM7J0auijEahJsVys1wkdq0meVqxpuqG6tRk5CmkJo9KHjBdG0cyeVuwOK8b8YfELWddleOOWSKEnG0HtXd3jwXegOmMsBzXl1pHFNdSIwHyt0qXuVSSWthNMuZ7cL5mWLHkmutt5XMSuxOMViXcIiVCVwBWukmbFdvXFV0G9WQ6hdbnCZ61i3cEn2xdy/Iatssz3sbbeM1v39iZokeNfmxRYNjF8oW9q8hACgZrE8K6lDfau9tkFi3y12d5pct14YvcjDohxXhfh3UX03XIrj5sRSDOf1qG7OxvRpe0hJrdH0d4ck/s/UZILltuQSua4fxRLPc63cgZK9q6zXyup6LaarYHDBAWIrEi2TAyMAXIwT61bOeOmp5LaQpNq7x3DEfMa1LjTxA2EUsSeKoXltKnilkAPzSZz7Zr2rw34VW7NvcyRho1wTxUJXOurU5LPuje+G2gRxeHVur9dmACAak1/wAVLayxWtinyk4JFdPqEPnWKQRDy7ZRyV4rynWdStLTXkt41Zvm+9jirRwL3m2zsFhutRvrdljbacEnFdLraQ2sUKDBYAZFcrb6/eWrxLCq+WR1xVLXdblS48yd/lI5oCzbNnWprF7BmJUMFr5/8V3qTao6IAQG4rf8T+I2maVLd+ADnBrzuIvd6go3fMzcmok7HZh6TXvM9q+HhZLaLbkfSvonwnAg09Jio3sOpFeD+EbZbSzt+cnAr0jxB4s/srQEgtjiZ1wCO1Ukcs9ZaF7x743jsEax01w143BPpWF4F8Km+uTqerMZHY7huOa5HwxpM2q6ytxdFnLtuJNe2SNZ2VkkKuqnA4zTb6IiTt6mbrfiJNIYWtvbF+MAr0qquopp+ny6jeERsVyA1TreaejvJeKCqchmr59+NPxCF7cS2GmybbdeCVNCstQpU3UkooyfiL46bUNQuPJk3Akgc9K8pu70PIx6sTmqs908hODjPU+tV84OawnPmZ9BQwsaSHPtK5ydxNMozzTkUuwUd6zOvYmti5PHI71618L/AAuLhRfXKcZyua868P6a99qdvaQgsZGGa+odM0qPR9Ht4Cu1to7VUFeVjy8dVt7sTqfDYW3RFVflFdSG88gdhXMaVKn2ZVUZb1rpbDCoCa3seLLcvW77G2npV1QQwI6GsxCZJ+OlaMcoQhTQxIvRjiimqeKKDtp25UeMTOQ/FaAk/wBGx3rMlyZlAq7LlYlAFV0OaW5etM7fapI2USkN1ptid8PFNlw02E+9QQSeIVW40WRTyQtfOWsb0vrmLouTxX0OhaWOWKQcY714L45t3tdWuNvAOazlozow/YpeAC02rNbw5yTXfavpk1tcqJc4PNeY/DbUfsevGRvvda9avNRk1hshfujrWnRM0rK02cxqxURNDGc5qLTLq2sLMm8uIoIh/FIwUfrUlxb/AL9w3LCsPXbC0v8ATZo75gixgsJj1Q+v/wBapvbUIRUpJS2NG6+J+jabaSwWkc19KQQCnyIPxPP6V5ffeKtQnupZbdhahyTiPqPx61gOoDEA5AOM+taPhqy/tDXLO2IyjSAv/ujk/oKxcnJnsRw1KlG9j17SrR7fw3YRTs73Tr5srOctubnB+nA/CtzQUE04RzhR1zVeErJMqHAHSrQgFnKWVhuYcYrdKx4tSXM2zpX0iJ1DQAM1WdcsprCwtpWjK7iK53RPEi6XqSx3jZUt0Nd/4i1a31mwhW3GVXBpsxd09TH8SGOz8Nb48fvUwwr5wuvDl5LcvJbRGSN3OCPc17V4pvpJrB7YZAVcVk/DNPLE7agoKIcruFS43Z0UajpRbRvaRpdxo/w4SK6H71lwAa5aeKe2tosHBY5NdBrfi8avdCyhULBEccVj6yftUsNtB8xY447UzNX+0ZkNpFqniC1tLaLfMSAzAV9LeH/Di2OjRwt9/bzXM/DfwTp+j26ahcrm5Izlu1dfeeKbG3DKHG4UGc5czMy7jMltJaiMrjgtXP6z4S0VNIeaR0+1YyDxnNN1fxlB5xiiYbn715t4w8RXAuQschKnsDTsTCLJ9S1P+z7XYgDMvTNYGr6mb/TX3DEuOlY13qcrzBpRlR2NSSTefbl419qVzpUbHBzSSQyzKwJZuKXw9C8uoqwByDXZafpcUpea5UEU2FLS0umaJRkdAKi2p1OsrNI7LTdS+x26tMeRwFNbelRzazOJrtWEf8INZfgvw1c+ILtLm5BS2Tt0r0iRbKwKxjakcfGatanBOSvZHQ+HdNtNO00zOVD44rjPEF+brUPludqKegNYXxA+IltpulPFayq0xGFUGvn678Zam8shN1JlieB2ouo7mtDCzq6o9c+J/j1Lew/s7T5AZiMMwPSvBb+5aZ2y25m5JzTLm8nupi7sxY8nnmrFtpk8kXmNDIQe+OKylNy0R6tChHDq8tzMwRRVy6tjH0QqR1BqnWbVjsjJSV0KBnoMmnoTETx838qSJwjE4ye1b/g3QZfEOtxQKpKbsyEDjGaQTkoJtnqHwB8LPNcnVrxDsH3Nwr2fWtk8gCnpwBTNCtoNK02GwtUC4XBxVxrUGbca6KceVHzdeq6s3Jj/AAzARKd/TtXSKSC2O1ZNgVR/l4rTgOS3vVI55FrT5fn5PNa8IV/m4yK5+0jYTnng1roxi5HSkI1IzxzRUcMuUyaKDqpyXKjx84WcZHQ1Yuph5YA61VkGZvxpZBnrTWxi1qzS0+YJDnvRG5Fz5mPlqjbE4AzxV2QkJtHemS0WvOBlyFAB4ryn4tacPM82IdRzXq8UX+iA/wAVct460qW40x5dhO0VE0aUpcsj598IxmPWyxwAM16zpl+IYXKqSTwMV5rpVo/9oTZJU7sCvU9EfTtMtY5NSlVEX5nZ+Ao7k1UPhN67vIzLyH7Pby3t4RFFtLFn4AFeK+KfED6ncPFbFls1bIHQufU103xf+IC+LdRFppCNb6Jb/Ki4w07D+Nh6eg/PngR/Dfwi93fW19qduTAcNDG44f0Yj09PX+eTbk7I76NKOHh7SruZvhXwe+rJIbx3gLp+6GOQezEHtW/4F8MXOk6rfyanEY5YcQxnqGzyWHqMAc+5HFehyaS1hqhkxkv2rTj077VPm5bb6Zq1BKxzVMbOakujMdbB7i5hFqpJ4yRXa6Z4Hnvp45pjhVGcGqNtd2Wik7irN2q6PHU9rbSeUn3gQKs4Xd7Hm3j3S1j8WCKNsCPrg1uafrUdjZeWTlsVymsXU97qk1zMT5jniq9zP9g055rhvm7D1qU7I3ceayNHUtcFzOV+6CeSadYfa9TP2TTCeeGK15hqGrz3ExKnaO2K9R+BOotZ3FxcXCllB4JHtRF3ZrUounDmGr4bvrHUVhKtvY/MSK7bwzoQj1SN7gZ24PNdZYQLqd1NqMwCxDpxVPVNRtrSN3hYGQnAwaaORzbNrxh4iSz0wQWh+YDGBXjet69O5CI7GVj0Bq74o1tvsxZsliOlcr4UuIrnUZJ7k8J0BoLhCyuWJLbVGxOXI78msq5mm80tOdxHeuuv79b0sI12oOOKyGsluG2RoxY+1DLTOdubpWALdK0bGXzLYRRDLNXQ6P4BuNTuAsgwvWu0sPBNtp17DC4XfkYpDlOKVjkvDPhO71SUREsN1dxp3wmgtbkS3b984NekWumWug2gum2qFWuS1fxS95LNcpIEgjHBHemlcwc29jP8V65beEtP+z2hVQBgkYrw7xd8Q7i+VobV9oOdzVn/ABD8Ty6zqUyJIzRg461zmg+GNT125AtrdnVj949BUznbRHfh8PFLnqmPf3097IWldnOeuetbPhXwhqGv3aRwRsEJ5fHA/wAa9q8G/BOEKk+qHc/XBGB+VetWfh3T/D9gBbRqCBgcVmouWrLq4+MFy0keV+E/gtZwSxS3rebjnDVteLtA06yhMNtAiqgxwK9P0eCRYGuLjIU9M15v8RrtWdktzy3FbQikec606ktWfO/ieBEvpfL+6DXIN1rtPGsf2KQqSDI+STXGxoXcKOpNY1Nz3sJ/DuySytpLqdYolJZiBxX0h8K/CyaHpQuJ0HnvznFcb8LPBLy3EV5dJgDkAjpXtywgyxwxjCJjpRCN3dnBjcTzvkjsaVhDtRpnHJ6VKh3sc8VKCFQKOgFUZZybjYgrc8s0rePBODV23dYlYsaqWwITrzSSI7HBoJZr6efOOegrSkTAGOazrAeXGoxzWpnKj1qRFqFT5YoqWIYjGaKZTR5IsYY5PWo5V5waWJsDnqKax3Pk8CmW9yaGPagJqVG3SgE9KrSSZQbT0ptvkNuoEb8OQy5+5Wx5VvqNrJbuBgjFcyblmULxV2CSaNRLETx1pNXViGjx/wAa+GH0XUrm5UBLdMuznhQO5NeNeLfFE+sEW8TFbNO3TzD6n29q+mfipolz438LyWOl3hg1CI+Z5JwFucfwMe3t2z19R5B8Ofg5qurLLf65bPaW8TFY7eRSHlYHBJHUKCPx/nlJNaHrYOdKMHVm9UcJ4a0gGSO9v491uDuWNv4/c+38/pXrWl+JU+1RyyKAF4GKbrfha6spHheEgDjOOK5o6fLFMEwetVC0TOvW9u7s9OGrW93qcEshAjqLx9q0NrJB9hblsdK4rVHaKxj8tiHFMlhu76CGRjkLjqa0OZR6kWpXlxPfQgknOCa6mVkSwjXOXxWPBbCW4jVFLSDvitnWPsui6Y1xfuPMxwuaXQe7sjmdYnhs83EzDI/hrgvEGty6lMcfLGvAWoda1OXUrx33Hyy3yj2qC2s3muY4kUlnIArNu+iO+lSVNc0h+jafJqN/DBGpJZgDivqzwT4CgsPDsclwgjJXJ4rlPg74DS2mju7uPIX5ssO9egePfEix27Wdk20IMEqcVaVjixFd1Zcq2OI8Z+KDpsf9m2BwG+XIrkkuZUZZLhyQecE1nXk4uLyR7g52ngmsLUtXIJjRiRnAp3sEKd9BvjHVmubxYLcnHTip/D1nM0iWlupkmk64rLt7NjcLO4LO3QV7x8FPBxW5/tO9Tp93IqS6klCPKi54G+HUm1ZNRUqhAODXeL4O0i0YOsSZHtW3fanBBKLZWHmHsO1V7GUXt60fVYutOxxObbK1vokMLNOoCRgZ4rD0PS01HW5r+4Y+RCflyateNdf2XCaRYHMrf6wj+EV5x8RvHyeHdEOnWDD7QwwxB5qrDjFydkM+N3xEiiVtO0+UbU4bBryO28UX2rwLpdmCrScFq4XUtQudTvSWdpJXPPfqa9x+DngGSJY9QvU/eHkbuwqJTu7I9CVGFCneW4nhv4MC4SO51CXcDyVzjNexeHfD2n6LbpDbQKCoxkAVqKixxBF4A44qRPlXcKFE4Z1pT3ZIpJ4WoLuN7uSONRkA/NT0fgk/L7morvU4rNQsRDu3HFUYieJtViSySytTmXGCB2rxjxhqNpaO32mQbxk9a6fx74htvD9s91K4adxwtfM3inXrjVb+S5mYnceFzwBTclFHbhcO6sir4q1I6jqUj5O3PA9q2Pht4efWdYR2QmGM8/WuWsraW8uVVQSSea+i/hjpVvpumoqJmYjJOOprn1nI9TEVFQp+zjud1p9imn2KxwqA2McVqWMPlxFnHzmq1ojFw0nT0rQDhiVFbpWPCk7iMcKcVDbKDNmi9lWCFj3pumnzI/MBpsRsD5RkUyKQyT47Cq5m3cA1JaEK5PegVjftiMAGre8RgMelZ1u2VFXLceY21+lIksyXvC7V7UUtyiRhADjiilYbPKo+XJNSmPehIFNYBJDU1uctg9KZrJ6lRMbinep1Xyzj1ps6KlwCop87qgBJoAdyTlelH9ptAGTimxS7mA7GopdLaaYupOOuKbFoLbsfNFwhw2a3Td3dqi3XmAqeorn4P3TNE/Fcr4s8Xpo8LRSSZXsKLgoObsj0W71nSbxP9MVAx6k1nSaDoeogtbSxB/Y182a94yu7yVvs7siZ6is3TvFusWFzvhun/E1HNHqdUcHUtdHvet+DY9x2SAjPFVJdDNnaqrthPWvHbn4j60znNyeO2K1NP8bajqlqYLqUjAzuppx7lPDVYq8jv9a1fTPDVj50bCS4I4HXJrxnxJr95r1401y52g/KoPAFLrd9JfyhA5kVaxn+QEVnKR1Yeioq73HISSB6V7H8HfBz6lL9vvITsX7pIriPhp4Zk8R+IIYNpMSsC5r7K0nSLTR9HisbdFVyoHA56VUFZXOfG1re4jNsJIrPS5EiAUgYrx/xzehJXSNsux55r1nxZGulaW7BgCwzXzj4r1ZReu5bLc1V+px0YOTuY2vX4hQorfvCKz9CtRfXG6UnGc1nXBm1K+URgl2OAK9N8G+DpwkKyA5bk1O7O6VqcPM1vBnh2PU9QiBX93H1r1vUfEkGgWy2NiB5ijGBWFa28WgosMOPNI5xWP8AZnOqNdTnf3watHC/eepq+GL281HWZLu+bbGPWrmvfEXTdANwlqym4PU1wniPX7uJJo7SPy1weRxXg+tarNNdytNIxck9TTclHc2oYZ1noeqn4hMmoXNy7F7mbIDA5xXmXiu8vL/UpJZ2Zmc5GewpNBt5b26jEXzHIr3vw98PILqyiub2NS2AeRUOTlsdF4YaVzzX4V+BJtQvoL25jxEpBCkdfevpyziSyto4YgFAGOKy9E02PTItkCAAegrVB39RzRGNjir1nWldlhVY9T1pXuBFwelQmUq2KhlYOeRxVGFiKSS41CfyrfgVZfTIrSEy3J3MozS2ki2yloxye9ZniO9dtNlIJ3Y9aa3H6Hz98bro3OpJtfMakjANeVmAzuo5z0AFdl40Ms+pOJicZOM1Z8J+HPtDrKy59Kzqaux69CoqVMt+B/DgZ0LLl2xz6V754a0SCygRicn0rn/CWgC1jWRwAe1dqq+UoweKcY2OCvVc5akl3jIKDGKrRyBHO6nTOAM5yaz5leVuOlWYpE8xFy+zsaaiSWRAXJSpLbbBjf1NXCVkTDc5oDYiEqsV2nk9auW7hDgjmqUduIZPMxkVfjaOXB6GkJmnA52AgVftlaSVCeKrWO1UGRxV2INJJlOAKRBX16YxTRgHtRVHxCzGePd1ANFbJaDOK+aVwR0qZiQQBxUOnkvErDpUs3OcVkaPdkM2dwI60roXjBaiLOfm6UTEqc/w0DGRhlA+U4Bq+l0xICHHrVJLgyjy1HHrWV4r1iHQ9NkkLDzNpobsCjzOxn+OvFVnpMEiiRftHoDzXz/rusT6tctJOxIzwKZruqTarfy3EzElmyB6VRhieaRUjVmZjwF61i5cx6tCgqauxAwXoM0+OzupclIJGHqEJr2D4e/B+41lILu/3RxMQSK+g9E8BaPp1skf2WNyBjJFHIzOpjYQdonw9/Z12rEtby8/7BroNC8Ia1qUJa1tZFVuMkEZr7JufBOj3Dgm1jGOwFa9ppNjp1ttihjjjQZzgU4wsYzx7a0R8xf8K5Twp4OuNV1sp9pdPlB7V41awyXt4IYgWd2AA+tev/tGeOBrWpjR9NkH2S2OG29C1YHwX8PjUNZSZ48qhwPr3o5bysdEJyp0nVnuz3j4K+EYNE0eK4eMee4ySetelTFLXdczHkdBT9GtUtrGNQuAoFVNWvLbBMxXYnJGa0Z48pOUrvqedfEO5uryN5ZcpCo+UZr5o1+US6lMQS2Dj1r1P4r+OH1HUDpumL8g4+Wuf0DwqJLYy3K7pW5waTR20f3a5mX/AIReEjqcq3bpkA5zXt2k6cItTSFEHAxwKqfCzTBp2lMvlhc9K7fSreOCaSeUqCO5ppHNVqOUmcZ4osBZaoskp+90zXB+JvEltpMhLsD7Va+M/je3TVVhtpBiMckGvnfxDrs2p6gWlY4JwBnpQ2o7nTh8PKqdP4y8c/a9y2abN3U+tcDaWlxqNxlVZiTzW1o/hyfWm/dEAD1r0Lwx4Hns50RuQSMnFZu8md/tKeHhaO4/4XeDLkXa3M6fJ6V75GBHbpEDgKMcVT0iyj03TkiUAPjqBU4BIxnmtIqyPJq1HUldl+BtqcDNNZyuTmo4X2RHFRqxkYluBTMieFSWLOeKldo8YPSosjbkHgVUlcucA96YWLXmgtsXpWN4iJFq49a10CpGv96svWx5kZB70Ia0Z4zqPh0anqRJHOa7bwz4b+w7Ny/KK1tN05EnLsveungRBFhhU2u7m0qjtYqxocBUwFHFSvMEQhuopQPLJP8ADVaT52PpVGW7IBOzz4A4zWmigIDjk1Tt41jkyRV4NnkGgCpeLkjtVqAAItVb5sYzUtvMCqgUMC8mMYboaDCAwMR5pEYEc1PaoDJk9KRJdiZhb7Tw3rWlp3mxpluQaz3O8qqDpWpbSFQkZHNJkmH4lkcXMWR1Boqfxa8cc8G5gCVPU/SitlsSzhPD8gNqVPLCrrD94c1j6IDBqEsbdNx610dzGAAwHasnsmby+JmfnJIoiUTkp6VTuZDDKCTwara94js9D01pZGVXK8UDUW9EVfFWv2ug2bsGXzO1eD+K/EV9rcheVm8nPAqLxV4gm1nUXkZj5WeBmpZp7f8AsaOCJQ0jdTWbfMj0KdL2Vm1qc7bwPcTpFGpZ2OABX0f8IfhPHFHDqWrIHZhuCsOlZPwQ+HSXlwmqX6ZVPmUEV9LW8CwxKiKAqjAApxioo58ViuZ8kNhllaRWsKxQoFReAAKtAUAUtVucIgAHNePfHj4hL4e086VYuDfzrg4PKivUfEOqQ6No9zfXDAJEhbn1xXxe811498ey3E7M6vLkZ6KueBSv0OnD01L3pbI5ttOuruVZZAzPKcknqc19RfBTwcmlaElzKv7xucmuej8FR2tzaCVQFGO1ewQzW+n6KkMThQFxxTirK5WIruaUSXVdXisrJlQ/P0FeL+OvEstvbSBZDvfPGaveMPEyWYZFcvIT0rzDxPcG7ERkY+YzcLmqM6UNdSLwlprXOrNdXS7txyM1694e0sT3aIRhPTFYHgfSAYYmYY4Br0DTLiG3vhGMAikkVVndnVJFDp9uFBCgCvFvit8RZdOd7Syk+cjHBrtvHPiFLCykkeQABT3r5O8WaudS1ea5Zs7m+UZ7UOXKrl4TD+1ldlXWNVnvJnmnkLyOc8mn6Jpx1C4VccnrRpulz6lKPJQnHGa9Q8G+EZICruvzdaxV5O7PSq1Y0o8sdzZ8G+F2tUQoDjrXoFrA0F3GCoxT9ItWhiRSMVeu4ipRhWqPIlNyd2XsGWXnoKru7LKQM4FPDlIgVPOKaOmT1NMzLMciiLnk1ETnIHAqMDkdacGywFAWFZmEZWi3XHLUyc7SDTYpctzTCxe4YgCs/UCNwDdKso37zk1k6ozS3KrHQCRZhRcfLVtCSvXpVS2BQBW64qwwJGF6UimMuJS/7pDTo1EceO9RBQkmc8092560CFxlqdG/UDqKQMOMmo3GxsrQMS4Uv96nWi84ApQcr83WpYlC8imIuwIMDNaECqKzomyBV+FwCKRJoW8Y3ggVpwBfMG4YOKoWjDcD2q+qgOHzxSEedfEu4ZdUhVWIAU9/pRR8SRAdStzvGSpz+lFdKJMbUUNtqjEZHzf1rpYSGtUZucis3xRbgs0qYPOeKtaVN5mnKD1Fc0fhsbT11IrvT4pWEkrhEHNfP3xh1VbvWRaW5PlR+h617V4xllSxfy2I49a+aPFEjvqchYknPWs5s68HG8rsxyMuFUZNer/Cz4e3GuXEU11Eywgg8iuL8A2cF54ht1useWCM5r7V8K2ljaabCtmFAK9RVwhZcxeMruPuIu6DpUGk6fFbW6BVVQDjvWoOlIKcKZ5e+oUdqK4L4veNofCHh2V1YG9lUrEvfNBcIuTsjy39o3x+sv8AxTulyEtn9+yn9K5v4SaONOmjurgDzHIOPauT8HaRP4j1efVNQy6lt+W5ya9U8P6dcyXZdVIhTgYojo7nbVtTh7OJ0XjfW2VoFgYBuOlVW1h007dJLl8dM1T1e0MkpLnJAwKx51+zxNJM3yr2JqkznUUVZreO4me7vD8oORmsA6d/aOtxypzEp4FZeu+JWuJGht2xGpwcV3fgSKOexEz4yozS3NmnFXOphZNIsA5PzbeB+Fc/FrpW8kmkyPStX7FLqkzO7EQoOnauV8TvbQxTLGwDKCCQadzJK7OL+Jni2S+3W6P8vfB/SvK2Ys2T1rT1hpJ7pzyRuNPTR5TbLcYYpXPOXMz3MPGFCnqdz8N2BcKVzz1r6B8P2sQt1bA6CvDfh9YstmJFUhic17f4VuFe2CPwwFbRWh4+Jd5to2JY1Vcp1qMjcMP0p8p+fANFxgRjHWnY5kQyfIBikDkjk1ErFshqEXLHmgZKCd/tQ7BTmkR1DY71HNDIzg4+WgYjbiCzHinRjfgr2pLrIjCrUEAmT7vQ0wLzuFRmJ6Vm2z5leRuanuI3lhJBxUVmgELButALQsxEvlqlZv3eB1qG34VqeR8uaQisd6gs3NTx4Me5utRF95KU8JgAE4FMYEgnOagubooPlXNWCg+tNZEVDuGTQBXS5eQDjFaEEvyDNUreH5yw6elOcMG+WgGascoxxViCVi/PSqFrJhRuFadmFkNIlmnYzBjitSPLYB+7WTbRhXGK3bVSwHHFJsg8c+Kk6xaxCu7+E/0oqL4yJEmu2+WwSh/pRXSXFOx1GsWptolicl8jrWdpFwIJjE/3TXQ2cX2rRYJblt0jKMmuf1KAR3A8sYrn2Y073RW8Vw+bbOV5BFfN3jSDytSYY5Jr6m8gXGmuH5YCvnP4jaXMuqSMFO0GsamjOzBvUj+HulJe6lbrExMpPOK+vPCmniysokZizKo718ifDLU10rVwz/eJ4Br6r8Ea5HfxgM4MhHArpirw0MMZfn1OyFOpopazOVAWCqSegGa+Pvjxrh1/x61ok2be3Owc8A96+kPid4stvC3hu6uJZFE7IVRc8kmviqKW41XWnlOXnnk3evJNS3qjvwcN6j6HtXgK3ikt0gtwFjXqRXrCNZ2mltHbBWk284FeXaSn9h6PDEB/pMgH616H4Zs/+JYZblsk881ppY55u7uY32WWVJJ5uF7ZrzzxVcu6zRI3HTiu+8ZaulvYPFbN7HFeZNi5gd3JJakXDucZHpssm54wSNxJzXrHhALDpCKOGPWuQtP9FLI65Q89K7HwY0d1PtU/IKIqxpVnzKx0k+oDT9OZehYV4V4zv5jeyFZCEfPGa9g8aOgiCL2rwfxpMY74r2A4pTdkXhYKU7GKvzy4969J8H6Yl7CttJyuK8vs5Q0oyOfXNewfDyeKVl2EA5xiopq514xOKSOt07SW0iPbGmYz7V0ugsq5bOPpWzZW0Vxa7XAziqdvYfZblgeFNabaHluVzTiZXO4GnTEhck1WHyvgdKmILcHpQRYrxOGZsilicrIc9Kgucxsewqza7ZIuvNMY2VgkoIHBq3NcDywAKp7PnO7pTZG3MAtIVhzNuarIkwgGBVInj3qzG42AGgYszsIW24qhaSEls9SauORtbms+IHzGA9aYIuhsDFLuITGaiJwuT2p2cx7hTCxCBtlLVJOHdAVNQxZaSpjJt4IpDHQHC4Y8ilkZdvJqBtzAlahUSs3z9DQFi7FIDwtWYxk9Kgt0VF9TVoDgYpCZdjjVlHy1ZiTysbRVa3bA+artoDI4z0oIZpWKFuTW3AQsdZ0ICJxVyEb168UhXPn/AON87f8ACRw88bD/AEoqj8dJPL8TQjP8B/mKK6jppfAj0XwDqg1XQYtxG4DFXNUtSSGxwK+e/BnxEOioUckIOmK2bz4wtMSqqcetYS5ZWdweGqKbstD1GLVTDeGGThOlcn4+tbSaN5VK8iufsfHdjewnzWCy+9ZOuaz/AGu6WNi5LucEg1E43Vh04OMtdDgblJLbUWe13Nhsgiu58AfEGXRtVja8JCDAPNdtovhHSdF0I3GpyxtOy7sMcnNeWap4e+3X9xcWzrHDk4NRGUqbt0OlunWVpH1JoXxK0nUNm64Vcj1q34m+IejaPpklx9pR5MfKoNfH76ReWcZaG5JP+yazdQOoOoNzJIwHAyc1cqkWtjGOCTektDoviP4zuvFurFmdvIU4RM8Vt/DbRoYtQjmuFBYYIBrn/CXhi5ul+3TRMIF5XcOteneCtCuXla4KEJ2qYu7uzWvOMI+zgad0outcj3D92nQV0d/q5it1s7Y8kY4rGvbC5s5HuXQqgHWuei1VEkluJGGVzjmtE7nI43JfF88dpp5SRwZnriodQWOEITyfesPxRrs+o6jIzMfLVuAKxDfuZlYk8Gp5kmdcKDcT0zT54bthFLgEiuk0pINNz5Ljca8oGpEPDJE+0nrVo+InE5HmE4qk1uZyoyOv8Y+IYogULAyV5D4hvGvZzIR+lXdWvGurh5GYkmswASsVNZVJX0O7DU1T95lOyXdJx1rt/B93caTqcTSqwjasHTNNbzN0eCQa9K0XShc26tcKNy9KVNPcMVWT0PVdI1IXFpG8TdRWxIxeJWJ5rznTJZLUeWhOB0FdPomr+axhn4PbNb7nkOJvJhhknml8zDcHiqSyYlKg8HpVgIR3pCE1BS8eRS2QIQVFcSlYyDzUunzq0TAdaBEryZOKaigZ9fWnTJ+6Lr1qKJiYjjrSGhJG2g1LCweP3qAnd1FSx4QZoGDZyQapKSLjAq9K4YcVU4WTJpiJ8ZBU01SVyKceoIokQjDCgYqYXDHrTnUMc0x8lB60ISBg0AOC7TjtQSAe1HUVE7DoeKYFmD5mwKs/c5qlBleQatITIeaQmTiUtgDpWrbXARQFHNZixZX5etatgmEBcUmQzRt2ZlBY8Vt2wHk5HpXPQs0swROFFdDDiOA7iMYpPewj5l+Ps0f/AAlUI3chG/pRXM/H28STxqwU8Kp7+9FdEtz08PTvTTPHTO5XGaSIOzgLn8DUVdp4F0JL6bzp/uL+teeo3PXqzjSjdmVZ6XezANHG5X1Nbek2t9pl0twq5YV6B9ljhASNAABjpVqG1RwFZB+VaRg1seTLEuW6PN9Z1LV9RuAbqSTYOgBOBQ15fSwi3hfYAcE+temS6RbPgMq81k6l4WBO614+lN83UUasNrHPQ6LfNZq4n3t1IrtfB/w6m19EN22FB5rmC97pbhMFkFdRonjq80+ILCwXIqlFS6mVSc/snrl54WstN0COwt1TeMDIFbfhbRYbe0SPaOBzxXnnhHXLrUr0T382Y85wa7HU/FcWn27mAZ461fJY45cz0KHxavbe10h4IceZt5xXytf61LukjViFJr1nxjrJ1O0uZWlyWz3rwPUZSsjAHkk1nJ8rPRwVJT0ZammL555zzVdpApG44qqZii4OC3rmoZHMjEmseY9SNGxpPchVyD09DVX7Y24+lVCaKbkaRpRRPLcu+cHANS2ZJ55qnUsEvlvntS6jlH3bI7DRt0QDHODXomhXyOiLkDiuC8NhbuHy8gsDxXS2mlXikGIEYroizxa6V7HYzMInWRenepLGVZ7xGU4I9DXPSSz20IE/as611aW1vlkU/ITVKxz8tz1q4cKish5HWr9tOZIFYVylnfC6iVw2QRW5o8uSUPSmZtF2Y5BBqlYTeTd7DyrVp3EDS2zmLqBXmF14qXTteFrcgg7sZoQJc2x6yW+QjsaoxTKk5jbvTrO5W5s45I2BDDPFQG3zcByeaRJZbIk46GpgMpVd25HTNShvlFAABgEVWkG6WrbYx71WyBJjHNAyzxtA70wthTmms3IxRIfkNNCGxMXY1IVqG3+cnHWnksh5FIY9sgZFQSozkEUNK5OAKkiJHDCmJEtuDgZq7CoDcVWQ4HNTQHDUhNmnCvzAVd37VC96oLII1DVbsgZm3t0oINTTowoyRya0b9T9idgcYFV7IAsAOlP19zDo9wy9kNEV7yEz4z+Ms8L+L5cHLAEN+dFcl49umu/FN9IzZ/eEfrRUVJ+8z6TDUP3UTnsV6x8NpYhp7DjcK5d/Bg3HF/8A+Qf/ALKtjQNGn0x/3V7uB6gxf/ZVnSkk9R4um6lOyO+lliU7nYDFRPqUBYBGGRXKX9vdzyY+27B6CP8A+vVT+y7nzAwvyMf9Mv8A69a8yPPWFk1c7aHUEZ9rMK2La7RYic5rzqOxud4JvM4/6Z//AF63bFJ+FM4I/wB3/wCvT5kyJYaSN6WOG4D+aBk9OK5e80fypmkTIXNbEEUpmAMwx/u//XrYjtBKoV2B4/u1Lt0IUZLQ4H/hKLiwu1twSiA4NdrZawur6a0Svl8da5rxd4WhlJlSbY/+5n+tZOg2Nzpsx8q8yDxgx/8A16IVLqzNZYbmjzLc0bm3Nva3CTvnOeteTaihNwxUEivW9a0+W6hybraW64T/AOvXJ3HhXfu/0zGc8+V/9lWdQ6sJCUG2zhD79aK68eDP+n//AMg//ZUf8IZ/0/8A/kH/AOyrM9I4+iuw/wCEM/6f/wDyD/8AZUf8IZ/0/wD/AJB/+yoA4+lHWuv/AOEM/wCn/wD8g/8A2VH/AAhn/T//AOQf/sqAMPRtSlsLlGjOMGvR7Pxz5cAzGScYPFc9H4TAjH+l9P8Apl/9ep08OERlPtY+vlf/AF61hPlRwV6UajvYt6n4r+1A4BGe1LaXUd3YZXhhWd/wixJ/4/f/ACF/9lVi08Py2zEpfcenlf8A16pVL7mbwtlodN4S1VhJ5LscV6LpshDK46GvMdJ0swyK4ny3+5j+temaHCxhUM+ePSqUkcVWi09DqrG8CA5GQRXD+MfBNvrVybuL5ZxzxXX2kOMjP6VLDERKfm6+1DszGKlF3RzXhVbiwgFtcZwvAzXQOxzu7VJcWi8nOD9KSOANGQW6e1NSQnBvUhjlVnwatRYNVWtQJVIbH4VeEAAGG/SjmQOmxkvGCOlV5SOverUkXyfe/SmR2YZWLPn8KOZCUGVkctxVjb+7560JAEPB/SnbP9o0cyB02Vom2yYFW2AYA0ySEYyDg062Ungn9Kd0LlYmzuBT1GetSiD/AGv0p6wf7X6UroOVkaqDU0agU7ytq8H9KijjLPy36UXQckidQXkC9q3bNAsYAqjZQDjnn6Vs28eB1pcyIcGXbPaoz3qn40nEHhi8kJ48s1LCGDn5jWH8TndfCdyqtgshGfSqg1zE8jZ8La7J52r3cg5zIf50V0c/hAySs5vvvEt/qff/AHqK5pyvJs+tpxtFI//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal spin-echo T2-weighted MR image obtained three months after embolization shows normal junctional zone thickness (arrow). The patient's symptoms improved significantly after uterine fibroid embolization. Follow-up MR of the pelvis one year later showed no changes from 3-month follow-up study and no evidence of recurrence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27542=[""].join("\n");
var outline_f26_57_27542=null;
var title_f26_57_27543="Pubertal events girls";
var content_f26_57_27543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52047%7EPEDS%2F72046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52047%7EPEDS%2F72046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sequence of puberty in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 498px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequence of events in girls with average timing of pubertal development in the United States. Black girls tend to reach a milestone at a younger age (left-hand side of the bracket) than white girls (right-hand side of the bracket). The median length of time between the onset of puberty (breast tanner stage 2) and menarche is 2.6 years, and the 95th percentile is 4.5 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Biro FM, Huang B, Lucky AW, et al. Pubertal correlates in black and white US girls. J Pediatr 2006; 148:234, and from: Tanner JM, Davies PS. J Pediatr 1985; 107:317.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Sequence of puberty in boys",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 506px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequence of pubertal events in boys with average timing of pubertal development in the United States.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Biro FM et al, Pubertal staging in boys. J Pediatr 1995;127:100; Karpati AM et al, Stature and pubertal stage assessment in American boys: the 1988-1994 Third National Health and Nutrition Examination Survey. J Adolesc Health 2002;30:205-12; Dore E et al. Gender differences in peak muscle performance during growth. Int J Sports Med 2005; 26:274; Neu CM et al. Influence of puberty on muscle development at the forearm. Amer J Physiol Endocrin Metab 2002;283:E103; and Tanner et al. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27543=[""].join("\n");
var outline_f26_57_27543=null;
var title_f26_57_27544="Use of the signal-averaged electrocardiogram in ischemic heart disease";
var content_f26_57_27544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of the signal-averaged electrocardiogram in ischemic heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Sanjiv M Narayan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Michael E Cain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27544/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/57/27544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) leading to sudden cardiac death (SCD) is a common problem in developed countries that is predominantly due to ventricular tachycardia (VT) or fibrillation (VF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The signal-averaged electrocardiogram (SAECG) is a noninvasive technique that enables detection of the substrate for reentrant arrhythmias such as VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It has therefore been applied to the identification of individuals at risk for SCD, particularly in the context of coronary heart disease, healed myocardial infarction, or left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with the substrate for VT, slowed conduction through myocardium &mdash; disrupted by inflammation, edema, fibrosis, or scar tissue &mdash; results in electrical potentials that extend beyond the activation time of normal surrounding myocardium but are too small for detection on the surface ECG. The SAECG uses computerized averaging of ECG complexes, obtained during sinus rhythm, to facilitate the detection of these small microvolt level signals as ventricular late potentials (",
"    <a class=\"graphic graphic_figure graphicRef72380 \" href=\"UTD.htm?19/22/19808\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of the SAECG in patients with CHD will be reviewed here. The potential use of the SAECG in patients with nonischemic heart disease, syncope, cardiac transplantation, and arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENTS WITH PRIOR VENTRICULAR TACHYARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with coronary heart disease (CHD) and sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) will be treated with an implantable cardioverter-defibrillator for secondary prevention of SCD. In such patients, further risk stratification testing including the SAECG is not likely to impact management. Possible roles for the SAECG in such patients would include guidance of adjunctive antiarrhythmic therapy and the identification of patients with chronic stable CHD who might benefit from reperfusion.",
"   </p>",
"   <p>",
"    Among patients with a remote myocardial infarction (MI), SAECG abnormalities are present in up to 93 percent of those with a history of VT, compared to only 18 to 33 percent without prior VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/5\">",
"     5",
"    </a>",
"    ]. This observation has inspired efforts to use the SAECG to predict future arrhythmic risk.",
"   </p>",
"   <p>",
"    Both time-domain and frequency-domain analyses can be performed on a SAECG, although time domain parameters are more commonly measured. Details of the various methods of SAECG analysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities in both time and frequency domain analyses are common in patients with a history of VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Such abnormalities may occur at the terminal QRS, within the ST segment or throughout the entire cardiac cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to time-domain analysis, the predictive accuracy of frequency-domain abnormalities is not affected by bundle branch block [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/9\">",
"     9",
"    </a>",
"    ]. This implies that the physiologic substrate critical to the initiation or maintenance of reentrant arrhythmias is independent of the deranged sequence or total duration of ventricular activation.",
"   </p>",
"   <p>",
"    SAECG abnormalities are less common in patients with a history of VF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In such patients, time- and frequency-domain analyses of the SAECG diverge. Late potentials on the SAECG are demonstrable in only 21 to 65 percent of patients with VF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Conversely, some studies report spectral abnormalities in these patients that may be qualitatively, quantitatively, and demographically similar to those seen in patients with VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION POST MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the reduced rates of arrhythmic events in patients treated with contemporary reperfusion and medical therapies, the utility of the SAECG is likely to be limited in low-risk, unselected post-myocardial infarction (MI) populations. However, further studies may define a clearer role for the SAECG in selected higher-risk post-MI cohorts defined in conjunction with additional risk-stratification tests. The high prevalence of SAECG abnormalities in coronary heart disease patients who have a history of ventricular arrhythmias, particularly ventricular tachycardia (VT), led to interest in the use of the SAECG in risk-stratification for arrhythmic events in patients who had an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies, mostly prior to the widespread use of primary reperfusion therapy, demonstrated correlations between SAECG abnormalities and future arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]. Time-domain analyses were most commonly used, and SAECG abnormalities generally refer to the presence of late potentials.",
"   </p>",
"   <p>",
"    The clinical significance of late potentials can be illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/15-17,23\">",
"     15-17,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late potentials had a negative predictive accuracy of 95 to 99 percent, suggesting that only 1 to 5 percent of individuals recovering from an acute MI with a normal SAECG will experience sustained ventricular arrhythmias or sudden cardiac death (SCD) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Late potentials had a positive predictive accuracy of 14 to 29 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of post-MI patients reported a greater than six-fold increase in arrhythmic events (sustained VT or SCD) in patients with an abnormal SAECG [",
"      <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the absence of late potentials indicates an excellent arrhythmia-free prognosis, their positive predictive accuracy is too low to guide therapy. Another limitation is that many of the above studies were performed before the use of contemporary therapies for acute MI that have been shown to improve outcome and reduce the rates of SCD (eg, rapid reperfusion, beta-blockers, angiotensin converting enzyme inhibitors, statins). Moreover, most SAECG studies were not designed to predict the need for an implantable cardioverter-defibrillator. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Primary reperfusion era'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Combination with other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The positive predictive value of the SAECG is modest, but improves considerably when combined with other risk factors including reduced left ventricular ejection fraction (LVEF), attenuated heart rate variability, high grade ventricular ectopy, or inducible VT on electrophysiologic study (",
"    <a class=\"graphic graphic_table graphicRef53211 \" href=\"UTD.htm?32/40/33419\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/5,18-22\">",
"     5,18-22",
"    </a>",
"    ]. An additional combination that shows promise is that of SAECG with TWA. These tests may complement one another by revealing abnormal conduction and repolarization, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In one series of 102 post-MI patients, the combination of an abnormal TWA study and an abnormal SAECG had a positive predictive value for ventricular arrhythmias of 50 percent (",
"    <a class=\"graphic graphic_figure graphicRef51831 \" href=\"UTD.htm?20/62/21486\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of the SAECG in high-risk patients was best illustrated in the MUSTT trial that enrolled 1925 patients with chronic coronary disease, left ventricular dysfunction, and asymptomatic nonsustained VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/27\">",
"     27",
"    </a>",
"    ]. In this population, an abnormal SAECG (filtered QRS duration &gt;114 ms) predicted a significantly increased risk of arrhythmic death or cardiac arrest, cardiac death, and total mortality. Furthermore, the SAECG was more predictive than results from electrophysiologic testing. The combination of an abnormal SAECG and LVEF &lt;30 percent identified patients at highest risk for arrhythmic or cardiac death (",
"    <a class=\"graphic graphic_figure graphicRef66009 \" href=\"UTD.htm?24/7/24702\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal time at which to obtain the SAECG post-MI is uncertain. Late potentials are present within three hours of an acute MI in up to 52 percent of patients and the incidence increases during the electrically unstable initial 24 to 48 hours post-MI. These abnormalities are more common in patients with a transmural MI, high cardiac biomarker concentrations, and inferior territory infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although their prevalence decreases after this initial phase, late potentials recorded as early as 24 to 72 hours post-MI may portend increased risk for VT and VF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/15\">",
"     15",
"    </a>",
"    ]. At 6 to 14 days post-MI, late potentials are detectable in up to 93 percent of patients who eventually develop VT or VF, particularly in the first six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the optimum time at which to record the SAECG is likely two to three weeks following the index myocardial infarction. This is consistent with the direct correlation reported between post-MI late potentials and inducible ventricular arrhythmias in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The detectability of late potentials falls over time and, when measured five years post-MI, late potentials are no longer seen in up to 50 percent of patients in whom they were detectable early after the infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. It is uncertain whether the arrhythmic risk of these individuals diminishes compared with those in whom late potentials persist. De novo late potentials rarely develop after the first month post-MI in the absence of further ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Frequency domain analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequency domain analyses have also been employed to predict VT in post-myocardial infarction (MI) patients. Abnormalities that predict VT have been described in the magnitude, phase, and spatial characteristics of fast Fourier transform analysis and in the wavelet correlative function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/7,8,30,31\">",
"     7,8,30,31",
"    </a>",
"    ]. The specificity of these abnormalities for VT likely exceeds that of traditional time-domain analyses. In addition, frequency domain abnormalities are not limited by bundle branch block or other restrictions to the application of time-domain approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/9\">",
"     9",
"    </a>",
"    ]. However, clinical studies are required to test these discriminators prospectively in a wider population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regarding the prediction of arrhythmic events, both time and frequency domain analyses have a significant false positive rate. False positives may occur in different patient populations for different reasons (eg, patients with inferior MIs may have more false-positive time domain results, while those with anterior MIs may have more false-positive frequency domain results). It has been suggested that the combined use of time and frequency domain analysis will improve the predictive accuracy of the SAECG in post-MI patients. This hypothesis was evaluated in a study of 602 patients who had a SAECG recorded 10 days post-MI and were followed for one year. The combined use of time domain and frequency domain (using a spectral turbulence technique) analyses resulted in a significantly higher positive predictive accuracy (35.8 percent) compared to the use of either technique alone (19.6 and 18.3 percent, respectively); the negative predictive accuracy for all three methods was the same (98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary reperfusion era",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the data discussed in this topic were generated prior to the widespread use of reperfusion strategies. Among patients treated with thrombolytic therapy or primary percutaneous coronary intervention (PCI), the prevalence of SAECG abnormalities is lower and their predictive value is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/33-40\">",
"     33-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\", section on 'Reperfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a number of mostly observational studies, the prevalence of an abnormal SAECG was lower in patients treated with reperfusion therapies (5 to 24 percent) compared to those treated conservatively (18 to 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/28,35,41-47\">",
"     28,35,41-47",
"    </a>",
"    ]. This was illustrated in a substudy of a randomized trial of thrombolytic therapy in which 310 patients had a SAECG prior to discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/48\">",
"     48",
"    </a>",
"    ]. The incidence of late potentials was 37 percent lower in patients assigned to thrombolytic therapy compared to placebo. It is not known if the lower prevalence is due to reductions in infarct size or restoration of patency in the infarct-related artery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/34,43,45,49,50\">",
"     34,43,45,49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link\">",
"     \"Coronary artery patency and outcome after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although primary reperfusion does not affect the physiologic basis of the SAECG, several studies have reported poor predictive value of the SAECG in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/36,38,39,51,52\">",
"     36,38,39,51,52",
"    </a>",
"    ]. The predictive value of the SAECG in patients treated with contemporary reperfusion and medical therapies was illustrated in a cohort of 1800 acute MI survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/39\">",
"     39",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      99 percent of the patients were treated with primary reperfusion therapy (91 percent primary PCI).",
"     </li>",
"     <li>",
"      The significant majority of patients received recommended medical therapy (99, 93, 90, and 85 percent received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , beta-blockers, ACE inhibitors, and statins respectively).",
"     </li>",
"     <li>",
"      Among 968 patients who had a SAECG, only 90 (9.3 percent) were abnormal.",
"     </li>",
"     <li>",
"      Over a mean follow-up of 34 months, SAECG abnormalities did not correlate with the primary combined end point of cardiac death and arrhythmic events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the SAECG was not a useful risk stratification tool in this unselected population of post-MI patients treated predominantly with primary PCI. However, this was a relatively low-risk cohort with &lt;1 percent annual incidence of the primary endpoint, a mean peak CK of 556",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and an average LVEF of 57 percent.",
"   </p>",
"   <p>",
"    The predictive value of any test is influenced by event rates in the population studied. Thus, the lower incidence of malignant arrhythmias and SCD in acute MI patients treated with primary reperfusion therapies may be responsible for the reduced value of the SAECG in this setting. In contrast, the SAECG may retain predictive value in subsets of post MI patients with other high-risk features (eg, reduced LVEF). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Combination with other risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of SCD stated that evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opinion was not fully established regarding the efficacy of the SAECG, but that it \"may be useful for improving the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk of developing life-threatening ventricular arrhythmias\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     AHA/ACC/Heart",
"    </span>",
"    Rhythm Society (HRS) scientific statement on noninvasive risk stratification stated that routine use of the SAECG to identify patients at high risk for SCD is not adequately supported at this time, a statement with which we agree [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/54\">",
"     54",
"    </a>",
"    ]. However, given the high negative predictive value of this test, it may be useful for the identification of patients at low risk, although a specific clinical setting for this use has yet to be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DETECTION OF ACUTE MYOCARDIAL ISCHEMIA AND REPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of the SAECG in patients with acute ischemia may vary with clinical setting. Consistent changes in the SAECG are not demonstrable during symptomatic angina or myocardial ischemia related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    &nbsp;or exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. In contrast, when comparing SAECGs obtained before, during, and after balloon angioplasty-induced ischemia, progressive reductions in RMS voltage, altered waveform configuration, and prolonged low amplitude voltage (&lt;40 mV) in the terminal QRS complex have been described, although the filtered QRS duration remained unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preoperative SAECG may provide information about functional myocardial recovery after coronary artery bypass surgery. One study of 45 patients with left ventricular ejection fraction less than 36 percent found that those with a normal baseline SAECG had a significantly greater improvement in ejection fraction after surgery than patients with an abnormal SAECG (15 versus 5 percent point increase) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27544/abstract/55\">",
"     55",
"    </a>",
"    ]. All patients whose ejection fraction did not improve or worsened after surgery had an abnormal preoperative SAECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signal-averaged electrocardiogram (SAECG) is a noninvasive technique that enables detection of the substrate for reentrant arrhythmias such as ventricular tachycardia (VT). In patients with the substrate for VT, slowed conduction through myocardium &mdash; disrupted by inflammation, edema, fibrosis, or scar tissue &mdash; results in electrical potentials that extend beyond the activation time of normal surrounding myocardium but are too small for detection on the surface ECG. The SAECG uses computerized averaging of ECG complexes, obtained during sinus rhythm, to facilitate the detection of these small microvolt level signals as ventricular late potentials (",
"      <a class=\"graphic graphic_figure graphicRef72380 \" href=\"UTD.htm?19/22/19808\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with coronary heart disease (CHD) and sustained VT or ventricular fibrillation will be treated with an implantable cardioverter-defibrillator for secondary prevention of sudden cardiac death (SCD). In such patients, further risk stratification testing, including the SAECG are not likely to impact management. Possible roles for the SAECG in such patients would include guidance of adjunctive antiarrhythmic therapy and the identification of patients with chronic stable CHD who might benefit from reperfusion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patients with prior ventricular tachyarrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the reduced rates of arrhythmic events in patients treated with contemporary reperfusion and medical therapies, the utility of the SAECG is likely to be limited in low-risk, unselected post-myocardial infarction (MI) populations. However, further studies may define a clearer role for the SAECG in selected higher-risk post-MI cohorts defined in conjunction with additional risk-stratification tests. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk stratification post MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The positive predictive value of the SAECG is modest, but improves considerably when combined with other risk factors including reduced left ventricular ejection fraction (LVEF), attenuated heart rate variability, high grade ventricular ectopy, abnormal T-wave alternans testing or inducible VT on electrophysiologic study (",
"      <a class=\"graphic graphic_table graphicRef53211 \" href=\"UTD.htm?32/40/33419\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Combination with other risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal time at which to obtain the SAECG post-MI is uncertain, but is likely two to three weeks post-MI. This is consistent with the direct correlation reported between post-MI late potentials and inducible ventricular arrhythmias in animal models. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Time course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although primary reperfusion therapy for MI does not affect the physiologic basis of the SAECG, several studies have reported poor predictive value of the SAECG in such patients. There is a lower incidence of malignant arrhythmias and SCD in acute MI patients treated with primary reperfusion therapies, which may be associated with the reduced value of the SAECG in this setting. Thus, the SAECG is not a useful risk stratification tool in unselected populations of post-MI patients treated with primary reperfusion therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Primary reperfusion era'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 2008",
"      <span class=\"nowrap\">",
"       AHA/ACC/Heart",
"      </span>",
"      Rhythm Society (HRS) scientific statement on noninvasive risk stratification stated that routine use of the SAECG to identify patients at high risk for SCD is not adequately supported at this time, a statement with which we agree. However, given the high negative predictive value of this test, SAECG may be useful for the identification of patients at low risk, although a specific clinical setting for this use has yet to be identified. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recommendations of others'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/1\">",
"      El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone. Circulation 1977; 55:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/2\">",
"      El-Sherif N, Hope RR, Scherlag BJ, Lazzara R. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 2. Patterns of initiation and termination of re-entry. Circulation 1977; 55:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/3\">",
"      de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988; 77:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/4\">",
"      Pogwizd SM, Hoyt RH, Saffitz JE, et al. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 1992; 86:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/5\">",
"      Signal-averaged electrocardiography. J Am Coll Cardiol 1996; 27:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/6\">",
"      Cain ME, Ambos HD, Witkowski FX, Sobel BE. Fast-Fourier transform analysis of signal-averaged electrocardiograms for identification of patients prone to sustained ventricular tachycardia. Circulation 1984; 69:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/7\">",
"      Cain ME, Ambos HD, Markham J, et al. Diagnostic implications of spectral and temporal analysis of the entire cardiac cycle in patients with ventricular tachycardia. Circulation 1991; 83:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/8\">",
"      Kavesh NG, Cain ME, Ambos HD, Arthur RM. Enhanced detection of distinguishing features in signal-averaged electrocardiograms from patients with ventricular tachycardia by combined spatial and spectral analyses of entire cardiac cycle. Circulation 1994; 90:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/9\">",
"      Lindsay BD, Markham J, Schechtman KB, et al. Identification of patients with sustained ventricular tachycardia by frequency analysis of signal-averaged electrocardiograms despite the presence of bundle branch block. Circulation 1988; 77:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/10\">",
"      Lindsay BD, Ambos HD, Schechtman KB, et al. Noninvasive detection of patients with ischemic and nonischemic heart disease prone to ventricular fibrillation. J Am Coll Cardiol 1990; 16:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/11\">",
"      Denniss AR, Ross DL, Richards DA, et al. Differences between patients with ventricular tachycardia and ventricular fibrillation as assessed by signal-averaged electrocardiogram, radionuclide ventriculography and cardiac mapping. J Am Coll Cardiol 1988; 11:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/12\">",
"      Martinez-Rubio A, Shenasa M, Borggrefe M, et al. Electrophysiologic variables characterizing the induction of ventricular tachycardia versus ventricular fibrillation after myocardial infarction: relation between ventricular late potentials and coupling intervals for the induction of sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1993; 21:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/13\">",
"      Freedman RA, Gillis AM, Keren A, et al. Signal-averaged electrocardiographic late potentials in patients with ventricular fibrillation or ventricular tachycardia: correlation with clinical arrhythmia and electrophysiologic study. Am J Cardiol 1985; 55:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/14\">",
"      Simson MB. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 1981; 64:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/15\">",
"      McGuire M, Kuchar D, Ganis J, et al. Natural history of late potentials in the first ten days after acute myocardial infarction and relation to early ventricular arrhythmias. Am J Cardiol 1988; 61:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/16\">",
"      Kuchar DL, Thorburn CW, Sammel NL. Late potentials detected after myocardial infarction: natural history and prognostic significance. Circulation 1986; 74:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/17\">",
"      Denniss AR, Ross DL, Richards DA, Uther JB. Changes in ventricular activation time on the signal-averaged electrocardiogram in the first year after acute myocardial infarction. Am J Cardiol 1987; 60:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/18\">",
"      Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987; 9:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/19\">",
"      el-Sherif N, Denes P, Katz R, et al. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. J Am Coll Cardiol 1995; 25:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/20\">",
"      Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/21\">",
"      Denniss AR, Richards DA, Cody DV, et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986; 74:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/22\">",
"      Pedretti R, Etro MD, Laporta A, et al. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993; 71:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/23\">",
"      Steinberg JS, Regan A, Sciacca RR, et al. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol 1992; 69:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/24\">",
"      Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol 2000; 36:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/25\">",
"      Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006; 47:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/26\">",
"      Ikeda T, Sakata T, Takami M, et al. Combined assessment of T-wave alternans and late potentials used to predict arrhythmic events after myocardial infarction. A prospective study. J Am Coll Cardiol 2000; 35:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/27\">",
"      Gomes JA, Cain ME, Buxton AE, et al. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation 2001; 104:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/28\">",
"      Turitto G, Risa AL, Zanchi E, Prati PL. The signal-averaged electrocardiogram and ventricular arrhythmias after thrombolysis for acute myocardial infarction. J Am Coll Cardiol 1990; 15:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/29\">",
"      Kuchar DL, Rosenbaum DS, Ruskin J, Garan H. Late potentials on the signal-averaged electrocardiogram after canine myocardial infarction: correlation with induced ventricular arrhythmias during the healing phase. J Am Coll Cardiol 1990; 15:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/30\">",
"      Arthur RM, Kavesh NG, Ambos HD, Cain ME. Phase and group-delay characteristics of signal-averaged electrocardiograms from patients with ventricular tachycardia. IEEE Trans Biomed Eng 1995; 42:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/31\">",
"      Reinhardt L, M&auml;kij&auml;rvi M, Fetsch T, et al. Predictive value of wavelet correlation functions of signal-averaged electrocardiogram in patients after anterior versus inferior myocardial infarction. J Am Coll Cardiol 1996; 27:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/32\">",
"      V&aacute;zquez R, Caref EB, Torres F, et al. Improved diagnostic value of combined time and frequency domain analysis of the signal-averaged electrocardiogram after myocardial infarction. J Am Coll Cardiol 1999; 33:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/33\">",
"      Pedretti R, Laporta A, Etro MD, et al. Influence of thrombolysis on signal-averaged electrocardiogram and late arrhythmic events after acute myocardial infarction. Am J Cardiol 1992; 69:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/34\">",
"      Zimmermann M, Adamec R, Ciaroni S. Reduction in the frequency of ventricular late potentials after acute myocardial infarction by early thrombolytic therapy. Am J Cardiol 1991; 67:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/35\">",
"      Gang ES, Lew AS, Hong M, et al. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 1989; 321:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/36\">",
"      Hohnloser SH, Gersh BJ. Changing late prognosis of acute myocardial infarction: impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. Circulation 2003; 107:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/37\">",
"      Malik M, Kulakowski P, Odemuyiwa O, et al. Effect of thrombolytic therapy on the predictive value of signal-averaged electrocardiography after acute myocardial infarction. Am J Cardiol 1992; 70:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/38\">",
"      Savard P, Rouleau JL, Ferguson J, et al. Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997; 96:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/39\">",
"      Bauer A, Guzik P, Barthel P, et al. Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era. Eur Heart J 2005; 26:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/40\">",
"      Denes P, el-Sherif N, Katz R, et al. Prognostic significance of signal-averaged electrocardiogram after thrombolytic therapy and/or angioplasty during acute myocardial infarction (CAST substudy). Cardiac Arrhythmia Suppression Trial (CAST) SAECG Substudy Investigators. Am J Cardiol 1994; 74:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/41\">",
"      Eldar M, Leor J, Hod H, et al. Effect of thrombolysis on the evolution of late potentials within 10 days of infarction. Br Heart J 1990; 63:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/42\">",
"      Tranchesi B Jr, Verstraete M, Van de Werf F, et al. Usefulness of high-frequency analysis of signal-averaged surface electrocardiograms in acute myocardial infarction before and after coronary thrombolysis for assessing coronary reperfusion. Am J Cardiol 1990; 66:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/43\">",
"      Aguirre FV, Kern MJ, Hsia J, et al. Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction. Am J Cardiol 1991; 68:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/44\">",
"      Santarelli P, Lanza GA, Biscione F, et al. Effects of thrombolysis and atenolol or metoprolol on the signal-averaged electrocardiogram after acute myocardial infarction. Late Potentials Italian Study (LAPIS). Am J Cardiol 1993; 72:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/45\">",
"      Hermosillo AG, Dorado M, Casanova JM, et al. Influence of infarct-related artery patency on the indexes of parasympathetic activity and prevalence of late potentials in survivors of acute myocardial infarction. J Am Coll Cardiol 1993; 22:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/46\">",
"      de Chillou C, Sadoul N, Brian&ccedil;on S, Aliot E. Factors determining the occurrence of late potentials on the signal-averaged electrocardiogram after a first myocardial infarction: a multivariate analysis. J Am Coll Cardiol 1991; 18:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/47\">",
"      Karam C, Golmard J, Steg PG. Decreased prevalence of late potentials with mechanical versus thrombolysis-induced reperfusion in acute myocardial infarction. J Am Coll Cardiol 1996; 27:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/48\">",
"      Steinberg JS, Hochman JS, Morgan CD, et al. Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. Circulation 1994; 90:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/49\">",
"      Ragosta M, Sabia PJ, Kaul S, et al. Effects of late (1 to 30 days) reperfusion after acute myocardial infarction on the signal-averaged electrocardiogram. Am J Cardiol 1993; 71:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/50\">",
"      Boehrer JD, Glamann DB, Lange RA, et al. Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction. Am J Cardiol 1992; 70:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/51\">",
"      Hohnloser SH, Franck P, Klingenheben T, et al. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. Circulation 1994; 90:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/52\">",
"      Kawalsky DL, Garratt KN, Hammill SC, et al. Effect of infarct-related artery patency and late potentials on late mortality after acute myocardial infarction. Mayo Clin Proc 1997; 72:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/53\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/54\">",
"      Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008; 118:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/55\">",
"      Cook JR, Flack JE, Gregory CA, et al. Influence of the preoperative signal-averaged electrocardiogram on left ventricular function after coronary artery bypass graft surgery in patients with left ventricular dysfunction. The CABG Patch Trial. Am J Cardiol 1998; 82:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/56\">",
"      Turitto G, Caref EB, Zanchi E, et al. Spontaneous myocardial ischemia and the signal-averaged electrocardiogram. Am J Cardiol 1991; 67:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/57\">",
"      Turitto G, Zanchi E, Risa AL, et al. Lack of correlation between transient myocardial ischemia and late potentials on the signal-averaged electrocardiogram. Am J Cardiol 1990; 65:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/58\">",
"      Block P, Debels M, Goosens C, et al. Detection of late potentials on the averaged QRS signal recorded at rest and during a standardized stress test after acute myocardial infarction. J Electrocardiol 1990; 23 Suppl:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/59\">",
"      Caref EB, Goldberg N, Mendelson L, et al. Effects of exercise on the signal-averaged electrocardiogram in coronary artery disease. Am J Cardiol 1990; 66:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/60\">",
"      Lenihan DJ, Coyne E, Feldman B, et al. Frequency of late potentials on signal-averaged electrocardiograms during thallium stress testing in coronary artery disease. Am J Cardiol 1992; 70:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/61\">",
"      Rubin DA, Sorbera C, Cook J, et al. Reversible late potentials due to ischemia. Pacing Clin Electrophysiol 1992; 15:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27544/abstract/62\">",
"      Abboud S, Cohen RJ, Selwyn A, et al. Detection of transient myocardial ischemia by computer analysis of standard and signal-averaged high-frequency electrocardiograms in patients undergoing percutaneous transluminal coronary angioplasty. Circulation 1987; 76:585.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 985 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27544=[""].join("\n");
var outline_f26_57_27544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENTS WITH PRIOR VENTRICULAR TACHYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK STRATIFICATION POST MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Combination with other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Time course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Frequency domain analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary reperfusion era",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DETECTION OF ACUTE MYOCARDIAL ISCHEMIA AND REPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/985|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/22/19808\" title=\"figure 1\">",
"      Positive SAECG following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/62/21486\" title=\"figure 2\">",
"      TW alternans and late potentials predict arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/7/24702\" title=\"figure 3\">",
"      Positive SAECG predicts outcomes with NSVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/40/33419\" title=\"table 1\">",
"      SAECG and VT after MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=related_link\">",
"      Clinical applications of the signal-averaged electrocardiogram: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=related_link\">",
"      Prognosis of nonsustained VT in the presence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=related_link\">",
"      Technical aspects of the signal-averaged electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_57_27545="Port wine stain midline demarcation";
var content_f26_57_27545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83601%7EDERM%2F59124%7EDERM%2F73978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83601%7EDERM%2F59124%7EDERM%2F73978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Port wine stain in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain in the V2 distribution is present on the face of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain, represented by an erythematous patch, is present in the V2 distribution on the face of this child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27545=[""].join("\n");
var outline_f26_57_27545=null;
var title_f26_57_27546="Management of postoperative pain";
var content_f26_57_27546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of postoperative pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Bhavani-Shankar Kodali, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Jasmeet S Oberoi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/57/27546/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/57/27546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of postoperative pain relieves suffering and leads to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Pain control regimens should not be standardized; rather, they are tailored to the needs of the individual patient, taking into account medical, psychological, and physical condition; age; level of fear or anxiety; surgical procedure; personal preference; and response to agents given.",
"   </p>",
"   <p>",
"    The major goal in the management of postoperative pain is minimizing the dose of medications to lessen side effects while still providing adequate analgesia. This goal is best accomplished with multimodal and preemptive analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multidisciplinary team approach (eg, acute pain service) is useful for formulating a plan for pain relief, particularly in complicated patients, such as those who have undergone extensive surgery, chronically use narcotics, or have medical comorbidities that could increase their risk of analgesia-related complications or side effects.",
"   </p>",
"   <p>",
"    This topic discusses the management of acute surgical pain. The management of chronic pain is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=see_link\">",
"     \"Evaluation of chronic pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGICAL PAIN MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical pain is due to inflammation from tissue trauma (ie, surgical incision, dissection, burns) or direct nerve injury (ie, nerve transaction, stretching, or compression) (",
"    <a class=\"graphic graphic_figure graphicRef56118 \" href=\"UTD.htm?26/16/26884\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/5\">",
"     5",
"    </a>",
"    ]. The patient senses pain through the afferent pain pathway (",
"    <a class=\"graphic graphic_figure graphicRef74589 \" href=\"UTD.htm?19/43/20146\">",
"     figure 2",
"    </a>",
"    ) which can be altered by various pharmacologic agents.",
"   </p>",
"   <p>",
"    Tissue trauma releases local inflammatory mediators that can produce augmented sensitivity to stimuli in the area surrounding an injury (hyperalgesia) or misperception of pain to non-noxious stimuli (allodynia) (",
"    <a class=\"graphic graphic_figure graphicRef53674 \" href=\"UTD.htm?19/18/19748\">",
"     figure 3",
"    </a>",
"    ). Other mechanisms contributing to hyperalgesia and allodynia include sensitization of the peripheral pain receptors (primary hyperalgesia) and increased excitability of central nervous system neurons (secondary hyperalgesia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analgesic therapy has traditionally targeted central mechanisms involved in the perception of pain using opioids (",
"    <a class=\"graphic graphic_figure graphicRef60488 \" href=\"UTD.htm?21/29/21983\">",
"     figure 4",
"    </a>",
"    ); however, it has become clear that a better approach uses several agents, each acting at different sites of the pain pathway. This approach lessens the dependence on a given medication and mechanism.",
"   </p>",
"   <p>",
"    Pain receptor activity can be directly blocked (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) or anti-inflammatory agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal anti-inflammatory agents) can be used to diminish the local hormonal response to injury, thus indirectly decreasing pain receptor activation.",
"   </p>",
"   <p>",
"    Some analgesic agents target the activity of neurotransmitters by inhibiting or augmenting their activity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , paracetamol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef76587 \" href=\"UTD.htm?0/32/516\">",
"     figure 5",
"    </a>",
"    ). Neurotransmitters are responsible for carrying electrical signals across the gap junctions between neurons. To produce analgesia, the activity of several neurotransmitters is targeted, including substance P, calcitonin gene-related peptide, aspartate, glutamate, and gamma-aminobutyric acid (GABA).",
"   </p>",
"   <p>",
"    Synergism between medications decreases the dosages needed and helps avoid the unwanted effects associated with the higher doses that would be required if only a single agent was used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREEMPTIVE ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive analgesia is the administration of analgesics prior to onset of noxious stimuli. Preemptive analgesia modifies peripheral and central nervous system processing of noxious stimuli, thereby reducing hyperalgesia and allodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Preemptive analgesia reduces postoperative opioid use and opioid side effects.",
"   </p>",
"   <p>",
"    Effective preemptive analgesic techniques use multiple pharmacological agents to reduce nociceptor (pain receptor) activation by blocking or decreasing receptor activation, and inhibiting the production or activity of pain neurotransmitters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Local",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetic can be injected prior to surgical incision and may promote preemptive analgesia. A meta-analysis of randomized trials found significantly decreased analgesic consumption and increased time to first rescue analgesic request, but no significant differences in postoperative pain scores in patients who had preemptive local anesthetic wound infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/8\">",
"     8",
"    </a>",
"    ]. Some randomized trials have shown that local anesthetic injection around small incision sites reduces postoperative somatic pain, but is inadequate for visceral pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/8-12\">",
"     8-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;For preemptive analgesia, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    800 mg (orally),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    30 mg (intravenously), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    600 mg (orally). COX-2 inhibitors are also gaining acceptance for preemptive analgesia but have precautions for their use. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Oral nonsteroidal anti-inflammatory drugs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'COX-2 inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/13-15\">",
"     13-15",
"    </a>",
"    ] have demonstrated decreased postoperative narcotic requirements.",
"   </p>",
"   <p>",
"    The effect of preemptive analgesia using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is more variable. In multiple randomized trials, gabapentin (also",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) in doses ranging from 300 to 1200 mg orally one hour before surgery reduced postoperative opioid usage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/4,16-22\">",
"     4,16-22",
"    </a>",
"    ]; however, two trials reported it was not useful in spinal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six of seven randomized trials reported preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      administration decreased analgesic requirements by at least one-third during the first 24 postoperative hours. The remaining trial found the analgesic requirement significantly reduced for postoperative days 2 through 10 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/4,16-22\">",
"       4,16-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other randomized trials of patients undergoing spinal surgery did not find a benefit. Patients undergoing lumbar discectomy showed no additional postoperative benefit from using more than 600 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      for preemptive analgesia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/23\">",
"       23",
"      </a>",
"      ]. In a double-blinded, placebo-controlled trial, preemptive gabapentin was not effective in reducing postoperative pain and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      requirements in patients undergoing lumbar laminectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NEURAXIAL (REGIONAL) ANALGESIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intraoperative epidural or intrathecal opioid injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative administration of epidural or intrathecal opioids reduces the need for systemic opioids postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/25-37\">",
"     25-37",
"    </a>",
"    ]. For major abdominal surgeries with extensive incisions, epidural infusions with local anesthetic provide superior pain relief as compared with conventional parenteral narcotics. With less extensive surgery, however, intrathecal narcotics alone can be used for postoperative analgesia. A single dose of intrathecally (spinal) administered narcotic can provide substantial pain relief up to 18 to 24 hours postoperatively. Neuraxial analgesia is also suitable for those patients who are chronically dependent on narcotics for pain relief.",
"   </p>",
"   <p>",
"    Delayed respiratory depression due to rostral spread of opioids to the respiratory center in the medulla is a concern with epidural or intrathecal administration of opioids. Respiratory depression may occur up to 18 hours after a hydrophilic agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , is injected. The incidence is approximately 0.1 percent at a dose of 0.2 mg morphine and occurs almost exclusively in obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies report the incidence of respiratory depression in patients given single-injection neuraxial opioids is in the range of 0.01 to 3 percent. A metaanalysis of randomized and observational trials comparing single-injection or continuous neuraxial opioids compared with parenteral (ie, intravenous, intramuscular, or intravenous patient-controlled) opioids found no significant difference in the incidence of respiratory depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2376946066\">",
"    <span class=\"h3\">",
"     Intrathecal injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small intrathecal doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (0.1 to 0.2 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (10 to 20 mcg) are administered during the placement of a spinal anesthetic. The onset of analgesia and its duration depend upon whether the drug is lipophilic or hydrophilic and how it is transported within the cerebrospinal fluid.",
"   </p>",
"   <p>",
"    Opioids administered in the subarachnoid space appear to act principally on mu receptors in the substantia gelatinosa of the dorsal horn of the spinal cord by suppressing excitatory neuropeptide release from nerve fibers (type C). The degree of uptake from the cerebrospinal fluid by the dorsal horn is determined primarily by the physicochemical properties of the drug, and in particular, lipid solubility. Lipid-soluble compounds enjoy greater direct diffusion into neural tissue as well as greater delivery to the dorsal horn by spinal segmental arteries.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is highly ionized and hydrophilic and does not penetrate lipid-rich tissues as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    . Morphine reaches maximum effect in about 45 minutes and lasts for 18 to 24 hours when administered by the spinal route. By comparison, fentanyl, which is lipophilic (lipid soluble) and penetrates into the lipid rich dorsal horn, acts more quickly, but its duration of action is shorter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncommonly, a patient has severe pain postoperatively in spite of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    administration. We usually supplement these patients with intravenous narcotics. Typically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (50 to 100 mcg intravenously) or morphine (3 mg intravenously) produces immediate pain relief. Once the initial pain is controlled, the intrathecal morphine that was administered at placement of the spinal block often provides adequate ongoing pain relief.",
"   </p>",
"   <p>",
"    In the rare circumstance when these measures fail, patient controlled analgesia (PCA) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    can be initiated. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Patient controlled analgesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The combination of PCA and intrathecal opioids does not increase the risk of respiratory depression over that with either modality alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2376946073\">",
"    <span class=\"h3\">",
"     Epidural injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    by the epidural route is about 5 to 10 times that of the intrathecal route. We use 3 mg of epidural morphine for lumbar and low thoracic epidurals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postoperative epidural analgesia with local anesthetics and opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics and opioids can be intermittently injected via an epidural catheter to provide analgesia postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/34\">",
"     34",
"    </a>",
"    ]. This approach is particularly useful in patients who already have an epidural catheter located at the lumbar or low thoracic level for surgical anesthesia; however, an epidural catheter can be placed postoperatively for this purpose. Typically, epidural analgesia is continued until the patient is able to tolerate oral medications.",
"   </p>",
"   <p>",
"    A combination of a local anesthetic and opioid is administered via a patient-controlled epidural pump (PCEA). This combination lowers the dose requirements for each drug, as well as lowers the frequency of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Commonly used combinations include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    (0.125 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    (0.2 percent) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/46-51\">",
"     46-51",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     Sufentanil",
"    </a>",
"    has also been used, but is costly without providing any anesthetic or analgesic advantage.",
"   </p>",
"   <p>",
"    A metaanalysis of randomized trials comparing the efficacy of epidural with local anesthetic alone versus epidural with local anesthetic and opioid concluded that combination therapy was associated with a significant reduction in visual analog scale pain scores on the first postoperative day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, analgesia is not satisfactory due to extensive surgery or patchy coverage of the epidural block. In these situations, we suggest administering a local anesthetic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    0.125 percent) via PCEA and opioid via intravenous PCA. We suggest postoperative epidural analgesia combined with opioids via PCA for reoperations, extensive resections, and opioid-dependent patients.",
"   </p>",
"   <p>",
"    We use a standard regimen of 6",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    basal rate of epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    (0.125 percent) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    allowing the patient to self bolus 2 mL of this combination of drugs, with a bolus lockout of 20 minutes and four-hour limit of 34 mL. For the mid and higher thoracic epidurals we use a mix of bupivacaine 0.0625 percent with hydromorphone (20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    and a basal rate of 4",
"    <span class=\"nowrap\">",
"     mL/hour,",
"    </span>",
"    keeping the remaining settings the same.",
"   </p>",
"   <p>",
"    Similar to earlier reports in obstetric patients and after different types of surgery, patient-controlled epidural analgesia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    provided as good postoperative analgesia as continuous epidural infusion of bupivacaine and fentanyl after total knee arthroplasty. PCEA provided as good analgesia as continuous epidural analgesia with a significantly smaller amount of bupivacaine-fentanyl solution [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidural infusions have to be fine-tuned to the patient's requirements. Usually, the epidural infusions are started prior to completion of the surgery to obtain pain relief at the conclusion of surgery. Occasionally, boluses of 4 to 8 mL",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    mix (0.125 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ) (20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    are given if the patient is uncomfortable due to pain upon emergence from anesthesia. Postoperative blood pressure and fluid requirements must be carefully monitored while providing such boluses. Usually two boluses are enough to provide pain relief if the epidural catheter is sited correctly. Once initial comfort is obtained, the PCEA epidural is continued as stated above. Occasionally, if the patient requires additional boluses over and above the normal PCEA set doses as described above, to maintain comfort, we usually either increase the basal rate to 8 to 10 mL with four-hour limit increased to a maximum of 64 mL. Increasing the continuous basal infusion avoids fluctuations in the level of analgesia, which occur with intermittent administration.",
"   </p>",
"   <p>",
"    Less commonly, epidurally administered alpha-2 agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ), NMDA receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ), and cholinesterase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    ) are used. They are opioid sparing and provide preemptive analgesia that improves postoperative analgesia for these patients without increasing the incidence of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/55-60\">",
"     55-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Morbid obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;For morbidly obese patients, it is beneficial to provide postoperative analgesia via the epidural route, particularly in those with a history of sleep apnea. Neuraxial analgesia is beneficial in obese patients, as they are susceptible to sleep apnea and respiratory depression that may be exacerbated by parenteral narcotics. Patients with sleep apnea and obesity are at increased risk for respiratory depression, and consideration must be given to using local anesthetic alone for the epidural infusions. Patient controlled analgesia is an alternative in the absence of epidural analgesia; however, the patients need to be closely monitored during the postoperative period. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Patient controlled analgesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to carefully monitor patients receiving neuraxial analgesics for side effects, which can be life-threatening. All patients with epidurals should be examined by a physician at least daily to assess the following: adequacy of pain relief; level of activity tolerated; whether there is any motor blockade from the epidural medication; presence of side effects such as nausea and pruritus; and whether there are signs suggestive of infection (erythema, tenderness, swelling, discharge) at the site of epidural catheter placement. Hypotension is not uncommon after major abdominal surgery, so a careful assessment of fluid balance and other potential causes of hypotension are warranted before implicating the epidural infusion as the source. Nausea or severe pruritus may warrant removing the opioid from the infusion mix. Management of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    -induced pruritus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link\">",
"     \"Pruritus: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parenteral or oral nonsteroidal anti-inflammatory agents can be used to supplement analgesia if narcotics are removed from the epidural infusions.",
"   </p>",
"   <p>",
"    Nursing protocols for patients with intrathecal opioids and epidural infusions should include monitoring respiratory rate at least every two hours, maintaining intravenous access, keeping ephedrine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    readily available, and not administering parenteral or oral narcotics or sedatives without pain service physician approval. In addition, the pain service physician and covering team physicians should be notified promptly if analgesia is inadequate, respiratory rate is less than 8",
"    <span class=\"nowrap\">",
"     breaths/minute,",
"    </span>",
"    systolic blood pressure is less than 80 mmHg, sedation or motor block increases, or temperature is greater than 101.5 degrees F on two occasions within eight hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H961448510\">",
"    <span class=\"h2\">",
"     Peripheral nerve blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics can also be administered, in a selective manner, perineurally. The monitoring protocols for regional blocks are similar to those described for neuraxial anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=see_link\">",
"     \"Overview of peripheral nerve blocks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commonly used perineural blocks include the brachial plexus block to manage upper extremity pain, and femoral or popliteal nerve block for lower extremity pain. These neural structures can be localized using ultrasound guidance or nerve stimulation techniques, and either a single shot of anesthetic injected or a perineural catheter placed to initiate continuous infusions. A loading bolus, usually of 20 to 30 mL of 0.5%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    , can be used for surgical anesthesia. For postoperative pain relief, a continuous infusion of 0.2% ropivacaine at a rate of 10",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    is most commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/64-69\">",
"     64-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H11#H11\">",
"     \"Peripheral nerve block: Techniques\", section on 'Upper extremity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H19#H19\">",
"     \"Peripheral nerve block: Techniques\", section on 'Lower extremity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For postoperative chest wall and abdominal pain, a paravertebral technique can be utilized. This approach delivers local anesthetic in the vicinity of the spinal nerves after their exit from the neural foramen. Usually, multiple spinal levels need to be blocked individually to provide effective pain relief. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H8#H8\">",
"     \"Peripheral nerve block: Techniques\", section on 'Paravertebral nerve block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE INTRAVENOUS MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Parenteral opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opiates provide swift and potent analgesia when administered parenterally. The most commonly used intravenous opioids for treatment of postoperative pain are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/70-73\">",
"     70-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    is not recommended for postoperative pain relief because it lowers seizure threshold, has a dysphoric effect, and is not as efficacious as other drugs available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/74\">",
"     74",
"    </a>",
"    ]. Additionally, it has a slower rate of metabolism in the elderly and in patients with hepatic and renal impairment, which leads to accumulation of meperidine and its active metabolite normeperidine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous opiates can be delivered in three different modes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bolus intravenous injections are often used for moderate pain, with doses titrated to analgesic requirements and the avoidance of respiratory depression and hemodynamic instability. Opioids given by intermittent injection generally are not able to maintain steady analgesic plasma levels for two to four hours. Therefore, it is important to give a loading dose: for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      the loading dose is 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      it is 0.01 to 0.03",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to achieve adequate basal plasma levels. Ideally, this loading dose is given intraoperatively to allow a smooth transition of pain control when the patient becomes awake and alert.",
"     </li>",
"     <li>",
"      Continuous intravenous infusions of opiates are used for moderate to severe pain which is poorly controlled with repeated bolus injections. After an initial bolus dose, a low continuous infusion rate is set with subsequent adjustment for adequate analgesia.",
"     </li>",
"     <li>",
"      Patient-controlled analgesia is useful in conscious patients (see below). This technique allows self-dosing with opiates up to a predetermined limit set by the physician. A low-dose continuous infusion may be added to establish a basal level of analgesia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patient controlled analgesia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All opiates share common side effects. These include somnolence, depression of brainstem control of respiratory drive, hypotension (more common in hypovolemic patients and following rapid injection), urinary retention, and emesis due to direct stimulation of the chemoreceptor trigger zone. Histamine release often follows",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    administration and may produce flushing, tachycardia, hypotension, pruritus, and bronchospasm. Gastrointestinal transit slows with prolonged administration, resulting in constipation and ileus in many patients; this effect is thought to reflect binding to local opiate receptors in the gut. Some data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    , a polar opiate antagonist which does not cross the blood-brain barrier, may diminish the peripherally-mediated side effects of opiates while maintaining central analgesic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or an NSAID with opioids reduces narcotic requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/75\">",
"     75",
"    </a>",
"    ]. This is particularly useful in patients with high narcotic needs (opioid tolerance or chronic use) and may decrease narcotic-related side effects.",
"   </p>",
"   <p>",
"    When pain is less severe and the patient is able to take an oral diet, oral pain relievers can be initiated and continued after discharge, as needed. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Oral opioids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is the prototype opiate and remains widely used. The onset of analgesia is rapid, with the peak effect occurring in one to two hours and an elimination half-life of three to five hours.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bolus intravenous injections of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      are initiated with a 2 mg dose, administered slowly over four to five minutes, and titrated upward in 1 to 2 mg increments every one to three hours.",
"     </li>",
"     <li>",
"      For continuous infusions, a bolus dose of 2 to 5 mg is followed by 1 mg per hour; subsequent dose adjustments in the hourly infusion rate are titrated to the desired level of analgesia. Continuous infusions may be of use in opioid-tolerant patients such as those on chronic opiate therapy who need parenteral administration.",
"     </li>",
"     <li>",
"      Intramuscular injection: 5 to 10 mg every three to four hours as needed. Subcutaneous injection is possible but not recommended, as repeated subcutaneous administration causes local tissue irritation, pain, and induration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;A synthetic derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is approximately 100 times more potent. It is also more lipid-soluble than morphine, which results in a more rapid onset of action, due to improved penetration of the blood-brain barrier, and a shorter half-life of two to three hours. Fentanyl usually is administered as a continuous intravenous infusion, mainly in an intensive care unit setting. Fentanyl is virtually devoid of histamine-releasing properties, and may therefore be preferred in the presence of hemodynamic instability or bronchospasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous boluses every one to two hours may, however, be given for moderate postoperative pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For moderate analgesia after outpatient surgery, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      is initiated with a 25 mcg to 100 mcg bolus administered over one to two minutes; additional boluses can be given every one to two hours as needed until oral medications can be instituted prior to discharge.",
"     </li>",
"     <li>",
"      For moderate to severe pain, a loading dose of 50 to 200 mcg is followed by a continuous intravenous infusion of 25 to 50 mcg per hour, with titration to adequate analgesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    for more than five days is associated with deposition of the drug in adipose tissue. These stores are mobilized following the cessation of drug and may result in prolonged sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hydromorphone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     Hydromorphone",
"    </a>",
"    (Dilaudid) is a semisynthetic opiate agonist which, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , has a more rapid onset of analgesia (within 30 minutes) and a shorter half-life (2.4 hours) than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    . For control of moderate to severe pain, 0.2 to 0.6 mg of hydromorphone is administered as an intravenous bolus every two to three hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sufentanil, alfentanil and remifentanil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     Sufentanil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"     Alfentanil",
"    </a>",
"    are derivatives of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    . Sufentanil is 10 times more potent than fentanyl, whereas alfentanil has about",
"    <span class=\"nowrap\">",
"     1/5",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    the potency of fentanyl. Due to their rapid onset of action (within two to three minutes of an injection) and short elimination half-lives (approximately 90 minutes), these agents are nearly always used as adjuncts to anesthesia and for immediate postoperative analgesia. Sufentanil appears to cause less hemodynamic instability, respiratory depression, and chest-wall rigidity than fentanyl or alfentanil. However, the high cost of sufentanil precludes its routine use for perioperative analgesia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     Remifentanil",
"    </a>",
"    , another derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , is an ultra short-acting agent with a context-sensitive half-life remaining at four minutes after a four-hour infusion due to its rapid hydrolysis by nonspecific tissue and plasma esterases. It has an analgesic potency approximately equal to fentanyl.",
"   </p>",
"   <p>",
"    For patients with renal compromise, the dose of these medications has to be decreased depending on the degree of renal insufficiency.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     Remifentanil",
"    </a>",
"    is the opioid agent least subject to alterations in bioavailability associated with hepatic insufficiency; however, its potency has other inherent dangers. It is advisable to refer to a drug formulary before prescribing these agents in patients with renal or hepatic insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ketorolac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal anti-inflammatory agents (NSAIDS) are useful in reducing the amount of opiates requested by the patient and decreasing opioid side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/75\">",
"     75",
"    </a>",
"    ]. NSAIDS also play an important role as adjuncts to other agents, such as epidural analgesia, and intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    can be given for preemptive analgesia. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Preemptive analgesia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25\">",
"     'Oral nonsteroidal anti-inflammatory drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    reduces narcotic consumption by 25 to 45 percent and indirectly lowers opioid side effects such as ileus, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/14,15,76-80\">",
"     14,15,76-80",
"    </a>",
"    ]. The usual dose of ketorolac in our practice is 30 mg given intravenously. NSAIDs are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     COX-2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;COX-2 inhibitors are another option for single dose preoperative administration. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Preemptive analgesia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two meta-analyses of randomized, placebo-controlled trials evaluating the efficacy of parecoxib (seven studies) and etoricoxib (five studies) found that single-dose treatments of these medications (parecoxib 20 or 40 mg and etoricoxib 120 mg) provided significantly more effective analgesia than placebo and was well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Significantly fewer participants receiving these COX-2 inhibitors required rescue medications over the study period.",
"   </p>",
"   <p>",
"    Several studies found that single-dose COX-2 inhibitors have greater analgesic efficacy and tolerability than opioid-containing analgesics, but were similar to nonselective NSAIDs in postoperative pain management [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/76,78,80,83-86\">",
"     76,78,80,83-86",
"    </a>",
"    ]. However, unlike nonselective NSAIDS, COX-2 inhibitors carry a \"black-box\" warning regarding cardiovascular risk, although this risk appears to be more relevant for long-term use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a noncompetitive inhibitor of the N-methyl-D-aspartate (NMDA) receptor. Ketamine reduces hyperalgesia and prevents opioid tolerance, therefore lowering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    consumption and its side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/87\">",
"     87",
"    </a>",
"    ]. It also acts as a bronchodilator. The clinical use of ketamine is limited due to its potential to cause hallucinations and a dissociative mental state. For this reason, experienced anesthesia personnel should be involved in managing the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/88\">",
"     88",
"    </a>",
"    ]. We suggest an infusion dose starting at 0.1",
"    <span class=\"nowrap\">",
"     mg/kg/hr",
"    </span>",
"    up to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg/hr",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of randomized trials evaluating the adjunctive use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    PCA consistently find significantly lower PCA morphine consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/58,89-92\">",
"     58,89-92",
"    </a>",
"    ]. However, results are variable with respect to measurement of qualitative pain control, with some trials showing significantly improved postoperative pain scores while others show no benefit.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    can be particularly useful as an adjunct when used in patients taking chronic opioids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    whose pain is poorly controlled in spite of high dose opioid therapy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Patients using opioids chronically'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Patients on methadone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intravenous lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    can be administered by infusion intraoperatively",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postoperatively for the management of pain. An initial bolus (1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be used with an intraoperative infusion dosage ranging between 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg/hour.",
"    </span>",
"    The infusion can be continued postoperatively but is usually at a lower dosage. The duration of postoperative therapy needed is poorly defined.",
"   </p>",
"   <p>",
"    The most significant benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    infusion is seen following major abdominal surgery, with significantly improved pain scores in the immediate postoperative period, and reduced incidence of postoperative ileus compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/93\">",
"     93",
"    </a>",
"    ]. There appears to be a trend toward a reduction in the length of stay; however, variability exists in the reported data [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The side effects of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1277062\">",
"    <span class=\"h2\">",
"     Intravenous acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be used in patients in whom oral or rectal administration is not an option. Intravenously administered acetaminophen has a more rapid and predictable onset of effect (5 to 10 minutes) and time to peak concentration (15 minutes) in most patients compared with rectal or oral administration (onset 10 to 60 minutes or more). In a meta-analysis of randomized trials, the addition of acetaminophen (intravenous or oral) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    following major surgery resulted in a small, but statistically significant, decrease in morphine use postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    to nonsteroidal anti-inflammatory drugs (NSAID) regimens can improve pain control. A systematic review that compared the use of acetaminophen alone or in combination with NSAIDs for postoperative pain showed the combination to be more effective than NSAIDs alone in 64 percent of the studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduced dose is suggested for low weight adults and adolescents (body weight 33 to 50 kg) and in patients with mild or moderate hepatic insufficiency, chronic alcoholism, malnutrition, or dehydration.&nbsp;Patients with severe renal insufficiency (CrCl &le;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    may receive a usual dose, but not more often than once every six hours.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is contraindicated in patients having severe hepatic insufficiency or severe active liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PATIENT CONTROLLED ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient controlled analgesia (PCA) pump is the preferred mode of administering opioids for moderate to severe postoperative pain. The benefits include easier patient access to pain medication, reduced chance of medication error, and ready titration (",
"    <a class=\"graphic graphic_table graphicRef51791 \" href=\"UTD.htm?9/50/10029\">",
"     table 1",
"    </a>",
"    ). A meta-analysis of analgesia after intraabdominal surgery found that continuous epidural analgesia significantly improved control of postoperative pain compared with opioid PCA, but was associated with a higher incidence of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Neuraxial (regional) analgesia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    can be administered via PCA pump. The pump is discontinued when the patient is able to tolerate oral analgesics. A systematic review of randomized trials comparing PCA versus conventional administration of opioids evaluated 55 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/97\">",
"     97",
"    </a>",
"    ]. Compared with conventional parenteral analgesia, PCA provided better pain control, led to greater opioid use, and resulted in greater patient satisfaction in spite of a higher incidence of pruritus. There is insufficient evidence to draw comparisons about the other advantages and disadvantages of these two methods of pain relief. The incidence of other side effects was similar between the groups, with no differences observed in the length of hospital stay.",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    PCA may be used for patients with allergies or intolerances to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , but is less desirable in most patients because of its short duration of action. Fentanyl may be easier to titrate in patients with renal and hepatic insufficiency. Alternatively, hydromorphone can be used in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to opioid administration via PCA pump in specific subpopulations are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patients using opioids chronically",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are using opioids chronically should be monitored closely. &nbsp;The postoperative analgesic needs of these patients, which may already be high, will typically exceed their daily doses. Several options are available to meet the acute pain management requirements of these patients. A continuous PCA basal infusion may be needed to control pain effectively since routine dosing schedules may not be sufficient.",
"   </p>",
"   <p>",
"    Another method for providing a basal opioid level for opioid-tolerant patients is the addition of long acting opiates via a transdermal route (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    patch), with titration of shorter-acting agents for acute postoperative pain. Transdermal routes should not be used for the control of postoperative pain in nonopioid tolerant patients due to their slow onset of action (peak levels achieved 24 to 48 hours after patch placement), and potential harmful side effects, particularly respiratory depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patients on methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance for drug dependency or for chronic pain, we suggest restarting their usual methadone dose orally as soon as possible and covering postoperative analgesic requirements with additional opioids as needed via PCA pump. These patients may require high doses, which are usually safe for this population because of tolerance to serious side effects, such as respiratory depression. We suggest consultation with pain physicians. Conversion tables for the commonly used opioids can also be useful (",
"    <a class=\"graphic graphic_figure graphicRef67175 \" href=\"UTD.htm?36/31/37374\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE ORAL ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of oral pain medications are available for the treatment of acute pain.",
"   </p>",
"   <p>",
"    Choices include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      (325 to 1000 mg orally [or rectally] every four to six hours, to a maximum dose of 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      (300 to 800 mg orally three or four times per day)",
"     </li>",
"     <li>",
"      Narcotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       Codeine",
"      </a>",
"      15 to 60 mg orally every four to six hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       Oxycodone",
"      </a>",
"      5 to 30 mg orally every four to six hours",
"     </li>",
"     <li>",
"      Combination therapies such as Percocet (combinations of 325 to 650 mg",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"        acetaminophen",
"       </a>",
"       /2.5",
"      </span>",
"      to 10 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      , one or two tablets orally every four to six hours), Percodan (325 mg",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"        aspirin",
"       </a>",
"       /4.5",
"      </span>",
"      mg oxycodone, one or two tablets orally every four to six hours), Tylenol #2 (300 mg",
"      <span class=\"nowrap\">",
"       acetaminophen/15",
"      </span>",
"      mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , one to two tablets orally every four to six hours), Tylenol #3 (300 mg",
"      <span class=\"nowrap\">",
"       acetaminophen/",
"      </span>",
"      30 mg codeine, one to two tablets orally every four to six hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon the severity of the pain, prior allergies, prior patient experience and tolerance of these medications (nausea, gastrointestinal upset, bleeding disorders), any of these oral medications can be prescribed and tailored to the needs of the individual.",
"   </p>",
"   <p>",
"    A Cochrane review analyzed the data for single dose oral analgesics from 35 prior Cochrane Reviews treating about 45,000 participants for acute postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/100\">",
"     100",
"    </a>",
"    ]. No drug was found to produce high levels of pain relief in all participants. In patients with acute moderate to severe pain, 70 percent achieved good pain relief with the best drugs and pain relief for the worst drugs occurred in about 30 percent of the patients. The percentage of patients treated with placebo who achieved at least 50 percent maximum pain relief over four to six hours ranged from 5 to 15 percent. The period over which pain was relieved varied from two hours to 20 hours.",
"    <span class=\"nowrap\">",
"     Drug/dose",
"    </span>",
"    combinations with good (low) numbers needed to treat (NNT) for at least 50 percent maximum pain relief over four to six hours relative to placebo included [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/100\">",
"     100",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      400 mg (NNT 2.5, 95% CI 2.4-2.6)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       Diclofenac",
"      </a>",
"      50 mg (NNT 2.7, 95% CI 2.4-3.0)",
"     </li>",
"     <li>",
"      Etoricoxib 120 mg (NNT 1.9, 95% CI 1.7-2.1)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       Codeine",
"      </a>",
"      60 mg + paracetamol 1000 mg (NNT 2.2, 95% CI 1.8-2.9)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      400 mg (NNT 2.5, 95% CI 2.2-2.9)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"      <span class=\"nowrap\">",
"       500/550",
"      </span>",
"      mg (NNT 2.7; 95% CI 2.3-3.3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A long duration of action (&gt;8 hours) was noted for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Etoricoxib 120 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/41/25240?source=see_link\">",
"       Diflunisal",
"      </a>",
"      500 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"      <span class=\"nowrap\">",
"       500/550",
"      </span>",
"      mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      400 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       Oxycodone",
"      </a>",
"      10 mg plus paracetamol 650 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Oral nonsteroidal anti-inflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that pharmacological management of mild to moderate postoperative pain begin with a nonsteroidal anti-inflammatory drug (NSAID), unless there is a contraindication to these agents. Preoperative administration of oral NSAIDS prior to elective minor surgery reduces postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/15,76,83,101-103\">",
"     15,76,83,101-103",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Preemptive analgesia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Commonly used oral NSAIDS that can be used for postoperative pain are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    and paracetamol. If oral medication is not tolerated, rectal administration is an alternative route.",
"   </p>",
"   <p>",
"    NSAIDs are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Oral opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the patient is tolerating an oral diet, the opioid regimen for patients with moderate to severe pain can be switched from intravenous to oral opioids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    . General opioid dosing guidelines are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef82399 \" href=\"UTD.htm?23/57/24476\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Postoperative intravenous medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ideally, the dose should be calculated on the basis of the 24-hour PCA dose and appropriate conversion calculated (",
"    <a class=\"graphic graphic_figure graphicRef67175 \" href=\"UTD.htm?36/31/37374\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 2",
"    </a>",
"    ). As an example, a patient taking 40 mg of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    over 24 hours would be given 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    every four hours or 5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    every four hours. Patients with mild to moderate pain can be switched to NSAIDS or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Alpha-2 receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism by which alpha-2 agonists produce analgesia remains unknown; it is postulated that release of acetylcholine may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alpha-2 agonists also reduce the undesirable physiological and psychological effects of opioid withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/105\">",
"     105",
"    </a>",
"    ]. Studies indicate that alpha-2 agonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    exert a potent analgesic response, and that their potency is increased by concomitant opioid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/106,107\">",
"     106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    at doses of 150 to 200 micrograms preoperatively has been shown to provide perioperative hemodynamic stability and reduce the requirement of postoperative analgesics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/108-110\">",
"     108-110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8419304\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsant agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (Neurontin&reg;) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    (Lyrica&reg;) are effective in the management of chronic neuropathic pain conditions. These agents are gamma-aminobutyric acid (GABA) analogues; GABA is an inhibitory neurotransmitter that is widely distributed throughout the central nervous system. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Surgical pain mechanism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    exert analgesic and opioid sparing effects, and as a result, decrease opioid-related side-effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/111-116\">",
"     111-116",
"    </a>",
"    ]. A disadvantage to these agents is a dose-dependent sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/113,116\">",
"     113,116",
"    </a>",
"    ]. Several systematic reviews support an adjunctive role for these agents in the management of postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/57/27546/abstract/113,115-117\">",
"     113,115-117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PERSISTENT POSTOPERATIVE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, incisional pain gradually resolves over a period of days to weeks. Increasing pain or pain that persists for months warrants consideration of other etiologies, including local scar formation, infection,",
"    <span class=\"nowrap\">",
"     dehiscence/hernia,",
"    </span>",
"    foreign body reaction, conditions unrelated to the surgery (endometriosis, pelvic mass, malignancy, spinal radiculopathy), and incisional neuroma. Investigation of these patients should include a thorough history and physical examination with attention to the surgical site. Appropriate laboratory and imaging studies are ordered based on clinical findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain control regimens should be tailored to the needs of the individual patient, taking into account the patient's age, medical and physical condition, level of",
"      <span class=\"nowrap\">",
"       fear/anxiety,",
"      </span>",
"      personal preferences, type of surgical procedure, and response. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest preemptive analgesia with drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      , COX-2 inhibitors and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      before induction of general anesthesia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These agents are particularly useful to decrease postoperative pain scores in ambulatory surgical patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preemptive analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following ambulatory surgery under sedation, we suggest treatment of acute pain in the recovery room with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , followed by oral pain relievers such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"        acetaminophen",
"       </a>",
"       /codeine",
"      </span>",
"      combinations, or nonsteroidal anti-inflammatory drugs upon discharge (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Postoperative oral analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following open or laparoscopic surgical procedures under general anesthesia, we suggest patient controlled analgesia using intravenous narcotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      for postoperative analgesia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Addition of nonsteroidal anti-inflammatory drugs, if not contraindicated, lowers the narcotic requirement and improves quality of analgesia. The narcotics are switched to the oral route as soon as the patient tolerates oral fluids. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patient controlled analgesia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Postoperative oral analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing major abdominal surgeries with extensive incisions and those who are chronically dependent on narcotics for pain relief, we suggest neuraxial anesthesia (epidural or spinal anesthesia) in addition to general anesthesia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition to preemptive analgesia, the neuraxial approach provides postoperative analgesia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preemptive analgesia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Intraoperative epidural or intrathecal opioid injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neuraxial anesthesia, epidural or intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      (morphine 3 mg for epidural, Duramorph 0.2 mg for spinal) can be used to provide postoperative pain relief for about 18 to 24 hours; this can be supplemented with nonsteroidal anti-inflammatory drugs without increasing the risk of postoperative respiratory compromise. If the pain relief is not satisfactory with this combination, additional intravenous narcotics (patient controlled analgesia [PCA]) are provided and monitored by the pain service personnel.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      can be used as an adjunct, as well, especially in opioid-dependent patients and in situations where neuraxial anesthesia is contraindicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preemptive analgesia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Intraoperative epidural or intrathecal opioid injection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Patient controlled analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients in whom the pain relief is required for a longer duration than can be provided by a single dose of neuraxial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , we suggest postoperative patient controlled epidural analgesia (PCEA) as long as needed, via a lumbar or low thoracic epidural catheter placed preoperatively (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Postoperative epidural infusions are monitored by the postoperative pain service personnel. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Postoperative epidural analgesia with local anesthetics and opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      , we suggest restarting their usual dose of methadone if the situation permits (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); however, opioid-dependent patients often require dosing over and above their baseline dose. We suggest postoperative epidural catheter analgesia, even if the surgery is expected to result in average pain levels, because it lowers opioid requirements (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A continuous infusion of narcotics is also acceptable; this decision has to be individualized depending on the surgery and patient. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Patients on methadone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For morbidly obese patients, we suggest postoperative analgesia via the epidural route to reduce the risk of respiratory depression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The use of only epidurally administered local anesthetics is an option. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Morbid obesity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/1\">",
"      de Beer Jde V, Winemaker MJ, Donnelly GA, et al. Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. Can J Surg 2005; 48:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/2\">",
"      Recart A, Duchene D, White PF, et al. Efficacy and safety of fast-track recovery strategy for patients undergoing laparoscopic nephrectomy. J Endourol 2005; 19:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/3\">",
"      Watcha MF, Issioui T, Klein KW, White PF. Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. Anesth Analg 2003; 96:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/4\">",
"      Kehlet H, Dahl JB. The value of \"multimodal\" or \"balanced analgesia\" in postoperative pain treatment. Anesth Analg 1993; 77:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/5\">",
"      Kelly DJ, Ahmad M, Brull SJ. Preemptive analgesia I: physiological pathways and pharmacological modalities. Can J Anaesth 2001; 48:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/6\">",
"      Woolf CJ, Chong MS. Preemptive analgesia--treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/7\">",
"      Suzuki H. Recent topics in the management of pain: development of the concept of preemptive analgesia. Cell Transplant 1995; 4 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/8\">",
"      Ong CK, Lirk P, Seymour RA, Jenkins BJ. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth Analg 2005; 100:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/9\">",
"      Ke RW, Portera SG, Bagous W, Lincoln SR. A randomized, double-blinded trial of preemptive analgesia in laparoscopy. Obstet Gynecol 1998; 92:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/10\">",
"      Ghezzi F, Cromi A, Bergamini V, et al. Preemptive port site local anesthesia in gynecologic laparoscopy: a randomized, controlled trial. J Minim Invasive Gynecol 2005; 12:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/11\">",
"      Updike GM, Manolitsas TP, Cohn DE, et al. Pre-emptive analgesia in gynecologic surgical procedures: preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incision. Am J Obstet Gynecol 2003; 188:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/12\">",
"      Leung CC, Chan YM, Ngai SW, et al. Effect of pre-incision skin infiltration on post-hysterectomy pain--a double-blind randomized controlled trial. Anaesth Intensive Care 2000; 28:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/13\">",
"      Yanagidate F, Hamaya Y, Dohi S. Clonidine premedication reduces maternal requirement for intravenous morphine after cesarean delivery without affecting newborn's outcome. Reg Anesth Pain Med 2001; 26:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/14\">",
"      Pavy TJ, Paech MJ, Evans SF. The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery. Anesth Analg 2001; 92:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/15\">",
"      Mixter CG 3rd, Meeker LD, Gavin TJ. Preemptive pain control in patients having laparoscopic hernia repair: a comparison of ketorolac and ibuprofen. Arch Surg 1998; 133:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/16\">",
"      Dirks J, Fredensborg BB, Christensen D, et al. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 2002; 97:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/17\">",
"      Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg 2002; 95:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/18\">",
"      Dierking G, Duedahl TH, Rasmussen ML, et al. Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta Anaesthesiol Scand 2004; 48:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/19\">",
"      Pandey CK, Priye S, Singh S, et al. Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirements in laparoscopic cholecystectomy. Can J Anaesth 2004; 51:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/20\">",
"      Turan A, Karamanlio��lu B, Memi�� D, et al. Analgesic effects of gabapentin after spinal surgery. Anesthesiology 2004; 100:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/21\">",
"      Turan A, Karamanlio��lu B, Memi�� D, et al. The analgesic effects of gabapentin after total abdominal hysterectomy. Anesth Analg 2004; 98:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/22\">",
"      Rorarius MG, Mennander S, Suominen P, et al. Gabapentin for the prevention of postoperative pain after vaginal hysterectomy. Pain 2004; 110:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/23\">",
"      Pandey CK, Navkar DV, Giri PJ, et al. Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study. J Neurosurg Anesthesiol 2005; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/24\">",
"      Radhakrishnan M, Bithal PK, Chaturvedi A. Effect of preemptive gabapentin on postoperative pain relief and morphine consumption following lumbar laminectomy and discectomy: a randomized, double-blinded, placebo-controlled study. J Neurosurg Anesthesiol 2005; 17:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/25\">",
"      Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology 1984; 61:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/26\">",
"      Gwirtz KH, Young JV, Byers RS, et al. The safety and efficacy of intrathecal opioid analgesia for acute postoperative pain: seven years' experience with 5969 surgical patients at Indiana University Hospital. Anesth Analg 1999; 88:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/27\">",
"      Palmer CM, Nogami WM, Van Maren G, Alves DM. Postcesarean epidural morphine: a dose-response study. Anesth Analg 2000; 90:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/28\">",
"      Abouleish E, Rawal N, Rashad MN. The addition of 0.2 mg subarachnoid morphine to hyperbaric bupivacaine for cesarean delivery: a prospective study of 856 cases. Reg Anesth 1991; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/29\">",
"      Chestnut DH. Efficacy and safety of epidural opioids for postoperative analgesia. Anesthesiology 2005; 102:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/30\">",
"      Chadwick HS, Ready LB. Intrathecal and epidural morphine sulfate for post-cesarean analgesia--a clinical comparison. Anesthesiology 1988; 68:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/31\">",
"      Satoh O, Hatakeyama Y, Miyazawa F, et al. [Intrathecal morphine for postoperative pain relief after transvaginal hysterectomy]. Masui 1992; 41:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/32\">",
"      Dual&eacute; C, Frey C, Bolandard F, et al. Epidural versus intrathecal morphine for postoperative analgesia after Caesarean section. Br J Anaesth 2003; 91:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/33\">",
"      Terajima K, Onodera H, Kobayashi M, et al. Efficacy of intrathecal morphine for analgesia following elective cesarean section: comparison with previous delivery. J Nippon Med Sch 2003; 70:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/34\">",
"      Sarvela J, Halonen P, Soikkeli A, Korttila K. A double-blinded, randomized comparison of intrathecal and epidural morphine for elective cesarean delivery. Anesth Analg 2002; 95:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/35\">",
"      Abouleish E, Rawal N, Fallon K, Hernandez D. Combined intrathecal morphine and bupivacaine for cesarean section. Anesth Analg 1988; 67:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/36\">",
"      Fassoulaki A, Gatzou V, Petropoulos G, Siafaka I. Spread of subarachnoid block, intraoperative local anaesthetic requirements and postoperative analgesic requirements in Caesarean section and total abdominal hysterectomy. Br J Anaesth 2004; 93:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/37\">",
"      Sarma VJ, Bostr&ouml;m UV. Intrathecal morphine for the relief of post-hysterectomy pain--a double-blind, dose-response study. Acta Anaesthesiol Scand 1993; 37:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/38\">",
"      Gadsden J, Hart S, Santos AC. Post-cesarean delivery analgesia. Anesth Analg 2005; 101:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/39\">",
"      American Society of Anesthesiologists Task Force on Neuraxial Opioids, Horlocker TT, Burton AW, et al. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology 2009; 110:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/40\">",
"      Devys JM, Mora A, Plaud B, et al. Intrathecal + PCA morphine improves analgesia during the first 24 hr after major abdominal surgery compared to PCA alone. Can J Anaesth 2003; 50:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/41\">",
"      Kong SK, Onsiong SM, Chiu WK, Li MK. Use of intrathecal morphine for postoperative pain relief after elective laparoscopic colorectal surgery. Anaesthesia 2002; 57:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/42\">",
"      Swart M, Sewell J, Thomas D. Intrathecal morphine for caesarean section: an assessment of pain relief, satisfaction and side-effects. Anaesthesia 1997; 52:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/43\">",
"      Niiyama Y, Kawamata T, Shimizu H, et al. The addition of epidural morphine to ropivacaine improves epidural analgesia after lower abdominal surgery. Can J Anaesth 2005; 52:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/44\">",
"      Wu CL, Hurley RW, Anderson GF, et al. Effect of postoperative epidural analgesia on morbidity and mortality following surgery in medicare patients. Reg Anesth Pain Med 2004; 29:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/45\">",
"      de Leon-Casasola OA, Karabella D, Lema MJ. Bowel function recovery after radical hysterectomies: thoracic epidural bupivacaine-morphine versus intravenous patient-controlled analgesia with morphine: a pilot study. J Clin Anesth 1996; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/46\">",
"      J&oslash;rgensen H, Fomsgaard JS, Dirks J, et al. Effect of epidural bupivacaine vs combined epidural bupivacaine and morphine on gastrointestinal function and pain after major gynaecological surgery. Br J Anaesth 2001; 87:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/47\">",
"      J&oslash;rgensen H, Fomsgaard JS, Dirks J, et al. Effect of continuous epidural 0.2% ropivacaine vs 0.2% bupivacaine on postoperative pain, motor block and gastrointestinal function after abdominal hysterectomy. Br J Anaesth 2000; 84:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/48\">",
"      Tanaka M, Watanabe S, Ashimura H, et al. Minimum effective combination dose of epidural morphine and fentanyl for posthysterectomy analgesia: a randomized, prospective, double-blind study. Anesth Analg 1993; 77:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/49\">",
"      Senard M, Kaba A, Jacquemin MJ, et al. Epidural levobupivacaine 0.1% or ropivacaine 0.1% combined with morphine provides comparable analgesia after abdominal surgery. Anesth Analg 2004; 98:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/50\">",
"      Senard M, Joris JL, Ledoux D, et al. A comparison of 0.1% and 0.2% ropivacaine and bupivacaine combined with morphine for postoperative patient-controlled epidural analgesia after major abdominal surgery. Anesth Analg 2002; 95:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/51\">",
"      Scott DA, Blake D, Buckland M, et al. A comparison of epidural ropivacaine infusion alone and in combination with 1, 2, and 4 microg/mL fentanyl for seventy-two hours of postoperative analgesia after major abdominal surgery. Anesth Analg 1999; 88:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/52\">",
"      J&oslash;rgensen H, Wetterslev J, M&oslash;iniche S, Dahl JB. Epidural local anaesthetics versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev 2000; :CD001893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/53\">",
"      Gambling DR, Yu P, Cole C, et al. A comparative study of patient controlled epidural analgesia (PCEA) and continuous infusion epidural analgesia (CIEA) during labour. Can J Anaesth 1988; 35:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/54\">",
"      Liu SS, Allen HW, Olsson GL. Patient-controlled epidural analgesia with bupivacaine and fentanyl on hospital wards: prospective experience with 1,030 surgical patients. Anesthesiology 1998; 88:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/55\">",
"      Chia YY, Chang TH, Liu K, et al. The efficacy of thoracic epidural neostigmine infusion after thoracotomy. Anesth Analg 2006; 102:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/56\">",
"      Lauretti GR, de Oliveira R, Reis MP, et al. Study of three different doses of epidural neostigmine coadministered with lidocaine for postoperative analgesia. Anesthesiology 1999; 90:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/57\">",
"      Wilson JA, Nimmo AF, Fleetwood-Walker SM, Colvin LA. A randomised double blind trial of the effect of pre-emptive epidural ketamine on persistent pain after lower limb amputation. Pain 2008; 135:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/58\">",
"      Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/59\">",
"      Farmery AD, Wilson-MacDonald J. The analgesic effect of epidural clonidine after spinal surgery: a randomized placebo-controlled trial. Anesth Analg 2009; 108:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/60\">",
"      De Kock M, Wiederkher P, Laghmiche A, Scholtes JL. Epidural clonidine used as the sole analgesic agent during and after abdominal surgery. A dose-response study. Anesthesiology 1997; 86:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/61\">",
"      Daly DJ, Myles PS. Update on the role of paravertebral blocks for thoracic surgery: are they worth it? Curr Opin Anaesthesiol 2009; 22:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/62\">",
"      Joshi GP, Bonnet F, Shah R, et al. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg 2008; 107:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/63\">",
"      Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy--a systematic review and meta-analysis of randomized trials. Br J Anaesth 2006; 96:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/64\">",
"      Chin KJ, Singh M, Velayutham V, Chee V. Infraclavicular brachial plexus block for regional anaesthesia of the lower arm. Cochrane Database Syst Rev 2010; :CD005487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/65\">",
"      Fredrickson MJ, Krishnan S, Chen CY. Postoperative analgesia for shoulder surgery: a critical appraisal and review of current techniques. Anaesthesia 2010; 65:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/66\">",
"      Wegener JT, van Ooij B, van Dijk CN, et al. Value of single-injection or continuous sciatic nerve block in addition to a continuous femoral nerve block in patients undergoing total knee arthroplasty: a prospective, randomized, controlled trial. Reg Anesth Pain Med 2011; 36:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/67\">",
"      Ilfeld BM, Mariano ER, Girard PJ, et al. A multicenter, randomized, triple-masked, placebo-controlled trial of the effect of ambulatory continuous femoral nerve blocks on discharge-readiness following total knee arthroplasty in patients on general orthopaedic wards. Pain 2010; 150:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/68\">",
"      Paul JE, Arya A, Hurlburt L, et al. Femoral nerve block improves analgesia outcomes after total knee arthroplasty: a meta-analysis of randomized controlled trials. Anesthesiology 2010; 113:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/69\">",
"      Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials. Br J Anaesth 2008; 100:154.",
"     </a>",
"    </li>",
"    <li>",
"     Wittels B, Sevarino FB. PCA in the obstetric patient. In: Acute pain: Mechanism and Management, Sinatra, RS, Hord, AH, Ginsberg, B, Preble, LM (Eds), Mosby-Year Book, St. Louis 1992. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/71\">",
"      Rapp-Zingraff N, Bayoumeu F, Baka N, et al. Analgesia after caesarean section: patient-controlled intravenous morphine vs epidural morphine. Int J Obstet Anesth 1997; 6:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/72\">",
"      Cade L, Ashley J. Towards optimal analgesia after caesarean section: comparison of epidural and intravenous patient-controlled opioid analgesia. Anaesth Intensive Care 1993; 21:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/73\">",
"      Wittels B, Glosten B, Faure EA, et al. Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates. Anesth Analg 1997; 85:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/74\">",
"      Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther 2002; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/75\">",
"      McDaid C, Maund E, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/76\">",
"      Bikhazi GB, Snabes MC, Bajwa ZH, et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. Am J Obstet Gynecol 2004; 191:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/77\">",
"      Varrassi G, Marinangeli F, Agr&ograve; F, et al. A double-blinded evaluation of propacetamol versus ketorolac in combination with patient-controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg 1999; 88:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/78\">",
"      Chui PT, Gin T. A comparison between ketorolac and diclofenac in laparoscopic sterilization. Eur J Anaesthesiol 1995; 12:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/79\">",
"      O'Hanlon JJ, Beers H, Huss BK, Milligan KR. A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on post-operative pain following laparoscopy. Eur J Anaesthesiol 1996; 13:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/80\">",
"      Ng A, Temple A, Smith G, Emembolu J. Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial. Br J Anaesth 2004; 92:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/81\">",
"      Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; :CD004309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/82\">",
"      Lloyd R, Derry S, Moore RA, McQuay HJ. Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; :CD004771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/83\">",
"      Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth 2003; 90:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/84\">",
"      Barton SF, Langeland FF, Snabes MC, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002; 97:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/85\">",
"      Malan TP Jr, Gordon S, Hubbard R, Snabes M. The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. Anesth Analg 2005; 100:454.",
"     </a>",
"    </li>",
"    <li>",
"     Bikhazi GB, Bajwa ZH, Snabes MC, et al. Parecoxib effectively treats post-laparotomy pain. Annual Meeting of the American Society for Reproductive Medicine Poster 2003; 481.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/87\">",
"      Webb AR, Skinner BS, Leong S, et al. The addition of a small-dose ketamine infusion to tramadol for postoperative analgesia: a double-blinded, placebo-controlled, randomized trial after abdominal surgery. Anesth Analg 2007; 104:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/88\">",
"      Buvanendran A, Kroin JS. Useful adjuvants for postoperative pain management. Best Pract Res Clin Anaesthesiol 2007; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/89\">",
"      Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999; 82:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/90\">",
"      Elia N, Tram&egrave;r MR. Ketamine and postoperative pain--a quantitative systematic review of randomised trials. Pain 2005; 113:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/91\">",
"      Carstensen M, M&oslash;ller AM. Adding ketamine to morphine for intravenous patient-controlled analgesia for acute postoperative pain: a qualitative review of randomized trials. Br J Anaesth 2010; 104:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/92\">",
"      Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; :CD004603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/93\">",
"      Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg 2008; 95:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/94\">",
"      McKay A, Gottschalk A, Ploppa A, et al. Systemic lidocaine decreased the perioperative opioid analgesic requirements but failed to reduce discharge time after ambulatory surgery. Anesth Analg 2009; 109:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/95\">",
"      Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/96\">",
"      Werawatganon T, Charuluxanun S. Patient controlled intravenous opioid analgesia versus continuous epidural analgesia for pain after intra-abdominal surgery. Cochrane Database Syst Rev 2005; :CD004088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/97\">",
"      Hudcova J, McNicol E, Quah C, et al. Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst Rev 2006; :CD003348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/98\">",
"      Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 2008; 4:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/99\">",
"      Murtagh FE, Chai MO, Donohoe P, et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/100\">",
"      Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev 2011; :CD008659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/101\">",
"      Thompson JP, Sharpe P, Kiani S, Owen-Smith O. Effect of meloxicam on postoperative pain after abdominal hysterectomy. Br J Anaesth 2000; 84:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/102\">",
"      Akarsu T, Karaman S, Akercan F, et al. Preemptive meloxicam for postoperative pain relief after abdominal hysterectomy. Clin Exp Obstet Gynecol 2004; 31:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/103\">",
"      Chan A, Dor&eacute; CJ, Ramachandra V. Analgesia for day surgery. Evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Anaesthesia 1996; 51:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/104\">",
"      Gordh T Jr, Jansson I, Hartvig P, et al. Interactions between noradrenergic and cholinergic mechanisms involved in spinal nociceptive processing. Acta Anaesthesiol Scand 1989; 33:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/105\">",
"      Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/106\">",
"      De Kock M, Crochet B, Morimont C, Scholtes JL. Intravenous or epidural clonidine for intra- and postoperative analgesia. Anesthesiology 1993; 79:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/107\">",
"      Omote K, Kitahata LM, Collins JG, et al. Interaction between opiate subtype and alpha-2 adrenergic agonists in suppression of noxiously evoked activity of WDR neurons in the spinal dorsal horn. Anesthesiology 1991; 74:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/108\">",
"      Sung CS, Lin SH, Chan KH, et al. Effect of oral clonidine premedication on perioperative hemodynamic response and postoperative analgesic requirement for patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Sin 2000; 38:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/109\">",
"      Hidalgo MP, Auzani JA, Rumpel LC, et al. The clinical effect of small oral clonidine doses on perioperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 2005; 100:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/110\">",
"      White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg 2005; 101:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/111\">",
"      Zhang J, Ho KY, Wang Y. Efficacy of pregabalin in acute postoperative pain: a meta-analysis. Br J Anaesth 2011; 106:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/112\">",
"      Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain--a systematic review of randomized controlled trials. Pain 2006; 126:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/113\">",
"      Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth Analg 2007; 104:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/114\">",
"      Dauri M, Faria S, Gatti A, et al. Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences. Curr Drug Targets 2009; 10:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/115\">",
"      Mathiesen O, M&oslash;iniche S, Dahl JB. Gabapentin and postoperative pain: a qualitative and quantitative systematic review, with focus on procedure. BMC Anesthesiol 2007; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/116\">",
"      Peng PW, Wijeysundera DN, Li CC. Use of gabapentin for perioperative pain control -- a meta-analysis. Pain Res Manag 2007; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/57/27546/abstract/117\">",
"      Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; :CD007076.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 398 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27546=[""].join("\n");
var outline_f26_57_27546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGICAL PAIN MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREEMPTIVE ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Local",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NEURAXIAL (REGIONAL) ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intraoperative epidural or intrathecal opioid injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2376946066\">",
"      - Intrathecal injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2376946073\">",
"      - Epidural injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postoperative epidural analgesia with local anesthetics and opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Morbid obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H961448510\">",
"      Peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTOPERATIVE INTRAVENOUS MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Parenteral opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Morphine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fentanyl",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hydromorphone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sufentanil, alfentanil and remifentanil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ketorolac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ketamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intravenous lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1277062\">",
"      Intravenous acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PATIENT CONTROLLED ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patients using opioids chronically",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patients on methadone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POSTOPERATIVE ORAL ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Oral nonsteroidal anti-inflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Oral opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Alpha-2 receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8419304\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PERSISTENT POSTOPERATIVE PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/398|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/16/26884\" title=\"figure 1\">",
"      Somatic sensory receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/43/20146\" title=\"figure 2\">",
"      Mechanism of acute pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/18/19748\" title=\"figure 3\">",
"      Peripheral chemical mediators of pain and hyperalgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/29/21983\" title=\"figure 4\">",
"      Primary pain pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/32/516\" title=\"figure 5\">",
"      Axon terminal and synapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/31/37374\" title=\"figure 6\">",
"      Equianalgesic opioid doses B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/50/10029\" title=\"table 1\">",
"      PCA dosing guideline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11760\" title=\"table 2\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/57/24476\" title=\"table 3\">",
"      Opioid dosing guideline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_57_27547="Tests in episcleritis scleritis";
var content_f26_57_27547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible laboratory investigations for patients with episcleritis or scleritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Blood and serologic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythrocyte sedimentation rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antinuclear antibody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis serologies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin converting enzyme levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antineutrophil cytoplasmic antibody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum uric acid concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urinalysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Skin tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculin skin test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergy tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radiologic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacroiliac joint x-rays",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     These recommendations should be modified as dictated by the findings of a thorough history, review of systems, and physical examination.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27547=[""].join("\n");
var outline_f26_57_27547=null;
var title_f26_57_27548="Preop radiation rectal cancer";
var content_f26_57_27548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected randomized trials of preoperative irradiation and surgery versus surgery alone in patients with distal rectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Dosage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        LC, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Five-year survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        C",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rx",
"       </td>",
"       <td class=\"subtitle2\">",
"        C",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Low-dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Princess Margaret",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        5 Gy",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medical Research Council",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        5 Gy/20 Gy",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Moderate-dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        EORTC",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        34.5 Gy",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Swedish-style",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Swedish Rectal Cancer Trial",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        25 Gy",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MRC/NCIC trial",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        25 Gy",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        79 (three-year)",
"       </td>",
"       <td>",
"        81 (three-year)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LC: local control; C: control; Rx: treated.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Can J Surg 1977; 20:335.",
"       </li>",
"       <li>",
"        Br J Surg 1989; 71:21.",
"       </li>",
"       <li>",
"        Ann Surg 1998; 208:606.",
"       </li>",
"       <li>",
"        N Engl J Med 1997; 336:980.",
"       </li>",
"       <li>",
"        J Clin Oncol 2006; 24:148s.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27548=[""].join("\n");
var outline_f26_57_27548=null;
var title_f26_57_27549="SAC unscored portion";
var content_f26_57_27549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Standardized assessment of concussion addendum",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Graded symptom checklist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Symptom",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         None",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Mild",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Moderate",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Severe",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Headache",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dizziness",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor balance",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blurred/double vision",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitivity to light",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitivity to noise",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ringing in the ears",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor concentration",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Memory problems",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not feeling \"sharp\"",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue/sluggish",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sadness/depression",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Amnesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic amnesia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\">",
"        Length:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retrograde amnesia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\">",
"        Length:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Strength",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right arm",
"       </td>",
"       <td colspan=\"2\">",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        Abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right leg",
"       </td>",
"       <td colspan=\"2\">",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        Abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left arm",
"       </td>",
"       <td colspan=\"2\">",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        Abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left leg",
"       </td>",
"       <td colspan=\"2\">",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        Abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensation",
"       </td>",
"       <td colspan=\"2\">",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        Abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coordination of limbs/gait",
"       </td>",
"       <td colspan=\"2\">",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        Abnormal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The unscored portion of the Standardized Assessment of Concussion (SAC) includes a graded symptom checklist, a brief neurologic examination, and records the presence of post-traumatic and retrograde amnesia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: McCrea M. J Head Trauma Rehabil 1998 ; 13:27.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27549=[""].join("\n");
var outline_f26_57_27549=null;
var title_f26_57_27550="Sestamibi coronary ischemia";
var content_f26_57_27550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Sestamibi perfusion scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Myocardial perfusion scan in a patient injected with Tc-99m-sestamibi in the emergency department during an episode of chest pain. The patient's ECG was nondiagnostic but perfusion defects can be seen in the anteroapical region of the heart (arrows). Cardiac catheterization the next day revealed a tight lesion in the proximal portion of the first diagonal branch of the left anterior descending coronary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas A Holly, MD and Robert C Hendel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27550=[""].join("\n");
var outline_f26_57_27550=null;
var title_f26_57_27551="48h postpneumonectomy PA";
var content_f26_57_27551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Expected chest radiographic changes in the early postpneumonectomy period",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forty-eight hours after surgery, fluid has quickly accumulated in the postpneumonectomy space after removal of the chest tube. Note the shift in the trachea towards the operative side (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_57_27551=[""].join("\n");
var outline_f26_57_27551=null;
